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Acanthamoeba Keratitis (AK) is a vision-threatening disease which can lead to 
blinding corneal tissue infection. Many patients who have been infected with 
Acanthamoeba in their eye do not respond to the current medical treatments 
involving polyhexamethylene biguanide or chlorhexidine despite the in vitro 
sensitivity of Acanthamoeba to these drugs. There is an urgent need for new 
therapeutic agents to eradicate the AK infection. This study focuses on the 
mechanism by which Acanthamoeba may distinguish between trophozoite, cyst 
and the newly identified lifecycle known as protocyst. The current study has 
tested 56 novel and existing therapeutic agents for their activity against 
Acanthamoeba spp. and their toxicity against a human epithelial cell line. The 
results of this research have revealed several compounds of interest for further 
study on their potential use in the treatment of AK. These compounds included, 
octenidine hydrochloride, alexidine, miltefosine and quaternary ammonium 
(didecyldimethylammonium chloride). The anti-amoebic effect of benzalkonium 
chloride, povidone iodine and tetracaine are superior to the current diamidines 
and slightly lower to the biguanides applied in the treatment for AK. The 
formulation of novel amidoamine compounds including myristoleyl-amidopropyl-
dimethylamine (MOPD) and palmitoleyl-amidopropyl-dimethylamine (POPD) into 
contact lens solutions showed complete kill at a 4.5-log reduction against 
trophozoites compared with myristamidopropyl dimethylamine (MAPD) as an 
existing compound. The combination of biguanide compounds with lipid–based 
carriers has improved the antimicrobial activity from 1-fold to around 7-fold 
against cysts of Acanthamoeba spp. compared with the use of biguanides alone.  
The findings of encystment investigation (the transformation of trophozoites into 
cysts) showed that the agonists in particular the β ultra-long against indacaterol 
stimulated the encystment and the antagonists β₁ metoprolol blocked the 
formation of cysts and protocysts. Two different  herbicides including 2,6-
dichlorobenzonitrile (DCB) and isoxaben were tested to target the biosynthesis 
of cellulose in the cyst form and also to evaluate their effects  on the formation of 
protocyst of Acanthamoeba. The results of this study showed that the DCB at a 




production of Acanthamoeba at 24.6%, whereas isoxaben inhibited the 
transformation of trophozoites into cysts to only 45% and the percentage was 
decreased for protocyst formation by 37.2%. The test results for DCB and 
isoxaben individually at concentration of 100 uM showed 31.8% and 68.8% 
respectively for the conversion of trophozoites into cysts. In addition, a similar 
concentration of both DCB and isoxaben was evaluated for protocyst formation 
and the inhibition was observed at 36.9% for DCB and a much higher rate of 
protocysts production was recorded at 63 % for isoxaben. The combination of 
both isoxaben and DCB at a concentration of 100 µM caused a reduction in 
encystment to 49.1% and lowered the transformation of trophozoites into 
protocysts to 45.7%, these findings suggested that an antagonistic effect was 
occurred relative to the use of DCB alone. Finally, the data from LC/MS analysis 
for sugars suggested that the protocyst and cyst are different stages of 
Acanthamoeba, as the analysis of cyst walls indicated the presence of cellulose 
while the protocyst wall analysis showed the existing of cellulose and methylated 
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1. Chapter 1: Introduction  
 
1.1  Background 
Acanthamoeba is a genus of free-living amoeba which is an opportunistic 
protozoan pathogen in humans. There are two distinct stages of the life cycle of 
Acanthamoeba: the vegetative, replicating and feeding stage, known as a 
trophozoite, and the dormant stage, known as a cyst. Acanthamoeba Keratitis 
(AK) is a severe, sight-threatening disease which potentially causes a blinding 
infection of the corneal tissue. An association between AK and the wearing of 
contact lenses has been identified and such wearers account for up to 90% of 
recorded cases (Carnt et al., 2018). There are several reasons for the problems 
caused by contact lenses, including lens hygiene practices, exposure to water 
(Joslin et al., 2007), types of lens-care solutions (Verani et al., 2009), showering 
while wearing lenses (Carnt and Stapleton, 2016), the frequency with which 
lenses are changed (Chalmers et al., 2007). Non-contact lens users can also 
become infected with AK, but this is often related to an injury of the corneal 
epithelium (Garg et al., 2017). 
Acanthamoeba reaches the eye either through contaminated water or on contact 
lenses and it starts to kill target cells in a contact-dependent process. There are 
two stages in corneal infections caused by Acanthamoeba. Firstly, the 
trophozoite adheres to the corneal epithelium mediated by a mannose binding 
protein (MBP) and in this primary step of adherence, mannosylated glycoproteins 
stimulate the liberation of a 133 kDa protein termed as the mannose-induced 
protease 133 (MIP-133) cysts (Hurt et al., 2003). Secondly, the serine protease 
MIP-133 causes apoptosis of the corneal epithelial cells via a cytosolic 
phospholipase A2α pathway, which enables trophozoite penetration into the 
corneal stroma and leads to extensive damage of the collagen matrix and causes 
inflammation (Niederkorn et al., 1999). The tear fluid formed by the lacrimal 
system, together with constant eye lid movement, provides the key line of defence 
against AK infection as the human tear has IgA antibodies that inhibit the 
adhesion of the MBP in the trophozoite to the corneal epithelial cells (Panjwani, 
2010). The mechanism of defence for IgA is the interface with (Fcα) receptors of 




inflammation and elimination of the Acanthamoeba. Supporting data for this 
mechanism, it has been shown that the rabbit anti-Acanthamoeba IgA antibody 
has improved the neutrophil-mediated eradicating the trophozoites in vitro (Said 
et al., 2004). The tear film is primarily composed of lysozyme, lactoferrin, b-lysins, 
immunoglobulin A (IgA) and other compounds with antimicrobial and 
immunological properties (Qu and Lehrer, 1998). The levels of IgA are reduced 
in patients with AK and the anti-amoebic IgA plays an important role in the 
prevention of AK infection (Walochnik et al., 2001). This is raised the possibility 
that IgA is an essential protective factor against Acanthamoeba infection at the 
corneal surface. In addition to the IgA prevention mechanism for the binding of 
Acanthamoeba trophozoites to epithelial cells, other IgA defence mechanisms 
have been identified including complement activation (Stewart et al., 1992), 
opsonisation (Said et al., 2002) and increase in neutrophil killing (Stewart et al., 
1994).  
A few of the immune mechanisms involved in corneal defence against 
Acanthamoeba. The conjunctiva is extremely vascular with lymphoid tissue and 
comprises mainly of IgA-generating plasma cells, T-lymphocytes, natural killer 
cells and macrophages, that have a high influence on the removal of 
Acanthamoeba and induce the response of humoral and T-cells (Khan, 2006). 
The tears comprise a complement made up of serum-borne molecules in a 
cascade-like manner. Acanthamoeba has been shown to directly activate the 
complement system through a substitute pathway. However, Acanthamoeba is 
resistant to complement-mediated lysis due to the expression of complement 
regulatory proteins, along with the decay accelerated factor (Khan, 2009b). 
Moreover, the regulatory complement proteins are produced in corneal cells and 
exist in tears, so the stimulation of the complement system has slight to no impact 
on AK resistance (Akpek and Gottsch, 2003). The Acanthamoeba genus is the 
aetiologic agent of a vision-threatening infectious disease that affects the human 
cornea known as Acanthamoeba Keratitis (AK). The increasing incidence of AK, 
which occurs mainly in immunocompetent individuals, is a public health problem 
with serious consequences for vision in view of the absence of a standard therapy 
and the complexity of the prognosis of the disease (Carvalho et al., 2009). The 




medical treatment involves the topical administration of polyhexamethylene 
biguanide (PHMB) or chlorhexidine at concentration of 0.02% (v/v) as 
monotherapy or in combination with diamidines (Papa et al., 2020).  
1.2  The discovery of Acanthamoeba  
Historically, Acanthamoeba research started with a work by Count Aldo 
Castellani in the 1930s, who detected Acanthamoeba as a contaminant in the 
culture of the yeast Cryptococcus pararoseus (Castellani, 1930). It is only after 
the work of this scientist that the amoeba was determined to have a diameter of 
13.5 to 22.5 μm and the cyst form showed a double wall with an average diameter 
of between 9 –12 μm. Based on these characteristics, it was placed in the genus 
Hartmannella and named Hartmannella castellanii in recognition of Aldo 
Castellani (Douglas, 1930). Around 3 decades later, Clyde Culbertson and 
colleagues discovered a contamination in a monkey kidney cell line whilst 
developing a polio vaccine (Culbertson et al., 1959, Culbertson et al., 1958). The 
existence of plaques on these cells led the researchers to believe that the 
contaminant was viral. However, when mice and monkeys were injected with 
these contaminates, they quickly died from fatal meningoencephalitis 
(Culbertson, 1971). Subsequently, the causative agent and contaminant was 
identified as Acanthamoeba and this was the first time that the free-living amoeba 
Acanthamoeba had been shown to be pathogenic. The strain was later termed 
Acanthamoeba culbertsoni (Singh and Das, 1970). The finding that 
Acanthamoeba spp. can cause disease in animals suggested that it could also 
be pathogenic to humans. The first recorded case of human infection related to 
Acanthamoeba spp. was in a patient with Hodgkin’s disease (HK) who developed 
granulomatous amoebic encephalitis (GAE) (Jager and Stamm, 1972). HK is a 
kind of lymphoma, which is a blood cancer that begins in the lymphatic system 
(Banerjee, 2011). The potential cause of HK patients being infected with GAE is 
related to their poor immune system (Bentivoglio et al., 2014).    
1.3  Classification of Acanthamoeba 
The genus Acanthamoeba was placed in the order of Amoebida, but it is now 
classified within the order of Centramoebida to differentiate it from 
Theacamoebida, the suborder Acanthapodina, and the family Acanthamoebidae. 




1975, the family Acanthamoebidae was first proposed and included the spiny or 
thread-like pseudopod-forming, slug-like amoebas that can form smooth, 
spherical cysts (Sawyer and Griffin, 1975). It was established that the 
Acanthamoeba species can be divided into three morphological groups, I, II and 
III, based on the size and shape of the cysts (Pussard and Pons, 1977). Group I 
of the Acanthamoeba species is designated on the basis of it having a large cyst. 
Group II is characterized as having a wrinkled ectocyst and an endocyst. Group 
III has a smooth endocyst and a rounded ectocyst (Pussard and Pons, 1977). 
However, this method of classification according to the morphology of the cyst 
has since been found to be uncertain, due to the fact that culture conditions can 
affect the morphology of the cyst (Stratford and Griffiths, 1978).  
Genetic typing based on 18S ribosomal RNA genes has been used to classify 
the Acanthamoeba into sequence groups from T1-T12 regarding human 
diseases associated. 18S ribosomal RNA is the structural RNA of a small 
component of the eukaryotic cytoplasmic ribosome, such that Group I includes 
sequence types T7, T8, T9, Group II includes sequence types T3, T4, T11, and 
Group III includes sequence types T1, T2, T5, T6, T10, and T12. So far, the genus 
Acanthamoeba has been classified into 15 different genotypes from T1 to T15, 
based on rRNA sequences  (Schuster and Visvesvara, 2004a). On the other 
hand, around 20 genotypes have been identified (T1–T20) according to the 
analysis of the ribosomal DNA (rDNA) gene of Acanthamoeba (Corsaro et al., 
2015). One year later, another genetic study identified two more genotypes 
induced T21 and T22 of Acanthamoeba through an analysis rDNA sequences 
(Tice et al., 2016). Prior investigations in the UK and Iran have looked at the 
genotype of AK isolates and it has been found that the highest numbers come 
from the T4 group (70.8%), whereas smaller numbers are from T2 (12.5%), T3 
(12.5%), and T11 (4.1%) (Maghsood et al., 2005). In addition, the same authors 
have proposed that the T2 genotype should be sub-divided into two groups, T2a 
and T2b, because of a sequence variation of 4.9% between these two groups 
























1.4  The life cycle of Acanthamoeba  
Most of the studies in the scientific literature have suggested that there are only 
two distinct stages in the lifecycle of Acanthamoeba, namely the trophozoite, 
which is the motile form and the double layered, dormant, mature cyst form 
(Siddiqui et al., 2012, Marciano-Cabral and Cabral, 2003). The cyst stage of the 
organism is only produced under adverse conditions while the trophozoite stage 
form when the conditions become favourable. However, there is another possible 
stage of Acanthamoeba known as a pseudocyst/protocyst, The protocysts are 
extremely resistant to the detergent lysis and they took less than 1 hour to form, 
in contrast with cysts which take more than 24 hours to form. Moreover, 
protocysts could not mature into cysts unless they were first transformed into 















Figure1-1:Classification scheme of Protist, based largely on morphological 

















1.4.1  The trophozoite stage of Acanthamoeba 
The term ‘acanth’ (a Greek word meaning “thorns”) was added to amoeba 
because of the existence of spine-like structures on the surface of trophozoites. 
These are now known as acanthopodia (as can be seen in Figure 1.3) and they 
are very important for adhesion to surfaces on hosts and for movement (Bowers 
and and Korn, 1973). The trophozoite is the vegetative stage of the 
Acanthamoeba in which the amoeba reproduces by binary fission (Martinez, 
1996). Under the inverted light microscopy, the trophozoite appears as an 
irregular, amoeboid-shaped organism and ranges in size between 20 and 45 μm. 
The trophozoites of Acanthamoeba possess a single nucleus with a nucleolus, 
abundant cytoplasm with multiple elongated mitochondria, lysosomes, 
endoplasmic reticulum, ribosomes, Golgi apparatus and vacuoles (Bowers and 
Korn, 1968, Martinez and Visvesvara, 1997). The main food source for 
Acanthamoeba is bacteria (Weekers et al., 1993). Acanthamoeba feed through 
the creation of a temporary structure named a food cup. The food cup is part of 
the cell wall and is expected out to grab bacteria, yeast and cellular debris (Pettit 
et al., 1996).  
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Cyst Stage Potential  3
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Acanthamoeba uses two distinct pathways to take up food: a nonspecific pathway 
called pinocytosis for the uptake of soluble material and another, highly-specific, 
receptor-mediated pathway called phagocytosis (Chambers and Thompson, 
1976). The pathogenic strains of Acanthamoeba have been shown to bind to 
target cells by using a greater number of acanthapodia structures. It has also 
been pointed out that the phagocytosis process in Acanthamoeba occurs through 
the formation of amoebastome, which is a characteristic of the Acanthamoeba 
phagocyte (Khan, 2001). The trophozoite is characterized by the existence of a 
large contractile vacuole, as illustrated in Figure 1.3 above, which periodically 
expels and then refills with water for the cell, and possibly excretes waste 
(Bowers and Korn, 1973). The force required to contract the vacuole is created 
by myosin which is used to regulate the water content of the cell. The contractile 
vacuole absorbs water by osmosis from the cytoplasm and moves to the surface 
of the cell when full and undergoes exocytosis (Doberstein et al., 1993).  
Figure1-3: The trophozoite stage of Acanthamoeba castellanii (ATCC 50370) 
with clear contractile vacuole (yellow arrows) and acanthopodia (red arrows). 




1.4.2  The cyst stage of Acanthamoeba 
The cyst is the dormant stage of Acanthamoeba and forms when the organism 
encounters unfavourable conditions, such as hyper- osmolarity (Cordingley et al., 
1996), heat cold desiccation and cysts can lay dormant for several years until 
food becomes available (Heaselgrave and Kilvington, 2016, Neff et al., 1964). 
The cyst is smaller than the trophozoite at about 12-20 μm in diameter, depending 
on the species, and under transmission electron microscopy, a thick cyst wall can 
be observed consisting of two distinct layers: the endocyst and the ectocyst. In 
the cytoplasm, the nucleus appears as a rounded structure which is black in 
colour with a nucleolus and the mitochondria is also visible as shown in Figure 
1.4. A & B. Furthermore, the most common holes to appear on the surface of the 
cyst wall are called ostioles. The excystment process occurs through these 
ostioles after digestion of the opercula covering the ostioles and they are also 
























Figure1-4:Morphology of Acanthamoeba castellanii (ATCC 50370) mature cysts. 
A) Non-Nutrient Agar (NNA) mature cyst with a double-walled viewed under 
phase contrast light microscopy at magnification x1000. (B) Transmission 
electron microscopy showing the double-walled of Neff’s mature cyst with 
ectocyst (Ec), endocysts (En), nucleus (NS), nucleolus (NU) and mitochondria 




The ectocyst has an irregular surface and by utilising quick-freeze, fracture/deep 
etching with TEM imaging, it has been shown that the endocyst is thinner and 
more fibrillar than the ectocyst (Lemgruber et al., 2010). The reasons for 
encystment have not been fully clarified. However, a cyst-specific proteins 21 kDa 
and 70 KDa in size, have been identified which are not found in the trophozoite 
stage of Acanthamoeba. This specific proteins are purified from guanidine-HCl 
extract in the cyst wall and has been shown to be hydrophilic and the expression 
of a cyst-specific protein is restricted to the early stages of encystment (Hirukawa 
et al., 1998, Rubin et al., 1976), suggesting that the biosynthesis of cyst-specific 
proteins 21 and 70 KDa are regulated at the mRNA level. Acanthamoeba cysts 
are extremely resistant to harsh environmental conditions and chemical 
disinfection due of the presence of the thick cyst wall. Previously, a soft 
multipurpose solution of MeniCare has been tested against cysts and it showed 
more than a 3-log reduction against the cysts of Acanthamoeba after 6 hours of 
exposure (Heaselgrave et al., 2010). Also, a hydrogen peroxide solution at a 
concentration of 7.5% with 30 minutes exposure has been shown to have only 
limited activity against different strains of Acanthamoeba isolated from river water 
and from a hospital water network (Coulon et al., 2010). 
It has been previously demonstrated that the effect of different agents on 
Acanthamoeba cysts is dependent on the production method of the cysts and the 
age of the tested strain. PHMB at a concentration of 3 µg/mL achieved a 3 to 4 
log kill against Neff’s and non-nutrient agar (NNA) cysts of  Acanthamoeba 
polyphaga (Ros-91 strain) after 6 hours of exposure, while the cysts from another 
tested strain, Ros-02 of A. polyphaga, were found to be more resistant to PHMB 
at the same concentration and exposure time, giving a 0.3 log kill for Neff’s cysts 
and 1.2 log kill against NNA cysts (Hughes et al., 2003b). Myristamidopropyl 
dimethylamine (MAPD) has been tested at a concentration of 20 µg/mL and 
exhibited activity over 6 hours between a 2.8 and 4 log reduction against Neff’s 
cysts and NNA cysts of A. polyphaga Ros-91 strain. The activity of MAPD 
improved against NNA and Neff’s cyst of A. polyphaga Ros-02 strain, ranging 




1.4.3  The discovery of Acanthamoeba pseudocyst/protocyst  
Latest outbreak of AK among contact lens users in the United States resulted to 
the withdrawal of the Complete Moisture-Plus® contact-lens solution from the 
market for concerns regarding its contamination with Acanthamoeba (Verani et 
al., 2009). Attempts were made to develop new products for the disinfection of 
contact lenses (Kilvington et al., 2008).  During the development of such products, 
an unusual, immature protocyst was observed with a single cell wall, see Figure 
1.5 (Kilvington et al., 2008). Earlier research into amoeba found that they contain 
a range of carbohydrate polymers. For example, Acanthamoeba and Balamuthia 
cysts contain cellulose (a carbohydrate polymer) (Lemgruber et al., 2010), whilst 
Entamoeba has been found to contain chitin and Giardia has N-
acetylglucosamine (Samuelson and Robbins, 2011). There is a clear difference 
in morphology between mature cysts and protocysts of Acanthamoeba: the 
protocyst consists of a single cell wall which provides an effective barrier against 














Figure1-5:Shows the immature protocyst with a single cell wall  (yellow arrow) of 
Acanthamoeba castellanii (ATCC 50370), viewed under light phase contrast 




1.5  Distribution of Acanthamoeba  
Acanthamoeba has been isolated from a wide variety of environmental sources 
and represents a sanitary risk for public health, particularly for contact lens users 
and immunocompromised patients (Rezaeian et al., 2008). It has been isolated 
from  bathroom and kitchen sinks (Carnt et al., 2020a) and has also been found 
in a variety of sources including soil, different types of water, dust, hospital units 
and ventilation areas (Schuster and Visvesvara, 2004a), air samples, laboratory 
eyewash stations and bacteria or cell culture media (Astorga et al., 2011). 
Furthermore, Acanthamoeba has been isolated from seawater, chlorinated 
swimming pools, domestic tap water, bottled water, dental treatment units (De 
Jonckheere, 1991).  The distribution of Acanthamoeba is not restricted only to 
water environments, as Acanthamoeba was found to exist in air samples from 
urban sites in a city in Mexico, with approximately 40% posing a potential 
pathogenic health risk (Rodriguez-Zaragoza and Magana-Becerra, 1997). 
Acanthamoeba has been isolated from the tap water of the homes over the 
seasons, and the findings showed that 29.6% the total of isolates during the 
summer and the percentage slightly decreased to 27.9% of the total isolates over 
the winter (Carnt et al., 2020b).  
1.6  Adrenergic receptors and Acanthamoeba encystment 
The adrenergic receptors are broadly classified into two categories included α 
and β types and they are further subdivided into 1 and 2 subtypes with their 
agonists and antagonists as presented in Table 1.1. There are numerous 
research studies concerning the ways in which Acanthamoeba senses and 
responds to environmental changes and also the signalling pathways involved in 
the encystment of Acanthamoeba. It was showed that the encystment process of 
Acanthamoeba can be mediated through catecholamines (Heaselgrave and 
Kilvington, 2016). The authors initially tested different concentrations of 
adrenoceptor agonists including epinephrine (5 mM),  isoproterenol (1mM) and 
the selective β₁ adrenoceptor agonist dobutamine (100 µM) which were found to 
produce levels of encystment of 93.2%, 92% and 92.4% respectively. When the 
selective β₂ agonist salbutamol was tested at a lower concentration of 10 µM, the 




salbutamol caused massive lysis of Acanthamoeba trophozoites at higher 
concentrations.  
Testing of the α/β nonspecific agonist epinephrine on its own at a concentration 
of 5 mM showed a higher level of encystment at 93.2%. In contrast, the 
encystment process was blocked when the selective β₁ antagonist metoprolol 
was combined with epinephrine at a concentration of 500 µM, giving only 18.8% 
encystment. The same study investigated the effect of different antagonists, 
including the non-selective β alprenolol, the non-selective α phentolamine and β₂ 
propranolol in the presence of 500 µM of epinephrine. The outcomes showed that 
α phentolamine had no effect on the encystment of Acanthamoeba, whereas β, 
β₂ antagonists alprenolol and propranolol reduced the encystment level to around 
30% (Heaselgrave and Kilvington, 2016). An earlier study by Coppi et al. (2002) 
showed that the trophozoites of Entamoeba release and respond to 
catecholamine when it triggers encystment. Using agonists and antagonists to 
induce encystment in Entamoeba was found to be in line with the existence of a 
receptor with the ligand specificities of the β₁ adrenoreceptor in mammalian cells. 
However, the α adrenoreceptor ligands were observed to have no effect on the 





Table 1-1: Types of adrenergic receptors and their agonists and antagonists 
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1.7  Anatomy of the human eye 
The human eye is composed of an anterior (front) segment and a posterior (back) 
segment. The front section consists of the cornea, iris and lens as illustrated in 
Figure 1.6.A (Oyster, 1999). The cornea is made up of six layers: the epithelium, 
Bowman’s layer, the stroma, Dua’s layer, Descemet’s membrane and the 























Figure1-6:The anatomy and the main components of the human eye. (A) The 
anterior section consists mainly of the cornea, iris, pupil, conjunctiva and the lens, 
the posterior section comprises of sclera, choroid and the retina. The source for 
image is Barar et al. (2009). (B) The cornea is composed of six layers. Image 







The epithelium is composed of 5–7 layers of epithelial cells connected with tight 
junctions. The epithelium layer is the major barrier which limits the rate of corneal 
penetration for most topical drugs, although lipophilic compounds have a 
tendency to penetrate the epithelium layer more easily than hydrophilic 
compounds (Prausnitz and Noonan, 1998). The reason for this difference is 
related to the corneal epithelium as it facilitates the absorption of lipophilic 
compounds (Davies et al., 2013). The stroma layer is located between the 
epithelium and the endothelium and accounts for about 90% of corneal thickness 
(Meek and Knupp, 2015). It predominantly consists of hydrated collagen fibrils 
that form a barrier which diffuses the penetration of lipophilic drugs. The stroma 
also aids in repairing damaged cells (Khan and Siddiqui, 2009). The corneal 
stroma is not structurally homogeneous throughout its depth and there is a 
difference between the anterior and posterior stroma. For example, the posterior 
stroma is more hydrated and susceptible to swelling than the anterior stroma 
(Freund et al., 1995).  
1.8  Pathogenicity of Acanthamoeba  
Pathogenic mechanisms were found most often in the strain of Acanthamoeba 
associated with AK rather than in those associated with encephalitis of the brain. 
The pathogenesis of infection and the biochemical determinants of virulence are 
poorly understood. However, the growth rate, adherence properties, cytolytic 
products formed by amebae, and immune evasion mechanisms seem to 
constitute the key factors in the pathogenicity of Acanthamoeba (Marciano-
Cabral and Cabral, 2003). The virulence factors in Acanthamoeba may be related 
to the distinct physiological characteristics of the strain rather than depending on 
suitable environmental conditions (Walochnik et al., 2000). It has been shown 
that the glycolipids of corneal epithelium react with Acanthamoeba and could also 
play an important role in the pathogenesis of AK. This occurs through mediation 
of the adherence of the amebae to the cornea (Panjwani et al., 1992). The 
adhesion molecule, which is distinct from the 136-kDa mannose-binding protein 
(MBP), plays a key role in the attachment of amebae to the host cells (Kennett et 
al., 1999). In vitro studies have used human epithelial cells, stromal keratocytes, 
and stromal cell homogenates as models of AK. Based on such studies, it is 




and via cytotoxic substances which are released by the Acanthamoeba (Stopak 
et al., 1991).  
 
Figure1-7: Showing the pathogenic steps of AK. Step (1) The trophozoites of 
Acanthamoeba attach to mannosylated glycoproteins, which are involved in the 
regulation on corneal epithelium in response to corneal abrasion. Step (2) 
Mannose exposure induces trophozoites of Acanthamoeba to release MIP133. 
Step (3) Trophozoites destroy Bowman's membrane and penetrate the 
collagenous stroma. Step (4) Trophozoites continue producing a number of 
proteases that contribute to the dissolution of the corneal stroma. Step (5) 
Trophozoites frequently clumps around corneal nerves, generating radial 
keratoneuritis and severe pain. Final step (6) AK very seldom progresses beyond 
the corneal endothelium to cause intraocular diseases. The source of image is 
Clarke and Niederkorn (2006). 
The pathogenesis of Acanthamoeba is extremely complex and involves 
numerous factors working together to produce the disease. The sequence of 
stages of infection for AK starts with penetration of the surface of the epithelium 
and keratocyte depletion by Acanthamoeba. Following this, the amoeba creates 
stromal necrosis and induces an intense inflammatory response (Vemuganti et 
al., 2004, Garner, 1993). Several studies have revealed that the majority of 




et al., 1998, Walochnik et al., 2000). It is still unclear why the Acanthamoeba T4 
genotype is the most abundant in human disease. However, it has been proposed 
that the main reasons for Acanthamoeba T4 isolates being linked with human 
infections are their greater virulence factors which improve their transmissibility 
and their reduced susceptibility to chemotherapeutic agents (Maghsood et al., 
2005). Many species of the genus Acanthamoeba have been linked with AK 
infection. According to the classification scheme provided in Table 1.2, most 
human infections are associated with isolates of the T4 genotype. For example, 
over 90% of keratitis disease has been associated with the T4 genotype. 
Similarly, T4 has been the main genotype linked with the disease encephalitis 
(Siddiqui et al., 2012). 
Table 1-2: Classification of Acanthamoeba genotypes based on the rRNA 
sequences and their links with human diseases. The table is redrawn from (Khan, 
2006). 
Acanthamoeba genotypes Human disease association 
T1 Acanthamoeba encephalitis 
T2a Acanthamoeba Keratitis & encephalitis 
T2b No disease association 
T3 Acanthamoeba Keratitis 
T4 Acanthamoeba Keratitis & encephalitis 
T5 Acanthamoeba Keratitis 
T6 Acanthamoeba Keratitis 
T7 No disease association 
T8 No disease association 
T9 No disease association 
T10 Acanthamoeba encephalitis 
T11 Acanthamoeba Keratitis  
T12 Acanthamoeba encephalitis 
T13 No disease association 
T14 No disease association 





1.9  Granulomatous amoebic encephalitis (GAE) 
Acanthamoeba is one of the causative agents of granulomatous amoebic 
encephalitis (GAE) which is a chronic disease of the central nervous system 
(CNS). GAE is an uncommon and often fatal infection, found most commonly in 
immunocompromised or severely debilitated individuals and this is the possible 
reason why a patient infected with Acanthamoeba Keratitis does not get GAE. 
The clinical symptoms for GAE include headache, fever, behavioural changes, 
aphasia, ataxia, vomiting, and seizures (Harwood et al., 1988, Kernohan et al., 
1960). GAE was first observed in 1972 (Jager and Stamm, 1972), and the term 
granulomatous amoebic encephalitis (GAE) was proposed 8 years later to 
describe the histopathological features of the disease (Martínez et al., 1980).   
GAE is uncommon, subacute, necrotising infection most commonly caused by A. 
castellanii, A. culbertsoni, or A. polyphaga and the related amoeba Balamuthia 
mandrillaris (Jayasekera et al., 2004). Other factors that can cause GAE include 
chemotherapy, steroid treatment, alcoholism, radiation therapy, systemic lupus, 
acquired immune deficiency syndrome (AIDS), and haematological disorders 
(Martinez and Visvesvara, 1997). GAE is different to primary amoebic 
meningoencephalitis (PAM), which is caused by an amoeba called Naegleria 
fowleria. This amoeba enters the brain in two stages. Firstly, the aspiration of 
contaminated water into the nasal cavity causes the entry of the amebae. 
Secondly, the amoeba penetrates the nasal epithelium and then moves up the 
olfactory nerve tracts to the brain (Schuster and Visvesvara, 2004a). A longer 
incubation period, ranging from weeks to months, has been recorded with GAE 
infection which differs from Naegleria infection (Schuster and Visvesvara, 2004a). 
The primary routes for Acanthamoeba to enter the body are through broken skin, 
the lower respiratory tract or the genito-urinary tract and it then moves around the 
body in the blood stream before reaching the CNS through hematogenous spread 























There is no evidence exists of the mechanisms used by Acanthamoeba to cross 
the blood barrier in humans. However, Acanthamoeba secretes a serine protease 
enzyme which leads to an increase of 45% in the permeability of the blood barrier 
and results in the breakdown of microvascular endothelial cells (Alsam et al., 
2005). It has been reported that the non-pathogenic Acanthamoeba lacks serine 
protease and is unable to exert a cytopathic effect on in vitro cell cultures (Khan 
et al., 2000).  
1.10  Acanthamoeba Keratitis (AK) 
AK infections are mainly associated with wearing of contact lenses. Patients 
infected with AK may suffering from a range of symptoms included pain with 
photophobia, epithelial defects and ring-like stromal infiltrates as shown in Figure 
1.9 below (Illingworth et al., 1995, Lindsay et al., 2007, Graff et al., 2006). The 
appearance of a ring infiltrate inside the cornea, thought to be made up of 
infiltrating inflammatory cells such as macrophages/neutrophils in response to the 
 
Step-1: Acanthamoeba inter the 
nasal and then moved to the lungs  
Step-2: Lung colonization   
Step-3: Lung penetration 
Step-4: Dissemination
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Step-5: Penetration of BBB
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Figure1-8: Diagram presenting the Acanthamoeba granulomatous encephalitis 
infection, Acanthamoeba may use several routes to enter the human body, 
including the nasal route into the lungs followed by an invasion of the bloodstream 
leading to haematogenous spread. The entry of the amoebae into the CNS most 
likely occurs at the site of the blood-brain barrier (BBB). The olfactory nerve may 
provide an alternative route of entry into the central nervous system. The diagram 





Acanthamoeba infection (Marciano-Cabral and Cabral, 2003). AK is associated 
with pain due to the fact that Acanthamoeba has a specific affinity to the nerve 
tissue and thus induces inflammation of the nerves in the cornea and hence pain. 
Several studies in the medical literature have revealed that if AK is not identified 
at an early stage and not treated adequately and aggressively, it may lead to loss 
of vision (Marciano-Cabral and Cabral, 2003, da Rocha-Azevedo et al., 2009, 
Visvesvara et al., 2007, Visvesvara, 2010). Acanthamoeba strains isolated from 
patients with severe AK secrete proteolytic enzymes of serine-like proteases. 
When the trophozoites reaches the corneal epithelium, two enzymes, gelatinases 
and collagenases, could be implicated in the activation of pathogenic cascades 
and subsequent digestion of the collagenous corneal stroma (de Souza Carvalho 
et al., 2011).  AK patients suffer severe eye pain which is thought to be associated 
with radial keratoneuritis and the trophozoites found along the corneal nerves 
lead to a thickening and distortion of these nerves (Yu et al., 2004). Subsequent 
stages of the infection can result in epithelial denudation, stromal necrosis 
(Rocha-Azevedo et al., 2009), nerve oedema and retinal detachment and if 
misdiagnosed or if a delay in treatment occurs, the infection will almost certainly 












Figure1-9: Clinical characteristics of Acanthamoeba Keratitis. A) Normal human 
eye, the image taken from(Online Science Notes, 2018). B) The white ring infiltrate 
(white arrow) can be seen within the central section of the cornea. The source of 




1.10.1  Acanthamoeba Keratitis and the immune response  
In spite of the widespread prevalence of Acanthamoeba in a variety of 
environments, the rate of infection related to AK persisted very low. This is based 
on the fact that Acanthamoeba are opportunistic pathogens, and their ability to 
produce diseases relies on the sensitivity of the host, environmental conditions 
and their own virulence (Khan, 2006). The antibodies in the serum do not protect 
against eye infection and inoculation of Acanthamoeba into the eye does not 
generate an adaptive immune response. The immune privilege of the cornea is 
partly due to the extraordinary lack of resident antigen cells in the central of the 
corneal epithelium. The peripheral antigen cells, called Langerhans cells (LC), 
can be provoked to move to the central of the cornea. The existence of LC in the 
cornea prior to the Acanthamoeba trophozoites infection has robbed the cornea 
of its immune privilege and has led to the production of delayed-type 
hypersensitivity (DTH) or serum IgG antibody responses (Klink et al., 1997). The 
failure of corneal infections with Acanthamoeba trophozoites to stimulate an 
adaptive immune response is correlated with the immune privileged nature of the 
eye (Klink et al., 1997). The trophozoites recognised by Toll-like receptor-4 
(TLR4), which begins the nuclear factor kappa B (NF-kB) and the MAPK/ERK 
pathways, and this contributes to the production of pro-inflammatory and 
chemotactic mediators such as interleukin 8 (IL-8) and tumor necrosis factor 
alpha (TNF-α), and interferon- β (IFN-β) and these mediators have no direct anti-
amoebic activity on killing trophozoites  (Ren et al., 2010, Alizadeh et al., 2014). 
Eye-derived immunological tolerance is termed anterior chamber-associated 
immune deviation (ACAID) and refers to a phenomenon in which antigen-specific 
systemic immunological tolerance is induced by an antigen that has been 
introduced to the anterior chamber of the eyes (Streilein, 2003). ACAID is an 
adaptive immune response and once the trophozoites of Acanthamoeba are 
attached to the corneal epithelium, ACAID does not produce a response to 
protect against AK infection. In the corneal transplant, the ACAID had a positive 
impact on the survival of the corneal allograft in the mice model and blocking of 
the ACAID by the destruction of the camero-splenic axis in mice resulted in an 
increase in the risk of corneal allotransplant refusal (Niederkorn and Mellon, 




specific downregulation of T-helper 1 immune responses (Niederkorn, 2006). It 
has been revealed that components of the adaptive immune response include 
complement fixing antibodies, which are unable to kill the trophozoites and cysts 
of Acanthamoeba (Clarke and Niederkorn, 2006). On the other hand, the use of 
killed trophozoites in mucosal immunisation trigger the production of IgA 
antibodies secreted in tears that prevent the adhesion of trophozoites to the 
epithelium layer. However, if immunisation is performed after trophozoites have 
penetrated the cornea, no activity against AK infection occurs (Clarke and 
Niederkorn, 2006). 
Macrophages and neutrophils are an innate immune response found in the 
tissues surrounding amoebic trophozoites and cysts, with macrophages capable 
of phagocytosis and killing Acanthamoeba cysts and trophozoites by inducing an 
inflammatory response, in particular secretion of macrophage inflammatory 
protein 2 (MIP-2) and leading to inflammation (Hurt et al., 2003, Marciano‑Cabral 
and Toney, 1998). Treatment with anti-Acanthamoeba antibodies increases the 
amoebicidal activity of activated macrophages, most likely by increasing immune 
recognition (Marciano‑Cabral and Toney, 1998). Inhibition of the conjunctival 
macrophage population was found to lead to an exacerbation in the severity and 
duration of AK infection in Chinese hamster models (van Klink et al., 1996). These 
findings highlight the role of macrophages in the defence against Acanthamoeba. 
However, macrophages are limited in their ability to kill trophozoites and this is 
likely due to the interactions of macrophage with trophozoites are not 
unidirectional. Furthermore, neutrophils can eradicate Acanthamoeba cysts and 
trophozoites by a myeloperoxidase-dependent mechanism and it has been 
shown that neutrophils are more effective than macrophages in the eradication 
of cysts (Alizadeh et al., 2002).  
1.10.2  Diagnosis methods for Acanthamoeba Keratitis 
Different methods are currently used for the diagnosis of AK. Microbiological 
culture is one of the best-known methods used to identify Acanthamoeba. This 
approach involves placing a culture of corneal scrapings from patients suspected 
of having AK on a non-nutrient agar plate seeded with a lawn of live Escherichia 
coli to allow for the observation of motile trophozoites. However, the major 




2006) and the long incubation period which often causes a delay in the diagnosis 
of AK (Bharathi et al., 2006). The use of quantitative polymerase chain reaction 
(qPCR) as a diagnostic tool has increased over the last two decades and the 
majority of more recent studies have used this technique for the diagnosis of AK 
due it is sensitivity, which ranges from 77% to 88% (Goh et al., 2018, Mathers et 
al., 2000, Pasricha et al., 2003). Moreover, PCR testing is faster and more 
sensitive than cultures, often returning a result within days instead of weeks, but 
similar to cultures, false negative results and misdiagnoses can occur. In vivo 
confocal microscopy (IVCM) is a clinical diagnostic method which is often used 
for diagnosing AK, as it has shown higher sensitivity values, ranging between 56 
and100 % (Chidambaram et al., 2016, Hau et al., 2010, Tu et al., 2008, Kanavi 
et al., 2007).  
The main advantages of IVCM are that it is non-invasive and gives a rapid 
diagnosis, but the major shortcomings are the potential difficulties in 
distinguishing pathogenic organisms from host cells, and diagnostic accuracy 
depends on the experience of the investigator (Hau et al., 2010). Formerly, three 
distinct methods were utilized to diagnose AK in patients: microscopy, a culture 
of corneal scrapings and qPCR. Outcomes indicated that qPCR is the most 
analytically-sound method, with a sensitivity of 89.3% compared to microscopy 
and corneal scrapings which had a sensitivity value of 21.8% (Khairnar et al., 
2011). A delay in the diagnosis of AK of less than 18 days between the onset of 
symptoms and the start of anti-amoebic treatment results in improved visual 
acuity and eliminates the need for urgent penetrating keratoplasty (Claerhout et 
al., 2004).  
1.10.3  Risk factors of Acanthamoeba Keratitis 
Most cases of AK are related to poor hygiene and improper handling of contact 
lenses, in addition to other risk factors (Herz et al., 2008, Khan, 2006). In contact 
lens wearers, more than 85% of AK cases are associated with individual 
behaviours. AK has been observed more often in young males compared to other 
users of contact lenses, which might be due to poor personal hygiene, inadequate 
handling and care of their lenses or lens storage cases (Niederkorn et al., 1999). 
Several factors associated with AK infection, including swimming or showering 




cleaning contact lenses and failing to wash hands before handling (Carnt et al., 
2018). Furthermore, the type of lens could generate risk factors for AK, It has 
been reported that the use of silicone hydrogel contact lenses while swimming in 
a home pool and with an inability to clean contact lenses with an appropriate 
disinfection solution has resulted in an infection of Acanthamoeba (Stapleton et 
al., 2009).  
1.11  Acanthamoeba act as reservoir for other pathogens   
Acanthamoeba has been shown to harbour Legionella pneumophila, which is 
linked with Legionnaires’ disease (Gast et al., 2011). Legionnaires’ disease is 
significant due its capacity to cause bacteria to persist in Acanthamoeba spp. 
within hot water tanks and within buildings such as hospitals (Muraca et al., 
1990).  Several other pathogens have also been shown to survive intracellularly 
within Acanthamoeba, including Escherichia coli O157, which causes diarrhoea 
(Barker et al., 1999), Vibrio cholera, which causes Cholera (Thom et al., 1992), 
Helicobacter pylori, a causative agent for gastric ulcers (Winiecka-Krusnell et al., 
2002) and Mycobacterium avium, which causes respiratory infections (Steinert et 
al., 1998). These bacterial pathogens do not simply survive intracellularly but they 
multiply within them and this can lead the bacteria to spread throughout the 
environment, evade chemotherapeutic drugs and produce infections (Khan, 
2006).  Acanthamoeba can act as a reservoir for many other pathogens and may 
aid their persistence in the environment. The protection of these other pathogens 
from biocides increases as a result of their intercellular location within 
Acanthamoeba. It has been demonstrated that PHMB produces a 4–log reduction 
in L. pneumophila in 6 hours but there has been shown to be only a 1–log 
reduction for those contained within Acanthamoeba (Barker et al., 1992). It has 
also been demonstrated that, at between 40 and 50C, Acanthamoeba provides 
10–fold resistance while 100-fold resistance is obtained at between 60 – 80C 
(Storey et al., 2004). 
1.12  Adhesion of Acanthamoeba and bacteria on contact lenses 
The worldwide standard ISO 19045 sets out the microbiological requirements and 
testing methods for products as well as procedures for the hygienic administration 




Standardization (ISO) evaluated certain disinfection agents against 
Acanthamoeba spp. and also assessed Acanthamoeba encystment caused by 
contact lens care products (Standardization, 2015). Contact lens cases can be 
considered as a reservoir for different types of gram-positive and negative 
bacteria which can lead to microbial keratitis in contact lens wearers. It has been 
estimated that the level of bacterial contamination in contact lens cases is higher 
than 50% (Wu et al., 2015). A case study was conducted at Moorfields Eye 
Hospital, UK, to assess the risk factors for microbial keratitis (MK) in different 
types of contact lenses and it has been shown that daily disposable contact 
lenses are associated with a higher risk of MK compared to rigid lenses and 
silicone hydrogel lenses with a lower risk of MK (Dart et al., 2008). Pervious in 
vitro study conducted by Dutta and Willcox (2013) showed that the bacterial 
adhesion to contact lenses is associated with a range of conditions, including 
contact lens material, the size of initial inoculum, nutritional content of media and 
the duration of incubation which played a crucial role in the bacterial adhesion to 
two types of contact lenses the hydrogel etafilcon A and silicone hydrogel 
senofilcon A. 
Besides, the chemical and physical characteristics of contact lens material have 
an impact on bacterial adhesion to the lenses as the water content of 
hydroxyethylmethacrylate (HEMA)-based lenses and their iconicity entail in the 
binding of bacteria to contact lenses. The greater numbers of bacteria have been 
correlated with the hydrophobicity of silicone hydrogel lenses in comparison with 
the HEMA-based lenses (Dutta et al., 2012). Acanthamoeba showed greater 
binding in contact lens wearers compared with those who do not wear contact 
lenses. Previously, it was shown that fluorescein isothiocyanate-labelled lectins 
(including mannose, glucose, galactose, N-acetyl-glucosamine, N-
acetylgalactosamine and N-acetyl neuraminic acid) bind to a range of sugars in 
soft contact lenses, see Figure 1.10. It is believed that the difference between 
wearers and non-wearers in terms of Acanthamoeba trophozoite binding is 
related to the presence of these saccharides on the surface of contact lenses 
(Klotz et al., 1987). A potential explanation for the increased binding of 
Acanthamoeba in contact lens wearers is that the molecules could serve as 
receptors for Acanthamoeba trophozoites leading to an increase in the ability of 




















1.13  Cellulose biosynthesis 
Adrenaline can promote the encystment of Acanthamoeba by activation an 
adrenergic receptor and one of the key biochemical processes is the biosynthesis 
of cellulose leading to the formation of the cyst wall. The cellulose biosynthesis 
pathway is found in plants, bacteria and some protists, including Acanthamoeba 
and Balamuthia. Cellulose is believed to be responsible for biocidal resistance in 
Acanthamoeba (Garajová et al., 2019). The cellulose synthesis inhibitors (CSI) 
used in this study are herbicides that target cellulose synthesis in plants. The 2,6-
dichlorobenzonitrile (DCB) is very effective against broadleaf and grass weeds in 
plants of different types, such as Tussilago, Aegopodium, Rumex and Equisetum 
spp. (Beynon and Wright, 1972), ), whereas isoxaben has been used to control 
broadleaf weeds in several species of plants, for instance, speedwell (Veronica 








Trophozoite of Acanthamoeba  
Figure1-10: The adhesion of Acanthamoeba trophozoites and bacteria to the 
surface of the contact lens. Their ability to adhere is increased by presence of 




nettle (Urtica urens L.) (Chandran and Derr, 1998). Cellulose biosynthesis in 
plants occurs in the plasma membrane forming rosettes, which represent a 
transmembrane system Figure 1.11. Cellulose synthase (CESA) protein 
complexes appear to be produced in the Golgi apparatus and then transferred by 
exocytosis to the plasma membrane (Somerville, 2006). The CESA complexes in 
the primary cell wall in the plant Arabidopsis thaliana are combined with three 
types of CESA subunits called CESA1, CESA3 and CESA6 (Persson et al., 
2007). Cellulose cell walls in plants and Acanthamoeba are considered to be 
structural support. Both plants and Acanthamoeba are susceptible to herbicide 
glyphosate [N-(phosphonomethyl) glycine] and this herbicide can kill most of the 
plant species by targeting the Shikimate pathway (Tzin and Galili, 2010). 
Likewise, glyphosate was reported to be capable of inhibiting Acanthamoeba 

















Figure1-11: Diagram showing the cellulose synthase complex for rosette in 
plants. Each subunit acts as segment comprising six CESA proteins which result 
in 36 distinct proteins in the rosette. Isoxaben targets CesA protein (yellow arrow), 
2,6-dichlorobenzonitrile targets cellulose synthase (red arrow). Adapted from 






Other proteins could also be involved in the formation of the cellulose synthase 
complex in plants, such as sucrose synthase, which breaks down to yield glucose 
and fructose (Amor et al., 1995). Another protein used in cellulose biosynthesis 
is membrane-anchored endo-β-(1-4)-glucanase, known as KORRIGAN (Nicol et 
al., 1998). This protein plays an crucial role in reducing cellulose crystallinity 
(Takahashi et al., 2009). The process of microfibril formation in the cellulose of 
plants is spilt into three stages: firstly, UDP glucose is utilised as the donor 
substrate; the next stage is the polymerisation of glucose into β-(1,4)-glucan 
chains and the final stage is the crystallisation of β-(1,4)-glucan chains into a 
cellulose microfibril (Peng et al., 2002). There are three different enzymes 
involved in cellulose biosynthesis in Acanthamoeba, including glycogen 
phosphorylase, UDP-glucose pyrophosphorylase and cellulose synthase, and 
the expression of these enzymes increases during encystment in Acanthamoeba 
(Moon and Kong, 2012). In Acanthamoeba cyst walls, the biosynthesis of 
cellulose begins by degrading the glycogen in the cytoplasm through catalytic 
action of glycogen phosphorylase, releasing glucose-1-phosphate. 
Consequently, UDP (uridine diphosphate) glucose is produced from glucose-1-
phosphate and UTP (uridine triphosphate) catalysed by UDP-glucose 
pyrophosphorylase. The glucose residues are polymerized into individual glucan 
chains which are translocated across the cytoplasmic membrane by the action of 
cellulose synthase. Glucan chains are likely to be assembled into elementary 
fibrils connected into microfibrils (Garajová et al., 2019). 
1.14  Drug targets for treatment of Acanthamoeba Keratitis 
The biguanide drugs including PHMB and chlorhexidine, are the most effective 
drugs used to treat the AK infection, as they target the cell membrane of 
Acanthamoeba and lead to disruption and eventually cell death . There is a 
growing body of scientific literature which identifies a variety of anti-
Acanthamoeba drugs, and these drugs have been categorised according to drug 
target and mode of action as presented in Table 1.3 below. The main challenge 
in AK therapy is the resistance of cysts to most antimicrobials. The cyst wall 
consists partly of cellulose and this has been the target of in vitro studies. Efforts 




cellulose synthesis inhibitors such as isoxaben and 2,6-dichlorobenzonitrile 
(DCB); concentrations of DCB as low as micromolar levels have prevented the 




Table 1-3: Classify the anti-Acanthamoeba drugs according to the targets and mechanism of action 
Category  Class Drug Mechanism of action Reference  
Causing 
damage in the 
membranes 
Biguanide Polyhexamethylenebiguanide 
(PHMB), alexidine and 
chlorhexidine digluconate 
Both PHMB and chlorhexidine are positively 
charged and binding to the mucopolysaccharide 
plug of the ostiole and causing penetration of the 
amoeba. Subsequent, the drug binds to the 
phospholipid bilayer of the cell membrane which 
is negatively charged causing changes in 
structural and permeability, ionic leakage, 
cytoplasmic disruptions producing cellular 
damage and cell death. 
(Khunkitti et 
al., 1997) 
(Lim et al., 
2008a) 
 Antibiotic Antibacterial included 
polymyxin B and linezolid 
Polymyxin B targets negatively charged 
membranes and disrupts the membrane 
integrity.  















Table 1.3 (continued) 
Category  Class Drug Mechanism of action Reference  
 Fluoroquinolone/ 
Antibiotic 
Moxifloxacin, Levofloxacin Moxifloxacin and levofloxacin are an inhibitor 
of DNA gyrase, a type II topoisomerase and 
topoisomerase IV which they required for 
DNA replication. 
(Aldred et al., 
2014) 
 Anaesthetic Proxymetacaine, 
tetracaine, oxybuprocaine 
and Lidocaine 
These drugs are inhibiting bacterial growth 
by disruption the cell membrane 
(Kaewjiaranai 




Diamidine Pentamidine isethionate, 
propamidine isethionate 
and hexamidine 
Diamidines inhibit the synthesis of DNA, 








MAPD and PAPD prevent the synthesis of 
DNA, RNA in Acanthamoeba. MAPD cause 
extensive damage for the plasma membrane 







Tobramycin This antibiotic binds to the 30s and 50s 
ribosome for most of the Gram-negative 
bacteria and blocking the formation of 70s 
complex. Consequently, mRNA no longer 
can be translated into protein and eventually 
lead to cell death 







Table 1.3 (continued) 




Antifungal Azoles agents included 
voriconazole, posaconazole 
and benznidazole.   
Amphotericin B Antifungal 
macrolide natamycin 
Azoles targeting the ergosterol which is one of 
the major sterols in the membrane of 
Acanthamoeba  
Amphotericin B binds to the ergosterol in the 
membrane and this binding disrupts osmatic 
integrity of the cell membrane, causing leakage 
in the intercellular potassium Mg⁺², sugars and 
then cell death.  
Natamycin binds to ergosterol in the plasma 
membrane of fungal and this binding leads to 












bromide and Polyquaternium-1 
These compounds producing enzymes and lead 
to denaturation of the key cell proteins and 





Antineoplastic Miltefosine Interfere with carrier proteins systems, leading 
to a reduction in essential nutrients, and 
eventually to cell death 






1.15  Treatment of Acanthamoeba Keratitis 
As detailed in section 1.1 of this chapter that the first line of medical treatment for 
AK is polyhexamethylene biguanide or chlorhexidine at a concentration of 0.02% 
(v/v), used as a single drug or in combination with diamidines (Papa et al., 2020). 
Other compounds that are used for AK treatment include antifungals, such as 
oral itraconazole, and the topical use of 0.1 % (v/v) miconazole (Ishibashi et al., 
1990). Although the T4 genotypes of Acanthamoeba are now recognised as 
being associated with pathogenic strains, other genotypes have also been 
identified in severe cases of AK that are resistant to present medical therapy 
(Arnalich-Montiel et al., 2014). A recent in vitro study investigated the effect of 
preserved propamidine (Brolene®) eye drops compared with propamidine as a 
pure drug and the findings showed that the presence of the benzalkonium 
chloride (BAC) as preservative in (Brolene®) is solely responsible for an 
improvement in antimicrobial activity against trophozoites and cysts of 
Acanthamoeba (Heaselgrave et al., 2019). BAC has also been used in different 
concentrations as a preservative of various classes of drugs, including 
antibacterials, antifungals, antivirals, anti-inflammatories/anti-infectives 
(NSAIDs), corticosteroids and anti-allergics (Tu, 2014).  
In most countries, the  standard treatment strategy for AK consists of a 
combination of biguanides, either chlorhexidine or PHMB, with a diamidine 
(propamidine or hexamidine), given hourly, then decreased to 2-hourly, by day 
for 3–4 weeks and then adjusted for each patient individually (Dart et al., 2009). 
However, most of these drugs are associated with toxic side effects for the cornea 
and therefore, following this treatment, most patients need to undertake 
keratoplasty for therapeutic purposes when the infection reaches an advanced 
stage (Dart et al., 2009). Antifungal agents, such as voriconazole and 
posaconazole, have been shown to have great activity against Acanthamoeba 
trophozoites and cysts in vitro (Iovieno et al., 2014a). Also, voriconazole has been 
given as an oral treatment for patients who are infected with persistent stromal 
AK and this antifungal has eradicated the stromal AK infection (Tu et al., 2010). 
Furthermore, cellulose synthesis inhibitors were found to be promising as a 
treatment for Acanthamoeba. They make the organism hidden within susceptible 




should also be used in combination with other compounds to improve its potency, 
resulting in better treatment of Acanthamoeba in vitro (Lakhundi et al., 2015).  
 
1.16  The aims and objectives of this project  
 
Part 1: The aim is to  develop novel therapeutic agents for the 
treatment of Acanthamoeba Keratitis  
The specific objectives for this aim are described below:  
I. Screening of new drugs along with existing ones against  both trophozoites 
and cysts of Acanthamoeba castellanii (ATCC 50370) and Acanthamoeba 
polyphaga (ATCC 30461) to determine the minimum trophozoite inhibtory 
Concentration (MTIC), minimum trophozoite amoebicidal concentration 
(MTAC) and minimum cysticidal concentration (MCC) values. 
II. Test a variety of topical ophthalmic drugs against both species of 
Acanthamoeba, the drugs including anaesthetics used in the corneal 
scrapes, empirical antibiotics/antivirals which are often given prior to an 
AK diagnosis. 
III. Conduct toxicity studies against human epithelial cell line to define the 
toxicity of the drugs.  
IV. Perform time kill analysis to determine the kinetics of cysticidal activity 
V. Assess the antimicrobial activity for different drugs in combination against 
trophozoites.  
Part two: The aim is to investigate the receptor involved in the 
encystment and examine the effect of cellulose synthesis 
inhibitors (CSI) on the formation of  cyst and protocyst stages   
The certain objectives for this aim are specified below:  
I. Test several agonists and antagonists on the transformation of  
trophozoite of Acanthamoeba spp. into cyst to demonstrate which drug 




II. Assess the effect of agonists and antagonists on the conversion of 
trophozoite into protocyst which is the new stage of Acanthamoeba.   
I. Test different concentrations of (CSI) including isoxaben and 2,6-
dichlorobenzonitrile in their own and in combination on the conversion of 
trophozoites into cyst and protocyst forms.  
Part three: The aim is to study and confirm the potential 
existence of a 3rd life cycle stage pseudocyst/protocyst of 
Acanthamoeba  
The particular objectives for this aim are stated below:  
I. Prepare solutions of standard sugars for LC/MS analysis for the purposes 
of comparison. 
II. Carry out acid hydrolysis and LC/MS for cellulose/chitin as standards to 
compare with cyst and protocyst samples.   
III. Perform enzymatic treatments for cysts and protocysts to digest the 
intercellular elements.  
IV. Do acid hydrolysis and LC/MS analysis for cyst and protocyst walls to 



































2. Chapter 2: Materials and Methods  
This chapter is describing the methodological approaches taken in this study. 
2.1  Chemicals 
All chemicals and most of the materials used in this study were obtained from 
VWR, (Lutterworth, Ltd, U.K.). 
2.2  Media and solutions 
Two methods have been used for sterilizing the solutions or media including 
autoclaving at 121C for 15 min or by the passage of solution through a 0.2 µm 
filter. 
2.3  Test organisms 
Table 2-1: The organisms and cells which were used for the drug sensitivity, time 
kill, toxicological testing, encystment studies, cellulose biosynthesis 
investigations and sugars analysis. 
Amoebae Strain 
Acanthamoeba  castellanii ATCC 50370 
Acanthamoeba  polyphaga ATCC 30461 
Acanthamoeba  castellanii ATCC 30868 
Human cell line Strain 
Human epithelial cell type 2 ECACC #86030501 
Gram – negative bacteria Strain 
Escherichia coli ATCC 8739 
 
Acanthamoeba castellanii (ATCC 50370), A. polyphaga (ATCC 30461) and A. 
castellanii (ATCC 30868) were obtained from the American Type Culture 
Collection (ATCC) (LGC Standards, Teddington, U.K.). The human cell line was 
obtained from the European Collection of Cell Cultures (Centre for Applied 





2.4  Cultivation of Acanthamoeba spp. 
The cryopreserved cells of the trophozoites were recovered from the freezing at 
-80°C and thawing them rapidly in a 37 °C water bath. Once melted, the 
suspension was added to a fresh, prewarmed Ac#6 growth medium in 25 cm² 
small culture flasks and incubated at a temperature of 32°C. The medium was 
replaced with a fresh Ac#6 medium after 6 hours to reduce any toxicity caused 
by the DMSO. After 24 hours of incubation, the cells were viewed under an 
inverted microscopy to check the confluency level of the cells and if the cells fully 
confluence then they were sub-cultured in 75cm² medium culture flasks and 
incubated at 32°C for 24 hours. In order to grow a sufficient number of cells for 
the experiments, the cells of the trophozoites were sub-cultured in large flasks 
182.5cm² and incubated at 32°C for a further 24 hours.  
The ingredients for this medium were based on a study by Hughes and Kilvington 
(2001), and comprised 20 g Biosate peptone (SLS, Nottingham, U.K.), 5 g 
glucose, 0.3 g potassium dihydrogen phosphate (KH2PO4), 100 µL vitamin B12 
and 3 mL L-methionine per 800 mL of distilled water. The pH of the medium was 
adjusted to pH 6.5 – 6.6 with 1 M aqueous sodium hydroxide (NaOH) and then 
made up to 1000 mL and the resulting solution was aliquoted into 250 mL portions 
and autoclaved. Finally, a concentration of penicillin at 100 U/mL and 0.1 mg/mL 
was added to the medium and the completed medium was stored at room 
temperature and used within 1 week. 
2.5  The cryopreservation of Acanthamoeba spp. 
The trophozoites of the Acanthamoeba species were grown in an Ac#6 growth 
medium and the cells were pelleted by centrifugation at 500 × g for 5 min and the 
final pellets were resuspended in an Ac#6 growth medium containing 5% (v/v) 
dimethyl sulfoxide (DMSO) as a cryoprotectant and placed in a 1 mL cryotube. 
The cells were then placed in a Mr Frosty freezing container containing propan-
2-ol and placed in a -80°C freezer for 2 days. The propan-2-ol plays a major role 





2.6  The cryopreservation of the human epithelial cell line 
A Dulbecco’s Minimum Essential Medium (DMEM) was used to grow the human 
epithelial cells type 2 (Hep2) and the cells were harvested by centrifugation at 
500 × g for 5 min. The resulting pellets were resuspended in a DMEM medium 
containing 5% (v/v) DMSO as a cryoprotectant and the mixture was transferred 
to a 1 mL cryotube. The Hep2 cells were then placed in a Mr Frosty freezing 
container containing propan-2-ol and stored in a freezer at -80°C for 48 hours. 
The main reason for using the propan-2-ol was to reduce the speed of freezing 
to 1°C /min and to aid the decline of cellular damage. The Hep2 cells were 
recovered by taking the cell vails out of the -80°C freezer and melting them 
quickly in a 37°C water bath. Once the medium had dissolved, the suspension of 
human epithelial cells was added to a fresh, prewarmed DMEM medium and 
incubated at 37°C, then a fresh medium was substituted after 6 hours in order to 
decrease any toxicity resulting from the DMSO. 
2.7  The preparation of Acanthamoeba mature cysts in Neff’s 
medium  
Cysts were produced using the Neff’s encystment medium (NEM) method as 
described by Kilvington and Lam (2013). Trophozoites were seeded in 182.5 cm² 
tissue culture flask at a density of 1 × 105 cells/mL in 50 mL of Ac#6 growth 
medium and incubated for 48 hours at 32 °C. The trophozoites were harvested 
by centrifugation at 500 × g for 5 min and washed three times with a ¼ strength 
Ringer's solution (SLS, Nottingham, U.K.) and the final pellet was resuspended 
in 50 mL of NEM at a density of 5 × 105 cells/mL in a 75 cm² tissue culture flask. 
The cultures were incubated in an orbital shaking incubator at 32°C and 120 rpm 
for 7 days. The cysts were harvested for antimicrobial testing after 7 days of 
incubation in NEM and the maturity of the cysts was then confirmed using an 
inverted microscopy before harvesting. The flask sides were swabbed to remove 
any adhering cysts which washed three times with a ¼ strength Ringer’s solution 
and centrifuged at 1000 x g for 10 min. The pellet was adjusted to 5 × 106 cells/mL 
using a modified Fuchs Rosenthal haemocytometer and the batch of cysts was 




2.8  The preparation of Acanthamoeba mature cysts in NNA 
medium  
A different approach was used for the preparation of a smaller number of cysts, 
the non-nutrient agar (NNA) method, which was adapted from Kilvington et al. 
(1990). The non-nutrient agar plates containing 2.5% (w/v) agar and 1 tablet of 
¼ strength Ringer’s per 500 mL of deionised water were autoclaved then poured 
on the plates and allowed to dry overnight. Acanthamoeba trophozoites were 
centrifuged at 500 x g for 5 min and the resulting pellet was resuspended in the 
Escherichia coli (ATCC 8739) stock. 2-3 drops of the Acanthamoeba trophozoite 
E. coli suspension were spotted onto the lawn of E. coli.  
The plates were then incubated at 32°C for 7 – 10 days for the encystment 
process to complete. During the 7 – 10 day period, the plates were examined on 
a regular basis to check for any contamination and as well as to verify amoeba 
replication. Once the Acanthamoeba have spread out to cover the whole plate, 
the bacterial lawn is quickly depleted triggering the amoeba to encyst. For 
harvesting, roughly 20 mL of ¼ strength Ringer’s solution was poured onto the 
agar surface and firm pressure was applied in a circular motion using the rubber 
teat. The resulting cyst suspensions were collected and pelleted by centrifugation 
at 1000 x g for 10 min and washed three times in a ¼ strength Ringer’s solution 
to remove any trace of E. coli.  Finally, the cells were resuspended in a ¼ strength 
Ringer’s solution and the cell density was assessed by microscopy using a 
modified Fuchs Rosenthal haemocytometer and adjusted to 5 × 106 cells/mL and 
then stored between 2 – 8°C and tested within two weeks.  
2.9 The preparation of Acanthamoeba protocysts in Neff’s 
medium plus 0.5% propylene glycol 
For the transformation of trophozoites into the form of protocysts, The method 
used for this experiment has been adapted from the work carried out by Kilvington 
et al. (2008). The trophozoites were harvested by shaking the flask and 
centrifuging it at 500 x g for 5 min. The pellet was then washed three times with 
a ¼ strength Ringer’s solution. The resulting pellet of trophozoites was 
resuspended in 30 mL of Neff’s + 0.5% (v/v) propylene glycol (Neff’s-PG) in a 75 




at 32°C and 120 rpm for 2 hours. The trophozoite cells were rapidly differentiated 
into protocysts as confirmed using an inverted microscopy. The protocysts were 
harvested by swabbing the flask sides to remove any adherent protocysts and 
washed three times with a ¼ strength Ringer’s solution and centrifuged at 1000 
× g for 5 min. The final pellet was adjusted to the desired concentration in a ¼ 
strength Ringer’s solution and then stored between 2 – 8 °C and tested within 7 
days. 
2.10 The preparation of Escherichia coli stock for the 
Acanthamoeba food source 
E. coli (ATCC 8739) was cultured on a tryptic soy agar (TSA) plate and incubated 
overnight at 37 °C to allow for colony growth. Single colonies of E. coli were 
selected and placed in 100 mL of tryptic soy broth (TSB) in a 182.5 cm2 tissue 
culture flask and incubated overnight at 37°C and at 120 rpm in an orbital shaking 
incubator. The E. coli suspension was aseptically transferred to two 50 mL 
polypropylene tubes and centrifuged at 3000 × g for 30 min to pellet the bacteria. 
The supernatant was then discarded, and the pellet was washed by re-
suspending in a ¼ strength Ringer’s solution. The pellet of E. coli was washed 
twice in order to remove the growth broth and to avoid further multiplication of the 
bacteria. The final E. coli pellet was resuspended in 10 mL of ¼ strength Ringer’s 
solution and then stored between 2 – 8°C and used within 14 days. 
2.11  In vitro evaluation of drug antimicrobial activity 
Many compounds were screened during the present study in order to identify their 
potential antimicrobial activity using a method similar to that used by Elder et al. 
(1994). To set up the microtitre plate to assay antimicrobial sensitivity against 
trophozoites and cysts of Acanthamoeba, 200 µL of a 1000 µg/mL solution of test 
compound was prepared in a suitable diluent and added to column 1, rows A – 
H, of the microtitre plate, as presented in Figures 2.1 and 2.2. The remainder of 
the wells were filled with 100 µL of a ¼ strength Ringer’s solution. Serial 2-fold 
dilutions were then carried out across the plate from column 1 to column 11, 
giving a wide range of drug concentrations from 1000 to 0.98 g/mL, which is 
double the preferred final concentration. Column 12 contained only a ¼ strength 
Ringer’s solution to serve as a control. Cysts were resuspended in a ¼ strength 




and added to the wells to give a final concentration of 1 × 104 cells/mL and change 
the drug concentration from 500 to 0.49 g/mL. The microtitre plates were 
transferred to the 32°C incubator and, after 24 hours of incubation, the plates 
containing trophozoites were examined, as described in section 2.12. The plates 
containing cysts were checked after 48 hours for further experimentation as 
detailed in section 2.13.  
2.12  Evaluation of drug activity against trophozoites  
After completing the trophozoites assay, the wells of the microtitre plate (Figure 
2.1) were checked after 24 hours to see if there was any contamination. 
Furthermore, after 48 hours the plates were examined under an inverted 
microscopy at x 100 objective and x 200 objective. By making a comparison of 
the test compounds with the control wells, it was possible to determine the 
following:  
❖ Minimum Trophozoite Inhibitory Concentration (MTIC): The concentration 
at which there is approximately 50% inhibition of Acanthamoeba trophozoite 
replication compared with the controls. 
❖ Minimum Trophozoite Amoebicidal concentration (MTAC): The 
concentration at which all the Acanthamoeba trophozoites were non-motile, 
round or lysed.   
 
Figure 2-1: Microtitre plate showing the three replicates used for in vitro drug 





2.13  Evaluation of drug antimicrobial activity against cysts  
In order to assess the antimicrobial activity for the drugs against Acanthamoeba 
cysts, an assay was performed by exposing the cysts to the drugs for 48 hours. 
After 2 days of incubation at 32°C, the wells of the microtitre plate (Figure 2.2) 
were aspirated using a Vacusip to remove the drug and leave only the cysts 
adhering to the bottom. The wells were refilled with a ¼ strength Ringer’s solution 
and allowed to stand for 15 min for the cysts to reattach and the liquid was again 
aspirated as before. This process was then repeated three times to ensure the 
drug was fully removed from the wells. An E. coli suspension at an OD520 of 0.1 
– 0.2 was then added to each well of the plates. The plates were incubated at 
32°C and examined daily under an inverted microscopy for up to 7 days to 
determine whether still-viable cysts had excysted and the trophozoites replicated 
in the wells. It was possible to determine the following:  
❖ Minimum Cysticidal Concentration (MCC): The lowest concentration of test 
solution that results in no encystment or trophozoite replication.  
 
Figure 2-2: Microtitre plate showing the three replicates used for the in vitro drug 







2.14  Time kill testing for Acanthamoeba spp. 
All of the compounds which showed great antimicrobial activity against cysts of 
Acanthamoeba spp. were further tested using a time-kill method, based on an 
approach described by Kilvington (2004). The microtitre plate was set up for this 
assay by adding 180 L of 0.1 % (v/v) Tween 80 and 0.35 % (w/v) Soybean 
Lethicin neutralisers to columns A and H with the remaining wells being filled with 
180 L of a ¼ strength Ringer’s solution as shown in Figure 2.3. The purpose for 
used neutralisers (Tween 80 and Soybean Lecithin) is to neutralise the drugs in 
order for growth, replication and encystment to occur. 
 
Figure 2-3: Microtitre plate showing the time-kill assay for cysts or trophozoites 
of Acanthamoeba spp. 
All the time kill experiments were carried out in triplicate in 50 mL polypropylene 
centrifuge tubes, with each tube containing 5 mL of an appropriate test solution 
or control. The cysts or trophozoites of Acanthamoeba were added to each 
centrifuge tube at a density of (50L of 5 × 106 cells/mL) at time 0 and vortexed. 
At time intervals of typically 0, 1, 2, 4, 6  and 24 hours, 20 L aliquots containing 




and transferred to the wells of a microtitre plate containing a 0.1% (v/v) Tween 
80 and 0.35 % (w/v) Soybean Lecithin neutraliser solution. Once the aliquots 
were neutralised, a series of 10-fold dilutions were performed. For example, the 
contents of A1 – 4 were transferred into B1 – 4 then into C1 – 4 and then into D1 
– 4. Each well was then seeded with a 1:40 dilution of the E. coli stock and the 
plates were incubated at 32°C for 7 – 14 days. On a daily basis, the plates were 
examined for encystment or trophozoite growth using an inverted microscopy.  
The number of viable organisms at each time point was calculated using the 
Spearmann-Karber formula, as illustrated below:  
Log10 organism = (X0 – (d/2) + d (Σ ri / ni) 
Where: X0 = log10 of the lowest dilution at which all test inocula are positive 
d = log10 of the dilution factor 
ni = number of test inocula used at each dilution 
 ri = number of positive test inocula out of ni 
(Σ ri / ni) = Σ (P) sum of the percentage of positive tests showing a 100 % positive 
result 
 
Here are two examples to clarify the Spearmann-Karber formula above:  
 
Example-1: If 4 wells contained viable cysts or trophozoites at the 10⁻1, 10⁻2, 
10⁻3 dilutions and 1 out of 4 at the 10⁻4 dilution, using the formula below: 
Log10 organism = (X0 – (½) + 1 (4/4+4/4+4/4) = 5600  
 
Example-2: If 4 wells contained viable cysts or trophozoites at the 10⁻1 dilution 
and 1 out of 4 at the 10⁻2 and 10⁻3 dilutions, using the formula below: 
Log10 organism = (X0 – (½) + 1 (4/4+1/4+1/4) = 100 
 
2.15  Data analysis for time kill experiments   
To assess the reduction in viable Acanthamoeba, the decrease in numbers was 
plotted as log viability at each of the time points and the reduction was determined 





Log reduction = log Tn – log T0 
Where Tn  indicates the viable cell count at any given experimental time point  
 T 0 indicates the initial viable cell count 
A template was created in excel spreadsheet to perform the delta log calculation 
and graphs were generated.  
2.16  Cultivation of human epithelial cells  
Human epithelial type 2 (Hep2) cells were grown in a medium consisting of 
Dulbecco’s Minimum Essential Medium (DMEM) (SLS, Nottingham, U.K.) plus 10 
% (v/v) foetal bovine serum, 2 mM L-glutamine. 100 U/mL and 0.1 mg/mL 
respectively of penicillin/streptomycin were added to the final concentration. The 
Hep2 cells were cultured in 75 cm2 tissue culture flask and placed in an incubator 
at a temperature of 37°C and in an environment of 5 % CO2. The DMEM medium 
was added to the flasks and the medium was replaced every 3 – 4 days. When 
the medium became acidic, it converted to a yellowish colour. Depending on the 
confluence of the Hep2 cells, they were either sub-cultured or maintained for up 
to 5 days in a maintenance medium which was the same as the growth medium, 
but it contained only 3% (v/v) foetal bovine serum.         
2.17  Sub-culture and maintenance of human epithelial cells 
Initially, the DMEM medium was gently removed from the flask and the monolayer 
was washed once in 10 mL of Dulbecco’s phosphate buffered saline (DPBS) 
(SLS, Nottingham, U.K.), pre-warmed to 37°C, in order to wash away any residual 
buffer. 3 mL of trypsin-EDTA solution was then added to the flask. The cells were 
incubated for 4–5 min at room temperature in the trypsin-EDTA (Sigma, Dorset, 
U.K.) solution until rounding of the cells was observed when viewed under an 
inverted microscopy. The flask was then knocked against the hand to remove the 
cells from the flask. Confirmation that this had occurred was again achieved by 
viewing under an inverted microscopy. The flasks were re-incubated, and 
knocking was repeated if all cells had not detached. The resulting cell suspension 
was then divided into fresh medium at a ratio of between 1:2 and 1:4, depending 
on the level of confluence of the monolayer, and placed in the growth medium 




2.18  In vitro toxicology assay 
Experimental human epithelial type 2 cells were used to establish the toxic effects 
of the novel and existing antimicrobial compounds tested in this study. In vitro, 
the microtitre plates were seeded with human epithelial cells at a density of 2 × 
104 cells/mL and the plates were incubated at 37°C and 5% CO2 for 48 hours or 
until the monolayer reached 80 – 90% confluence. The spent growth medium, 
comprising 10% (v/v) foetal bovine serum, was removed from all the plates by 
aspirating the wells using a Vacusip and then replaced with 100 L of 
maintenance medium. The antimicrobial compounds were serially diluted across 
the microtitre plates in a series of 2–fold dilutions, accomplishing a range of 
concentrations as done for the testing of antimicrobial activity in Acanthamoeba 
as described in sections 2.11 – 2.13.    
To identify the toxic effects of the test compounds, two different methods were 
used in the present study. The first of these is called the CellTiter 96 AQuous 
One Solution Cell Proliferation Assay (Promega, Southampton, U.K.), which is a 
colorimetric method. This approach combines a tetrazolium MTS compound (3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxy methoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium salt) with PES (Phenazine ethosulfate), an electron-coupling agent. If 
the cells are metabolically active, the MTS compound is reduced by the NADPH 
or NADH enzymes, generating a coloured formazan product. Subsequently, 5 L 
of the CellTiter 96 assay was added to each well of the microtitre plate and the 
plates were incubated overnight at 37°C and 5% CO2. The quantity of coloured 
product produced in a colorimetric approach was measured 
spectrophotometrically in an MRX microplate reader at 490 nm and compared 
with a predetermined calibration curve. Furthermore, toxicity was also 
established using a light inverted microscopy in a similar way to the 
Acanthamoeba drug sensitivity assay. The following elements of the toxicological 
profile was estimated: 
❖ Minimum Inhibitory Concentration (MIC): The minimum concentration at 
which inhibition of cell division and localised detachment of the monolayer 




❖ Minimum Cytotoxic Concentration (MCT): The minimum concentration at 
which all human epithelial cells were rounded and lysed with general 
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3. Chapter 3: Evaluation the effect of topical ophthalmic agents and 
anti-Acanthamoeba drugs on Acanthamoeba spp. viability  
 
3.1  Introduction 
3.1.1  Current medical treatments for Acanthamoeba Keratitis 
The medical therapy for Acanthamoeba Keratitis (AK) involves the topical 
administration of a biguanide, either 0.02% (v/v) polyhexamethylene biguanide 
(PHMB) or 0.02% (v/v) chlorhexidine as monotherapy (Papa et al., 2020) or in 
combination with 0.1% (w/v) of propamidine or hexamidine is still unlicensed (Dart 
et al., 2009). It has been reported that chlorhexidine and PHMB are the most 
effective agents against both the trophozoites and cysts of the Acanthamoeba 
species (Lim et al., 2008b, Lorenzo-Morales et al., 2013). A recent publication 
has shown that octenidine hydrochloride is more active against cysts and 
trophozoites then PHMB and chlorhexidine (Heaselgrave et al., 2019).  
Octenidine hydrochloride is derived from pyridine that has a broad spectrum of 
activity and it can be used as an effective antimicrobial against most gram-
positive and gram-negative bacteria (Hübner et al., 2010). Early research 
conducted by Sedlock and Bailey (1985) showed that octenidine (OCT) is more 
active than chlorhexidine (CHLX) and at lower concentrations of 2.0 µM and 
within only 15 min of exposure, it caused more than a kill of 99.99% for a range 
of species of bacteria, including Staphylococcus epidermidis, Proteus mirabilis, 
Streptococcus pyogenes, Klebsiella pneumoniae, Escherichia coli, 
Pseudomonas aeruginosa, Serratia marcescens, and fungi of Candida albicans. 
However, a higher concentration of chlorhexidine at 40 µM was required to 
achieve a similar antimicrobial activity and exposure time with OCT at 99.99%. 
At present there are around 4.1 million contact lens wearers in the United 
Kingdom (Efron, 2016). In spite of the sight threatening risk with AK, in most 
series, it accounts for <5% of all contact lens associated with other forms of 
keratitis (which includes bacterial, fungal and herpes simplex keratitis). The 
reported incidence rates in contact lens users are 1 to 2 per million in the United 




Galarreta et al. (2007) investigated the fungal keratitis related to the contact 
lenses over 12 years and found that the rate of this keratitis is 4.5 cases per year 
and this is a relatively low incidence compared to the another study conducted 
by Ong et al. (2016) in Moorfields Eye Hospital which reported a higher rate of 
fungal keratitis associated with contact lenses between 2007 and 2014 period 
was 14 cases per year. A much higher global incidence of HSV keratitis is 
approximately 1.5 million, involving 40,000 new cases of severe monocular visual 
impairment or blindness every year (Farooq and Shukla, 2012). AK is very rare 
and the latest research from a tertiary hospital in the United Kingdom reported an 
incidence rate of only 2.3% for Acanthamoeba over a 12-year period from over 
1500 keratitis cases (Tan et al., 2017).  
Many antimicrobial agents have been tested against Acanthamoeba species and 
most of these agents do not warrant any further investigations. Povidone-iodine 
has been found to be an effective agent against the cysts of Acanthamoeba 
(Sunada et al., 2014). Furthermore, alexidine has been shown to be active at a 
concentration of 10 µg/mL against trophozoites of Acanthamoeba castellanii, 
Acanthamoeba polyphaga, and Acanthamoeba rhysodes. However, a 
concentration 10 times higher (100 µg/mL) of this agent was required against 
cysts of A. castellanii, A. polyphaga, and A. rhysodes to achieve a complete kill 
(Hassan Alizadeh and Cavanagh, 2009). Despite the significant advances in 
medical treatment, rapid diagnosis and combination therapy, the mean treatment 
period for patients suffering from AK may be more than 5 months, with surgical 
operations possibly needed in 15% of cases and loss of vision of up to 6/8 or less 
may occur in more than 30% of patients (Pérez-Santonja et al., 2003, Larkin et 
al., 1992, Chidambaram et al., 2016).  
3.1.2  Anaesthetic, antibiotic and antiviral drugs 
Three topical anaesthetics, proxymetacaine 0.5%, tetracaine 1% and 
oxybuprocaine 0.4%, were tested in vitro against four different strains of bacteria: 
Staphylococcus epidermidis, Staphylococcus aureus, Pseudomonas aeruginosa, 
and Streptococcus pneumoniae. The proxymetacaine did not cause any inhibition 
of bacterial growth and exhibited a MIC of ˃5000 µg/mL. In contrast, the other 
two anaesthetics showed inhibition on all bacterial strains used in the review 




their effect on the viability of Acanthamoeba, as they used to anesthetise the 
patient eye for a corneal scrape. Another investigation compared the effect of 
commercial eye-drops containing oxybuprocaine 0.2 %, tetracaine 0.4 % and 
lidocaine 1 % on the inhibition of bacterial growth and the results indicated that 
lidocaine at a concentration of 1 % showed no impact on the growth of bacteria 
compared to the other anaesthetics tested (Labetoulle et al., 2002). It is very 
important for an ophthalmologist to use a suitable anaesthetic before a corneal 
scrape is performed. Empirical treatment with antibiotic fluoroquinolone drugs or 
other biocides prior to diagnosis showed that they could have an impact on the 
viability of Acanthamoeba. Bacterial keratitis is more likely and therefore empirical 
treatments with antibiotics is started initially. In addition to antimicrobial drugs, 
many ophthalmic preparations utilise benzalkonium chloride (BAC) as a 
preservative and it has been shown that BAC is highly toxic to Acanthamoeba 
(Tu et al., 2013). In a case study performed by Wolf et al. (2009), the topical 
anaesthetic proparacaine and the antibiotic moxifloxacin were used to treat a 
patient who suffered from photophobia and redness caused by the contact lens. 
After the treatment had been performed, the outcomes of the study showed that 
the cultures for bacteria and fungi were negative. However, the results confirmed 
that the  culture of  Acanthamoeba was positive in this case (Wolf et al., 2009). 
The possible reason for not detecting any bacteria is related to using the antibiotic 
moxifloxacin  
It was found that fluorescein and topical anaesthetics could interfere with the real-
time polymerase chain reaction (real-time PCR) which is called quantitative PCR 
(qPCR) to detect the herpes virus and Acanthamoeba resulting in false negative 
results (Goldschmidt et al., 2006). One potential reason for the low sensitivity of 
culture-based diagnostics for Acanthamoeba might be associated with the 
previous use of a topical therapy, such as anaesthetics and antibiotics, which was 
applied to the cornea prior to the corneal scrape being performed on the patient. 
The topical antiviral aciclovir has been used at a concentration of 3% as an 
ointment for the treatment of the herpes simplex virus (HSV) and it showed more 
activity in vivo then valaciclovir (Choong et al., 2010). Trifluorothymidine is 
another antiviral agent which acts as an inhibitor of thymidylate synthetase and a 




(Wilhelmus, 2007). HSV is more common that AK and in many cases the patient 
is misdiagnosed with HSV and treated with anaesthetics and antibiotics. We 
attempted to see if these drugs can negatively impact on AK diagnosis by 
reducing viability.  
3.1.3  Aim and objectives of this chapter 
 The aim of this chapter is to evaluate the antimicrobial activity of various agents 
on the viability of Acanthamoeba and to assess the toxicity on the human 
epithelial cell line. The objectives of this chapter are as follows:  
I. To test different groups of agents, including topical anaesthetics, antivirals, 
antibiotics, diamidines and biguanides, against cysts and trophozoites of 
Acanthamoeba spp.  
II. To evaluate the toxicity for these agents for human epithelial cell line. 
III. To investigate the effect of a number of agents on the morphology changes 
of Neff’s cysts of A. castellanii by inverted light microscopy and 
















3.2  Materials and Methods  
3.2.1  Preparation of organisms  
The Acanthamoeba castellanii (ATCC 50370) and Acanthamoeba polyphaga 
(ATCC 30461) were grown and prepared according to the methods detailed in 
chapter 2, sections 2.4 – 2.8.  
3.2.2  Drug sensitivity testing assays 
The drugs were diluted in the appropriate solvent and assayed to determine their 
activity against trophozoites and cysts using the microtitre plate assay as outlined 
in chapter 2, section 2.11 – 2.13. The Minimum Trophozoite Inhibitory 
Concentration (MTIC), the Minimum Trophozoite Amoebicidal Concentration 
(MTAC) and the Minimum Cysticidal Concentration (MCC) were determined for 
each of the compounds. 
Table 3.1: List of drugs evaluated for their antimicrobial activity against 
Acanthamoeba castellanii (ATCC 50370) and Acanthamoeba polyphaga (ATCC 
30461) and for their toxicity against human epithelial cell line. 
Drug Class/Use Solubility Supplier 
Proxymetacaine  Anaesthetic Minims Bausch & Lomb 
(London, U.K.) 
Tetracaine  Anaesthetic Minims Bausch & Lomb 
(London, U.K.) 




Anaesthetic Minims Bausch & Lomb 
(London, U.K.) 
Fluorescein sodium  
Use as diagnostic 
tool of corneal  
infections 
Minims Bausch & Lomb 
(London, U.K.) 
Levofloxacin (Oftaquix®)  Fluoroquinolone/ 
Antibiotic 
Minims Bausch & Lomb 
(London, U.K.) 
Levofloxacin (Pure drug)  Fluoroquinolone/ 
Antibiotic 
H2O Bausch & Lomb 
(London, U.K.) 
Moxifloxacin (Moxeza®,) Fluoroquinolone/ 
Antibiotic 














Table 3.1 (continued) 
Drug Class/Use Solubility Supplier 
Acyclovir  Antiviral H2O Sigma (Dorset, U.K.) 




Diamidine H2O Sigma (Dorset, U.K.) 
Propamidine (Brolene®) Diamidine H2O Sanofi (Reading, U.K.) 
Hexamidine (Pure drug)  Diamidine H2O Sigma  (Dorset, U.K.) 
Hexamidine 
(Desomedine®) 









H2O Arch Biocides (Castleford, 
U.K.) 





H2O Schulke & Mayr, 
Norderstedt, Germany 
Alexidine Biguanide H2O Sigma (Dorset, U.K.) 
Povidone iodine  Antiseptic H2O VWR (Lutterworth, U.K.) 
Benzalkonium Chloride Cationic 
surfactant  
H2O Sigma (Dorset, U.K.) 
Phenylmercuric Nitrate  Antimicrobial 
preservative  
H2O Sigma (Dorset, U.K.) 
 
3.2.3  Toxicological testing  
After determining the antimicrobial activity for all compounds against trophozoites 
and cysts of Acanthamoeba spp. A different in vitro method was used in order to 
identify the toxicity of each of the compounds for the human epithelial cell line. 
The human epithelial cell line was cultured, maintained and prepared as outlined 
in chapter 2, sections 2.16– 2.18. This approach is particularly useful in 
determining the minimum inhibitory concentration (MIC) and minimum cytotoxic 
concentration (MCT) for each compound and this method could be used on the 






3.2.4  Inverted light microscopy study of Acanthamoeba cysts 
Primary investigations were undertaken using inverted light microscopy to 
examine the effects of topical ophthalmic preparations or other biocide solutions 
on the Neff’s cysts of Acanthamoeba castellanii (ATCC 50370). The Neff’s cysts 
of A. castellanii were treated with tetracaine 1% and preserved chloramphenicol 
0.5 % or solutions composed of similar concentrations to those utilised in 
ophthalmic preparations (PHMB 0.02 %, unpreserved chloramphenicol 0.5 %, 
benzalkonium chloride 0.05 mg/mL and povidone-iodine 5 %). The cysts were 
incubated with ¼ strength Ringer’s solution as a control and then the samples 
were placed in incubator at 32 °C for 1 hour. Subsequently, the samples were 
removed from the incubator and washed three times with ¼ strength Ringer's 
solution and centrifuged at 1000 x g for 5 min in order to eradicate the agents. 
The final pellets of cysts were fixed overnight at 4°C with 2.5 % (v/v) 
glutaraldehyde buffered with 0.1 M HEPES at pH 7.2. Examination of the samples 
was conducted by using a pipette to place 10 µL of the fixed cysts on slides and 
overlaying with a cover slip. The cover slip was then sealed to the slide using a 
DPX mounting medium (Sigma, Dorset, U.K.) to prevent the suspension from 
drying out. The slides were then viewed using inverted microscopy at x200 
magnification.  
 
3.2.5  Preparation of the cysts of Acanthamoeba for study using 
transmission electron microscopy (TEM) 
Neff’s cysts of Acanthamoeba castellanii (ATCC 50370) were investigated using 
transmission electron microscopy (TEM). The Neff’s cysts were exposed to the 
test formulations using the following topical ophthalmic preparations: preserved 
chloramphenicol 0.5 % and tetracaine 1% or a solution made up to the same 
concentrations as those used in ophthalmic preparations (povidone-iodine 5%, 
unpreserved chloramphenicol 0.5%, benzalkonium chloride 0.05mg/mL and 
PHMB 0.02%). The Neff’s cysts were exposed to the test formulations at 32 °C 
for 1 hour and the control cysts were exposed to ¼ strength Ringer’s solution. 
The agents were removed by washing the cysts with ¼ strength Ringer's solution 
and centrifuged at 1000 x g for 5 min. The resulting pellets were fixed overnight 




3.2.6  TEM process for the Acanthamoeba cysts 
The fixed Neff’s cysts were centrifuged at 0.8 rpm for 5 min and then the speed 
was increased to 2.6 rpm for 10 min. The samples were washed twice in 0.05 M 
HEPES and centrifuged at 800 rpm for 10 min. The TEM process was performed 
as previously described by Glauert (1975). The cysts were postfixed in 1% 
osmium tetroxide and 1.5% potassium ferricyanide in 0.05 M HEPES for 90 min 
and then washed in 0.05 M HEPES for 20 min and a further wash was performed 
in the same buffer for 30 min and then stored at 4C. The pellets were dehydrated 
in 70% and 90% ethanol for 30 min and then washed three times in analytical 
grade ethanol for 20 min. The samples were infiltrated with propylene oxide plus 
Spurr’s resin for a different periods of time and embedded in Spurr’s resin twice 
for 3 hours. The samples were then polymerised at 60C for 16 hours. Finally, 
the samples were divided into sections approximately 70 nm thick using a Leica 
UC7 ultramicrotome, collected on copper mesh grids and then stained with 2% 
aqueous uranyl acetate for 30 min, followed by 5 min in Reynolds lead citrate. 
The samples were delivered to the TEM microscopy facility in College of Science 
and Engineering, University of Leicester, UK. The samples were viewed on a 
JEOL JEM-1400 TEM with an accelerating voltage of 100kV.  
3.3  Results 
The findings in this chapter are comparing the antimicrobial activity for a range of 
different agents including anaesthetics, antibiotics, antivirals, diamidines and 
biguanides on the viability of trophozoites and cyst of Acanthamoeba spp. and 
also the toxicity against the human epithelial cell line. 
3.3.1  The topical anaesthetics  
Lidocaine inhibited the trophozoites of both species of Acanthamoeba at the 
higher concentration range of 312 – 625 µg/mL, whereas the other anaesthetics, 
including proxymetacaine, tetracaine and oxybuprocaine, demonstrated MTIC at 
a lower concentration range of 9.75–39 µg/mL. The MTAC for the 
proxymetacaine, tetracaine and oxybuprocaine was in the range 19.5 – 250 
µg/mL.  However, against A. polyphaga and A. castellanii, the MTAC for lidocaine 




Cysticidal activity of proxymetacaine, tetracaine and oxybuprocaine was found in 
the range 39 – 250 µg/mL, whereas the MCC values of lidocaine were observed 
at the higher concentrations of 1250 and 10000 µg/mL against A. polyphaga and 
A. castellanii respectively. Furthermore, proxymetacaine, tetracaine and 
oxybuprocaine showed toxicity for the human epithelial cell line in the range 39 – 
156 µg/mL, while no toxicity was observed for lidocaine up to 5000 µg/mL against 
the Hep2 cells. The lidocaine MINIMS formulation contained fluorescein sodium 
and so, as a control, this was tested individually. The 2% concentration was found 




Table 3.2: Efficacy of topical anaesthetics and fluorescein sodium against Acanthamoeba spp. trophozoites and cysts, and 
toxicity to a human epithelial cell line (Hep2). 
In vitro drug sensitivities (µg/mL) 
 A. castellanii (ATCC 50370) A. polyphaga (ATCC 30461) Hep2 cells 
Drug MTIC* MTAC** MCC*** MTIC* MTAC** MCC*** MIC+ MCT++ 
Proxymetacaine 39 156 156 39 78 156 78 39 
Tetracaine 9.75 19.5 39 19.5 39 78 312 156 
Oxybuprocaine 31.3 250 125 15.6 125 250 250 125 
Lidocaine (+Fluorescein) 312 1250 10000 625 312 1250 10000 5000 
Fluorescein sodium (2%) ˃10000 ˃10000 ˃10000 ˃10000 ˃10000 ˃10000 2500 1250 
 
MTIC* minimum trophozoite inhibitory concentration, MTAC** minimum trophozoite amoebicidal concentration, MCC*** 
minimum cysticidal concentration, MIC+ minimum inhibitory concentration,  MCT++ minimum cytotoxic concentration. What is 
interesting about the data in Table 3.2 is that tetracaine had a significant effect on the viability of the cysts and trophozoites of 





3.3.2  The topical antibiotics and antivirals   
Two fluoroquinolones, levofloxacin, both as a pure drug and preserved with 
benzalkonium chloride (BAC), and moxifloxacin (Moxeza®), were tested in the 
current study and the findings are shown in Table 3.3. The levofloxacin 
(Oftaquix®) formulation demonstrated MTIC between 78 – 156 µg/mL and the 
MTAC was between 156 – 312 µg/mL against both species of Acanthamoeba. 
The activity was reduced when levofloxacin (as a pure drug without BAC) was 
tested, with the values ranging from 312 up to 1250 µg/mL against both species 
of Acanthamoeba. This amounts to a difference of a factor of 4 in magnitude when 
compared with commercial ophthalmic preparations. When levofloxacin 
(Oftaquix®) was tested against cysts, cysticidal activity was observed at 625 
µg/mL. This compared to cysticidal activity within the range of 2500 – 5000 µg/mL 
for levofloxacin in the pure drug version and moxifloxacin (Moxeza®). 
 Levofloxacin (Oftaquix®) and moxifloxacin were found to be toxic for the human 
epithelial cell line at concentrations of 39 and 156 µg/mL, respectively. Two 
versions of chloramphenicol were tested in this study: preservative-free 
chloramphenicol showed inhibitory activity against trophozoites at 39 to 312 
µg/mL whereas chloramphenicol as a pure drug showed inhibitory activity 
between 312 and 625 µg/mL. The cysticidal activity for the preservative-free 
chloramphenicol was found to be at the same values for the trophozoites 
inhibitory which produced by the chloramphenicol as pure drug, however, the 
chloramphenicol as pure drug showed activity against cysts at a higher 
concentration of 1250 up to 2500 µg/mL.  
Phenylmercuric nitrate, which is the preservative used in chloramphenicol, was 
tested in this study and its activity against trophozoites was observed in a 
concentration range of 1 – 3.9 µg/mL but activity declined against cysts at 
concentrations of 15.6 to 31.3 µg/mL. Benzalkonium chloride (BAC), which is 
typically added to ophthalmic preparations as a preservative, was also tested and 
the findings showed that it exhibited activity against trophozoites in the 1 – 7.8 





Two antiviral drugs, trifluorothymidine (TFT) and acyclovir, were assessed for 
their antimicrobial activity in the current study. TFT showed inhibitory activity 
against trophozoites at concentrations of between 312 – 625 µg/mL and 
amoebicidal activity at concentrations of 625 – 1250 µg/mL. The cysticidal activity 
was found at the highest concentrations of 2500 – 5000 µg/mL and the MCT for 
the human epithelial cell line was at 156 µg/mL. Aciclovir ophthalmic ointment 
(Zovirax®) could not be applied during in vitro testing due to its soft paraffin base 
and, therefore, a solution was made up from the pure drug and tested in the 
present study. Aciclovir showed inhibitory activity against trophozoites at 
concentrations of between 63 – 125 µg/mL and the MTAC occurred at 125 – 250 
µg/mL against both species of Acanthamoeba. No activity was observed from this 
antiviral when tested against cysts at the highest concentration of >500 µg/mL 
and the toxicity for the human epithelial cell line occurred within the range 31.3 – 







Table 3.3: Efficacy of topical antibiotics, antivirals and preservatives against Acanthamoeba spp. trophozoites and cysts, and 
toxicity to a human epithelial cell line (Hep2). 
In vitro drug sensitivities (µg/mL) 
 A. castellanii (ATCC 50370) A. polyphaga (ATCC 30461) Hep2 cells 
Drug MTIC* MTAC** MCC*** MTIC* MTAC** MCC*** MIC+ MCT++ 
†Levofloxacin (Oftaquix®) 78 156 625 156 312 625 78 39 
Levofloxacin (Pure drug) 312 1250 2500 625 1250 5000 156 78 
Moxifloxacin (Moxeza®) 625 2500 2500 1250 2500 2500 312 156 
Chloramphenicol (Pure drug) 312 625 2500 312 625 1250 1250 625 
††Chloramphenicol (Generic) 78 312 625 39 156 312 1250 312 
Aciclovir (Pure Drug) 63 125 >500 125 250 >500 62.5 31.3 
†Trifluorothymidine 312 625 5000 625 1250 2500 312 156 
Benzalkonium Chloride 3.9 7.8 15.6 1 1.95 7.8 62.3 31.3 
Phenylmercuric Nitrate 1.95 3.9 31.3 1 1.95 15.6 7.8 3.9 
MTIC* minimum trophozoite inhibitory concentration, MTAC** minimum trophozoite amoebicidal concentration, MCC*** 
minimum cysticidal concentration, MIC+ minimum inhibitory concentration, MCT++ minimum cytotoxic concentration. † 
Compound is preserved with benzalkonium chloride (0.005% w/v). †† Compound is preserved with phenylmercuric nitrate 
(0.002% w/v). From the data in Table 3.3, it can be seen that benzalkonium chloride as preservative enhanced the antimicrobial 





3.3.3  The diamidines  
The antimicrobial activity of a range of diamidine compounds against the 
trophozoites and cysts of Acanthamoeba spp. and also their toxicity for the 
human epithelial cell line are presented in Table 3.4. Propamidine was tested as 
both a pure drug and in the Brolene® formulation (which contains BAC). 
Propamidine as a pure drug inhibited trophozoites at a concentration of 63 – 250 
µg/mL compared to a range of 7.8 – 15.6 µg/mL for the Brolene® formulation. 
Amoebicidal activity was observed at a higher concentration range of 250 – 500 
µg/mL for both species of Acanthamoeba in comparison with a range of 15.6 – 
31.3 µg/mL for the Brolene® formulation. Both the pure drug and the Brolene® 
formulation showed limited to no activity against cysts of both species.  
For pure drug propamidine, partial toxicity was observed at 250 µg/mL compared 
to 31.3 µg/mL for the Brolene® formulation. In this study, the same results were 
obtained when hexamidine as a pure drug and the desomedine® formulation were 
tested against trophozoites and cysts of both species and the human epithelial 
cell line. Pentamidine exhibited almost comparable activity to that of propamidine. 
BAC was relatively more effective than any of the diamidines tested in this study 
and showed activity against trophozoites at lower concentrations ranged from 1 
– 7.8 µg/mL and cysts 7.8 – 15.6 µg/mL as range and greater cytotoxicity for the 









Table 3.4: Efficacy of diamidine compounds against Acanthamoeba spp.  trophozoites and cysts, and toxicity to a human 
epithelial cell line (Hep2). 
In vitro drug sensitivities (µg/mL) 
 A. castellanii (ATCC 50370) A. polyphaga (ATCC 30461) Hep2 cells 
Drug MTIC* MTAC** MCC*** MTIC* MTAC** MCC*** MIC+ MCT++ 
Propamidine (Pure drug) 62.3 250 ˃500 250 500 ˃500 500 250 
†Propamidine (Brolene®) 7.8 15.6 500 15.6 31.3 250 62.3 31.3 
Hexamidine (Pure drug)  7.8 62.3 250 7.8 31.3 250 125 62.3 
Hexamidine (Desomedine®) 7.8 62.3 250 7.8 31.3 250 125 62.3 
Pentamidine (Pure drug) 62.3 250 ˃500 125 250 ˃500 250 125 
 
MTIC* minimum trophozoite inhibitory concentration, MTAC**  minimum trophozoite amoebicidal concentration,  MCC***  
minimum cysticidal concentration, MIC+ minimum inhibitory concentration,  MCT++  minimum cytotoxic concentration.  
† Compound is preserved with benzalkonium chloride (0.005% w/v). It is apparent from the data in Table 3.4 that benzalkonium 
chloride as a preservative in the formulation of propamidine (Brolene®) is responsible for enhanced activity of this compound 






3.3.4  The biguanides 
The effects of the biguanide compounds and povidone iodine on Acanthamoeba 
trophozoites and cysts, and their toxicity for the human epithelial cell line, are 
shown in Table 3.5. The concentrations at which inhibitory activity occurred for 
all of the biguanides tested in this study were between 0.5 – 1.95 µg/mL and the 
minimum amoebicidal concentration in trophozoites of both species was found to 
be in the range 1 – 15.6 µg/mL. Both octenidine and alexidine demonstrated 
greater cysticidal activity in the range 3.9 – 7.8 µg/mL, while cysticidal activity 
was reduced for PHMB and chlorhexidine in the range 7.8 to 31.3 µg/for both 
species. The toxicity of the biguanides against the human epithelial cell line 
occurred in the range 1 – 31.3 µg/mL, with PHMB having the highest value 
(minimum toxicity). Povidone iodine showed MTIC at 7.8 µg/mL and MTAC at 
31.3 µg/mL for both species of Acanthamoeba, whereas the MCC for this 
compound ranged from 7.8 – 15.6 µg/mL and it was not toxic for the human 










Table 3.5: Efficacy of biguanides and povidone iodine compounds against Acanthamoeba spp. for trophozoites and cysts and 
toxicity to a human epithelial cell line (Hep2). 
In vitro drug sensitivities (µg/mL) 
  A. castellanii (ATCC 50370) A. polyphaga (ATCC 30461) Hep2 cells 
Drug MTIC* MTAC** MCC*** MTIC* MTAC** MCC*** MIC+ MCT++ 
Polyhexamethylene 
Biguanide 
1 3.9 15.6 1 7.8 7.8 62.3 31.3 
Chlorhexidine 1 3.9 31.3 1.95 15.6 31.3 7.8 3.9 
Octenidine hydrochloride 1 1.95 7.8 0.5 1 3.9 3.9 1.95 
Alexidine 1 1.95 3.9 1.95 7.8 7.8 1.95 1 
Povidone iodine 7.8 31.3 15.6 7.8 31.3 7.8 250 125 
 
MTIC*  minimum trophozoite inhibitory concentration, MTAC**  minimum trophozoite amoebicidal concentration,  MCC***  
minimum cysticidal concentration, MIC+ minimum inhibitory concentration,  MCT++  minimum cytotoxic concentration. The most 
interesting aspect of the findings in Table 3.5 is that octenidine hydrochloride demonstrated a higher antimicrobial activity against 






3.3.5  Inverted light microscopy observation 
The effects of different agents on the morphology of Neff’s cysts were 
demonstrated using inverted light microscopy and the findings of these 
investigations are shown in Figure 3.1. The healthy Neff’s cyst in ¼ strength 
Ringer’s solution as control is shown in Figure 3.1.A. In healthy cysts, a thick cyst 
wall can be seen surrounding the encysted trophozoite. When the cyst was 
incubated with tetracaine, the cyst walls were disrupted (Figure 3.1.B). No 
changes were observed in morphology when the cysts were exposed to 
preserved chloramphenicol, propamidine pure drug, and unpreserved 
chloramphenicol (Figures 3.1.C, D, and F). When the cyst was incubated with 
BAC (0.05 mg/mL), povidone iodine (5% w/v) and PHMB (0.02 %), there was 
clear damaged and destruction in the endocyst and the walls of the ectocyst 
(Figures 3.1.E, G and H). 
3.3.6  Transmission electron microscopy study  
In order to confirm the preliminary results of the inverted light microscopy and to 
provide a detailed explanation of how these agents affect the intracellular 
elements of the cyst, Neff’s cysts of Acanthamoeba were exposed to various 
agents and changes in the morphology of the cyst were observed using TEM 
imaging. The results are presented in Figure 3.2. A Neff’s cyst exposed to ¼ 
strength Ringer’s solution as control and a healthy cyst can be seen in Figure 
3.2.A.  
The healthy cyst has a thick cyst wall surrounding the encysted trophozoite. In 
the plasma membrane, the trophozoite links with the endocyst wall taking up the 
whole space available inside the cyst. No change occurred in the cytoplasm and 
the nucleus is clear as a rounded structure including mitochondria and 
lysosomes. When the cyst was treated with tetracaine, the nucleus disappeared 
and the cytoplasm was completely full of micelles, which were produced by the 
breakup of the nuclear membrane (Figure 3.2.B). No alterations were observed 
in the intracellular organisation of either the cytoplasm or the nucleus when the 
cysts were exposed to preserved chloramphenicol, propamidine pure drug and 
unpreserved chloramphenicol (Figures 3.2.C, D, and H). Obvious damage 
occurred to the plasma membrane of the encysted trophozoite after exposing the 




Moreover, the nucleus was not visible, and the number of cytoplasmic micelles 
increased, a clear indication of membrane damage (Figure 3.2.E). Following the 
exposure of the cyst to povidone iodine (5% w/v) and PHMB (0.02%), intensive 
damage occurred to the plasma membrane of the encysted trophozoite which 
shrank away considerably from the walls of the endocyst. No defined nuclear 
structures were observed and there were significant numbers of micellar 
aggregations inside the cyst, indicating considerable plasma membrane damage 
























































Figure 3-1: Inverted light microscopy images of Acanthamoeba Neff's cysts 
following 1 hour of exposure to the subsequent 7 agents. (A) Untreated Neff's cysts; 
(B) treated with 1 % tetracaine; (C)treated with 0.5 % chloramphenicol (preserved); 
treated with 0.1 % propamidine; (E) treated with 0.05 mg/mL benzalkonium chloride; 
(F) treated with 0.5 % chloramphenicol (unpreserved); (G) treated with 5 % 































Figure 3-2: Transmission electron microscopy images of Acanthamoeba cyst 
after 1 hour exposure to the following 7 agents: (A) untreated healthy cyst as 
control; (B) treated with 1 % tetracaine; (C) treated with 0.5 % preserved 
chloramphenicol; (D) treated with 0.1 % propamidine pure drug; (E) treated with 
0.05 mg/ml benzalkonium chloride; (F) treated with 5 % povidone iodine; (G) 
treated with 0.02 % PHMB; (H) treated with 0.5 % unpreserved chloramphenicol. 





3.4  Discussion 
In this chapter, a variety of compounds have been tested in vitro which often given 
to AK patients including anaesthetics used to anaesthetise the eye, antibiotics 
applied in empirical treatment, antivirals used if misdiagnosed with herpes 
simplex keratitis and biocides including biguanides and diamidines.  
3.4.1 The effects of topical anaesthetics on the viability of 
Acanthamoeba 
AK is a sight-threatening corneal infection and prompt diagnosis is the most 
important factor in achieving a better prognosis and outcome for vision. In order 
to differentiate AK infection from the other types of keratitis, determine the risk 
factors and clinical examination are essential. The clinical indicators of AK are 
ring infiltrate or disease being limited to the epithelium when compared with other 
keratitis, including bacterial and fungal (Mascarenhas et al., 2014). Nonetheless, 
in epithelial disease, and particularly when linked with dendritic-type lesions, 
incorrect diagnosis of Acanthamoeba in vivo can occur, resulting in other causes 
of keratitis, such as herpes simplex (HSV) keratitis, being reported (Radford et 
al., 2002, Stehr-Green et al., 1987). There is an association between the amount 
of viable Acanthamoeba found in a corneal scrape or biopsy and the inhibitory 
effect of using of topical agents, including anaesthetics and vital stains, such as 
fluorescein, before microbiological sampling is performed (Goldschmidt et al., 
2006).  
There have been relatively few studies relating to the inhibitory effect of topical 
anaesthetics with, one study in the literature showed that proparacaine 
(proxymetacaine) did not negatively affect the polymerase chain reaction (PCR) 
(Thompson et al., 2008). However, another study conducted by Goldschmidt et 
al. (2006) found that oxybuprocaine inhibited the real-time polymerase chain 
reaction (real-time PCR) in detecting Acanthamoeba. The current study found 
that lidocaine had a limited antimicrobial effect on the viability of Acanthamoeba 
and, at therapeutic concentrations, it did not exhibit significant antimicrobial 





Although the lidocaine tested in this study was combined with fluorescein, the 
findings from testing fluorescein as a single therapy showed that it had limited 
antimicrobial activity against cysts and trophozoites of Acanthamoeba. These 
results differed from those relating to other topical anaesthetics, especially 
tetracaine, which demonstrated greater antimicrobial activity against trophozoites 
and cysts of Acanthamoeba. This agent was also toxic for the human cell line. A 
comparable effect was observed by proxymetacaine and oxybuprocaine against 
A. castellanii, but for A. polyphaga, proxymetacaine showed significant 
amoebicidal activity but it also showed higher toxicity for the human cell line. 
Based on the findings of this study, it is proposed that the use of topical 
anaesthetics, in particular tetracaine, may have greater anti-amoebic effects and 
they could contribute significantly to the low sensitivity of culture detected in a 
corneal scrape. 
3.4.2  Evaluating the activity of antibiotics and antivirals 
There is a link between the number of viable Acanthamoeba cells identified from 
a corneal scrape and the inhibitory effect of empirical treatment with antibiotics 
prior to microbiological sampling being performed (Thompson et al., 2008). 
Based on the antibiotics protocol used, empirical treatment with third or fourth 
generation fluoroquinolones is frequently prescribed as a first therapy for the 
treatment of microbial keratitis because of their broad-spectrum antimicrobial 
activity (Marangon et al., 2004). Preserved levofloxacin (Oftaquix®) with BAC 
showed strong antimicrobial activity against both species of Acanthamoeba. 
However, when this antibiotic was tested as a pure drug, its antimicrobial activity 
against cysts and trophozoites declined. This finding is not surprising as the 
activity of this preserved antibiotic is related to the BAC constituent rather than 
the antibiotic itself. Furthermore, the testing of a preservative-free preparation of 
moxifloxacin (Moxeza®) did not show any significant effect against either species 
of Acanthamoeba.  
A prior study by Thompson et al. (2008) did not find any negative effects on PCR 
amplification in Acanthamoeba with either gatifloxacin or moxifloxacin. The 
gatifloxacin tested in their study (Zymar; Allergan, Irvine, CA) was preserved with 
BAC but the moxifloxacin was self-preserved. Also, the authors did not test BAC 




antibiotics indicates that the effect of BAC on PCR in detecting Acanthamoeba 
DNA could be lower compared to the amoebicidal and cysticidal assays 
performed in the present study. There was a significant difference between the 
two chloramphenicol preparations: the preserved drug exhibited greater 
antimicrobial activity against both species of Acanthamoeba, hinting that the anti-
amoebic effect may be associated with the preservative phenylmercuric nitrate. 
Moreover, the TEM images did not show much difference in morphology for the 
preserved and preservative-free versions of chloramphenicol. 
Aciclovir and trifluorothymidine are antiviral drugs which showed good 
antimicrobial activity against trophozoites of both species but limited or no activity 
was observed in either agent against cysts. Aciclovir is widely used to treat HSV 
keratitis and, as AK is commonly misdiagnosed as HSV, the potential inhibitory 
impact on Acanthamoeba trophozoites would need to be borne in mind. BAC is 
commonly used as a preservative in various multi-dose ophthalmic preparations 
in order to avoid contamination of the formulation. Consequently, the empirical 
use of BAC preserved eye drops before the diagnosis of AK is expected to have 
a negative effect on the viability of the Acanthamoeba present on the cornea, 
which could be contributing to the ongoing reported low positive culture rate for 
AK from corneal scrapes. 
3.4.3  The antimicrobial activity of diamidines 
There was a clear difference in anti-amoebic activity for preserved propamidine 
(Brolene®), a common-over-the-counter (OTC), anti-infective ophthalmic 
preparation in the UK, compared with the pure drug propamidine. In the past, it 
has been demonstrated that the concentrations of BAC often used in ophthalmic 
medicines are very toxic to Acanthamoeba trophozoites. An in vitro study carried 
out by Tu et al. (2013) reported that BAC inhibited Acanthamoeba trophozoites 
at concentrations in the range 10 – 30 µg/mL and the findings of their study 
showed a 4.5 log reduction in the viability of trophozoites after 6.5 hours of 
exposure. Nevertheless, the current study is the first to show the effect of 





This study found that the MTIC, MTAC and MCC values of BAC were significantly 
lower than the concentration of BAC present in both Brolene® (0.05 mg/mL) and 
Oftaquix® (50 µg/mL) ophthalmic preparations. In fact, the current study has 
shown that the existence of the BAC preservative in propamidine (Brolene®) eye 
drops is likely to be exclusively responsible for the observed antimicrobial activity 
against trophozoites and cysts of both species. Early in vitro studies tested 
preserved propamidine (Brolene®) and the results showed that the MTAC values 
were 5 – 25 µg/mL and 0.49 – 0.97 µg/mL. However, in investigations by both 
Elder et al. (1994), Hay et al. (1994b), only the BAC-preserved Brolene® was 
tested without comparing it with propamidine as a pure drug.  
To our knowledge, no attempt has been made to compare propamidine as a pure 
drug with propamidine (Brolene®) preserved with BAC. This study found a very 
significant difference in anti-amoebic activity, with MTAC values for Brolene® 
being in the range 15.6 – 31.3 µg/mL. These results are identical to those in the 
study by Hay et al. (1994b) and greater than the values found in the study 
conducted by Elder et al. (1994). This study was able to show that the anti-
amoebic activity of Brolene® is associated with the existence of BAC in the 
formulation, as, when propamidine was tested without BAC, the MTAC values 
were significantly higher, in the 250 –500 µg/mL range. Moreover, the amount of 
BAC in Brolene® (50 µg/mL) is much higher than the MTAC observed in this 
study, which is 12.8 times greater than the concentration found to inhibit 
trophozoites. Hexamidine (Desomedine®), which is another diamidine typically 
used in the treatment of AK, was tested in this study and the results were identical 
to those found for hexamidine as a pure drug. This result is not surprising as 
Desomedine® is not the same as the Brolene® and it does not contain any 
preservatives in the formulation. Furthermore, the current study assessed the 
activity of three different diamidines with increasing alkyl chain lengths between 
the aromatic benzene rings. The 6-carbon hexyl chain length compound 
hexamidine was found to have greater activity compared with propyl and pentyl 
diamidines. This observation is in line with a prior study accomplished by Perrine 
et al. (1995), which reported that the anti-amoebic activity of diamidine increases 





3.4.4  The antimicrobial activity of biguanides  
The results of the current study for chlorhexidine and PHMB are in line with earlier 
published studies, with PHMB exhibiting greater activity compared with 
chlorhexidine (Thompson et al., 2008, Kilvington et al., 2002). Typically, PHMB 
is used at a concentration of 0.02 % (200 µg/mL) for treating AK patients which 
is approximately 20 times the mean MCC for PHMB obtained from the present 
study. This finding agrees with the general in vitro sensitivities and clinical 
outcomes for PHMB compared to other anti-amoebic drugs (Alexander et al., 
2015). On the other hand, an in vitro study undertaken by Sunada et al. (2014) 
found their Acanthamoeba isolates had low in vitro susceptibility to PHMB. There 
are several possible explanations for these results, firstly, the authors used a 
different method for cyst production which was NNA-E. coli, so the cysts are 
strong enough. Secondly, the strain types, the ATCC 300100 strain used and 
Acanthamoeba isolates obtained from patients with clinically verified AK from the 
Osaka University Hospital also used and the collection time for the isolates was 
between 1994 and 2011 and stored at 4 °C. Thirdly, the exposure times were 1 
and 24 hours. Whereas in the current study we used Neff’s cysts which are less 
resistant to the drugs, only ATCC strains used in this study which are ATCC 
50370 and ATCC 30461 and the exposure time was 48 hours.  
The mechanism of action of biguanides has not been fully elucidated, but PHMB 
and CHLX have been shown to be taken up by Acanthamoeba trophozoites and 
cysts, disrupting the cell membranes producing pentose leakage. Furthermore, 
there is no direct association between pentose leakage and the activity released 
by the biguanides (Khunkitti et al., 1997). The cyst stage is harder to treat than 
the trophozoite stage due to cysts having a thick wall which is partly made of 
cellulose, making it very difficult for the drugs to penetrate deep inside the wall. 
There is a perception that PHMB and CHLX bind to the mucopolysaccharide plug 
of the ostiole enabling it to pervade inside the cell membrane of the amoeba 
(Seal, 2003). Interestingly, this study has found that both alexidine and octenidine 
exhibited great in vitro sensitivities and indeed octenidine was better than PHMB 
for both species in terms of MTAC and MCC, even though toxicity against the 
human epithelial cell line was relatively higher. As far as we are aware, no 




of Acanthamoeba. Octenidine is commonly incorporated into the surgical hand 
wash Octenisan® (Schuleke and Mayer, Sheffield, U.K.). Octenidine has been 
formerly tested at a concentration of 1% and was found to have great sterilising 
activity against the tissue forms of the tapeworm Echinococcus granulosus, a 
parasite which infects some animals, including  dogs and sheep, thus avoiding 
the transmission of infection during the eradication of a hydatid cyst (Altindis et 
al., 2004).  
The findings of this study relating to alexidine are consistent with those of 
Alizadeh et al. (2009), who found amoebicidal activity at a concentration of 10 
µg/mL, but they recorded a significantly higher MCC of 100 µg/mL. The specific 
reason for this variance is uncertain, but a possible explanation might be related 
to the concentration of cysts used in the above-mentioned study, which was 100-
fold greater at 1 x 106,  compared with 1 x 104 cells/ mL used in the current study 
and other published studies. At present, alexidine and octenidine are not used as 
treatments for AK in patients, but the antimicrobial activity of these agents against 
Acanthamoeba trophozoites and cysts, especially of octenidine, requires further 
investigation as they could possibly be useful in patients who do not respond to 
standard antiamoebic treatment. It has been reported that, when alexidine is 
encapsulated in one contact lens solution (AMO® RevitaLens OcuTec) at a 
concentration of 1.6 µg/mL, it showed great activity against Acanthamoeba cysts 
(Kilvington et al., 2010).  
Apart from alexidine, most multi-purpose contact lens solutions (MPSs) utilise 
PHMB on its own or in combination with polyquaternium-1. In this study, the 
minimum concentration at which alexidine showed inhibitory activity against 
trophozoites was in the range 1 – 1.95 µg/mL, which is comparable with the 
concentration of PHMB contained in MPSs. Consequently, the purpose of MPSs 
is to provide effective disinfectant properties through the prevention and inhibition 
of pathogenic organisms on the contact lens or the contact lens case and, 
therefore, it is likely that the release of a biocide from the contact lens can exert 
an inhibitory effect on the viability of Acanthamoeba on the cornea. All types of 
contact lenses are exposed to the uptake and release of biocides, but the 
interaction is complicated and differs according to many factors. Therefore, the 




lenses on the cornea is as yet unclear. The findings of this study showed that 
there is a strong relationship between in vitro sensitivity and TEM investigation in 
povidone iodine, as the damage caused to Acanthamoeba cysts when they are 
exposed to 0.5% of povidone iodine can be linked to the activity of this compound 
against cysts by using the microtitre method. Furthermore, the MCC value for 
povidone iodine was exactly the same as for PHMB and greater than for both 
propamidine and hexamidine. Also, the povidone iodine is not commonly used 
when a cornea scrape is performed, its potential inhibitory effect on the viability 
of Acanthamoeba must be taken into consideration. 
A major drawback of this study is that the findings from in vitro sensitivities do not 
always correlate with clinical outcomes (Alexander et al., 2015). This can be 
explained by several factors.  In the cysticidal assay, the cysts were exposed to 
the testing compound and then re-examined over a 7-day period for excystation 
and trophozoite replication. In a clinical setting, a corneal scrape for culture is 
performed immediately after the application of topical anaesthetics or vital stain, 
hence, a shorter assay period would be more representative. Furthermore, the 
interaction of the epithelium with a drug and the penetration of it into the stroma 
would be different with different types of drugs. There are limitations with in vitro 
sensitivity and efficacy studies of drugs on pathogens. Despite this, prior 
treatment with antibiotics to reduce pain before obtaining tissue specimens for 
culture or to investigate the potential adverse effects of the drugs used during 
clinical PCR on the viability of Acanthamoeba have to be considered. 
3.4.5  TEM and inverted images studies  
Initially, the Neff’s cysts of Acanthamoeba castellanii (ATCC 50370) were 
exposed to different agents and the outcomes from this investigation led us to do 
more work on the same agents using TEM imaging in order to validate their 
effects on the Neff’s cysts. Morphologically, the observations using inverted light 
microscopy were limited, as it can only show the cyst wall which encircles the 
encysted trophozoite. The other intracellular constituents, including the plasma 
membrane, the nucleus, the mitochondria and the lysosomes, were invisible. The 
TEM images presented a clear indication that BAC causes damage to the cysts. 
This observation is consistent with the findings of Sunada et al. (2014), who also 




outer walls when cysts were exposed to BAC. Moreover, in the above-mentioned 
study, the TEM images of cyst exposed to BAC and propamidine showed damage 
identical to that on encysted trophozoites. This observation can be explained by 
the fact that the authors did not use propamidine as a pure drug but instead they 
tested GoldenEye® eye drops, which contain 0.1 % w/v propamidine preserved 
with 0.05 % benzalkonium chloride.  
3.5  Conclusion  
Acanthamoeba keratitis is a serious and vision-damaging infection. The present 
study indicates that the anti-amoebic effect of benzalkonium chloride (BAC), 
povidone iodine and tetracaine is greater than that of the currently used 
diamidines and only slightly inferior to the biguanides used as a standard 
treatment for AK. Also, this study showed for the first time that the octenidine 
hydrochloride is better than PHMB and chlorhexidine. The use of specific topical 
anaesthetics and ophthalmic preparations containing BAC prior to specimen 
sampling may affect the viability of Acanthamoeba in vivo, resulting in a reduced 
culture yield and an inhibition of the effect on PCR amplification. In order to 
decrease false negative culture results, ophthalmologists should be aware of the 
















Screening antimicrobials against 
Acanthamoeba spp. to identify 
compounds that have improved 
therapeutic potential for the 









4. Chapter 4: Screening antimicrobials against Acanthamoeba spp. 
to identify compounds that have improved therapeutic potential 
for the treatment and prevention of AK 
 
4.1  Introduction 
 
4.1.1 Acanthamoeba infection and searching for better treatment  
In 1973, Jones and colleagues first identified Acanthamoeba polyphaga keratitis 
as a corneal infection in south Texas, USA (Jones, 1975). A study by Stehr-Green 
et al. (1989) in the USA reported 208 cases of AK and 85% of the cases were 
related to the incorrect use of contact lenses. The first successful medical 
treatment and diagnosis of AK infection in the USA was identified in the year of 
1995, and the treatment was consisting of propamidine isethionate (Brolene), 
neomycin sulfate-gramicidin polymyxin B sulfate (Neosporin or Ocutricin), and a 
1% (v/v) to 2% (v/v) clotrimazole suspension (D'Aversa et al., 1995). 
Furthermore, recent study in the UK, exposed the contact lenses control to the 
domestic sinks water of bathroom and kitchens, it was found that the incidence 
of Acanthamoeba in overflow kitchen 39.1% and bathroom 25.9% (Carnt et al., 
2020a). Patients with Acanthamoeba may suffer from strong pain in their eyes, 
photophobia and tearing. It appears from the scientific literature that AK is 
worldwide problem and mainly affects contact lens wearers. This issue is further 
complicated by the fact that there is no licensed treatment for this infection. The 
similarity of symptoms between AK and other keratitis infections such as herpes 
simplex keratitis, leads to inaccurate diagnosis of AK (Singh and Batta, 2018), 
and misdiagnosis plays an important role in the progression of this infection to its 
advanced stages.  
A range of compounds have been screened in this chapter, including aspirin 
analogues that tested against trophozoite and cyst, due Acanthamoeba has 
cyclooxygenase enzyme and these compounds block the action of this enzyme 
(Lanocha-Arendarczyk et al., 2018). Amidoamines were tested in this study, 
which are derivatives of naturally occurring plant and animal fatty acids and these 
compounds are available as surfactants in the cosmetic and hygiene industry 




myristamidopropyl dimethylamine (MAPD) and palmitamidopropyl dimethylamine 
(PAPD), new related compounds including myristoleyl-amidopropyl 
dimethylamine (MOPD) and palmitoleyl-amidopropyl dimethylamine (POPD) 
have been synthesized and tested against Acanthamoeba. The mechanism of 
action for amidoamine compounds is binding of the polar head group to the 
plasma membrane of Acanthamoeba and the carbon chain of the surfactant is 
integrated into the lipid bilayer of Acanthamoeba and then producing lateral 
amplification of the membrane (Denyer and Stewart, 1998). In addition, a different 
class of other drugs involving azole, macrolide, antineoplastic, antiparasitic, 
antiprotozoal and quaternary ammonium compounds were assessed for their 
antimicrobial activity against trophozoites and cysts. There are different 
mechanisms of action for the examined compounds included: azoles prevent the 
synthesis of ergosterol in Acanthamoeba. The antineoplastic interacts with carrier 
protein systems, causing a loss of key nutrients, and finally to cell death. The 
antimicrobial activity for quaternary ammonium compounds depends on the alkyl 
chain length and the mechanism of action for these compounds is denaturation 
of the important cell proteins of and Acanthamoeba.  
4.1.2  Failure of Acanthamoeba to respond to current drugs 
Acanthamoeba differentiation leads to the recurrent insufficiency of many 
therapeutic agents. The relationship between treatments and Acanthamoeba 
differentiation has been widely investigated and the trophozoite stage can be 
effectively killed compared with the cyst stage of Acanthamoeba (Turner et al., 
2000b). On the other hand, it has been suggested that the resistance of 
Acanthamoeba to drugs is related to a range of mechanisms, including alterations 
in cell permeability, the modification of drug- sensitive sites, the ability of a sub-
population of Acanthamoeba to develop drug resistance (Khan, 2009b). The 
mature cyst (endocyst) of Acanthamoeba is partly made of cellulose, which is 
resistant to most therapeutic agents, due the cyst consists of a thick walls, so it's 
difficult for the drug to penetrate inside the cyst (Lakhundi et al., 2015). The 
search continues for safe and more efficient novel therapeutic agents to combat 
Acanthamoeba spp. infection. The importance of a drug in preventing from the 




and the time at which drug intervention is commenced, the immune status of the 
patient and the lethal dose of Acanthamoeba (Schuster and Visvesvara, 2004b). 
4.1.3  Aim and objectives of this chapter  
In recent years, there has been increased awareness of AK and it appears from 
past studies that numerous in vitro investigations have been conducted in relation 
to its diagnosis and treatment. There is an urgent need to identify and develop an 
effective, new drug for this infection. The aim of the work described in this chapter 
is to examine the current therapeutic agents which are used to treat AK alongside 
new drugs and to assess their toxicity. To establish the antimicrobial activity for 
these drugs in combination against trophozoites of Acanthamoeba and evaluate 
the antimicrobial kinetics. The specific objectives of this chapter are listed below: 
I. Test a variety of agents including aspirin drugs, quaternary ammonium 
drugs, azoles and amidoamines against cysts and trophozoites of 
Acanthamoeba spp. 
II. Study the cytotoxicity of different drugs on human epithelial cell line. 
III. Carry out a time kill study for the novel synthesized of amidoamine 
alongside the existing compounds against trophozoites.  
IV. Evaluate the antimicrobial activity for several drugs in their own and in 
















4.2  Materials and Methods  
4.2.1  Preparation of organisms  
The Acanthamoeba castellanii (ATCC 50370) and Acanthamoeba polyphaga 
(ATCC 30461) test organisms were grown and prepared according to the 
methods detailed in chapter 2, section 2.4–2.8. 
4.2.2  In vitro evaluation of the drug antimicrobial activity 
The drugs were selected from different classes and included compounds 
previously been tested against Acanthamoeba, fungi , protozoa, parasite and 
aspirin analogues which have been found to inhibit the colorectal cancer cell lines 
in vitro and also prevent the in vivo colorectal tumour model in mice. The aspirin 
analogue compounds were obtained from Dr. Iain Nicholl in the Department of 
Biology, Chemistry & Forensic Science, University of Wolverhampton, U.K. The 
novel amidoamine compounds have been synthesised by my co-supervisor Dr 
Daniel Keddie in the Department of Biology, Chemistry & Forensic Science, 
University of Wolverhampton, U.K.  
Table 4-1: List of compounds, class and source of agents that tested for their 
antimicrobial activity in this study 
Drug Class/Use Solubility Supplier 
Natamycin Macrolide/ 
antifungal 
H2O Sigma (Dorset, U.K.) 
Voriconazole Antifungal  H2O VWR (Lutterworth, U. K.) 
Posaconazole Antifungal  H2O Sigma (Dorset, U.K.) 




H2O Sanofi, U.K. 
Benznidazole Antiparasitic H2O VWR (Lutterworth, U. K.) 
Miltefosine Antineoplas
tic 































H2O Sigma (Dorset, U.K.) 
Myristamidopropyl 
Dimethylamine  








Amidoamine H2O Synthesised by Dr 
Daniel Keddie (novel) 
Palmitoleyl-amidopropyl 
dimethylamine 
Amidoamine H2O Synthesised by Dr 
Daniel Keddie (novel) 
 
 
Table 4-2: List of aspirin analogue compounds that tested for their antimicrobial 
activity in against Acanthamoeba spp. 
Common name, Synonym Chemical name Solubility 
Aspirin, ortho‑aspirin Acetylsalicylic acid (aspirin) DMSO 
Diaspirin, DiA Bis‑carboxyphenylsuccinate DMSO 
benzosalin p-aminobenzoic acid (PABA) DMSO 
Fumaryldiaspirin, F‑DiA Bis‑carboxyphenyl fumarate DMSO 
Not applicable m‑bromobenzoyl salicylic acid DMSO 





meta‑aspirin 3‑acetoxybenzoic acid DMSO 
para‑aspirin  4‑acetoxybenzoic acid DMSO 
Thioaspirin, ortho‑TASP 2‑acetylthiobenzoic acid DMSO 
m‑thioaspirin, meta‑TASP 3‑acetylthiobenzoic acid DMSO 
p-thioaspirin, para-TASP 4‑acetylthiobenzoic acid DMSO 






The compounds were diluted in the appropriate solvent as outlined in Tables 4.1 
and 4.2, and then assayed to determine their antimicrobial activity against 
trophozoites and cysts as described in chapter 2, sections 2.11 – 2.13. In order 
to determine the Minimum Trophozoite Inhibitory Concentration (MTIC), the 
Minimum Trophozoite Amoebicidal Concentration (MTAC) and the Minimum 
Cysticidal Concentration (MCC) for each of the compounds. Compounds were 
considered to be appropriate candidates if the compound had similar or greater 
antimicrobial activity to the compounds that are currently used in the treatment of 
AK. In addition, diluent control experiments were conducted to establish their 
effect on trophozoites and cysts of Acanthamoeba (Data not shown).  
4.2.3  Toxicological testing against human epithelial cell line 
After determining the antimicrobial activity for all compounds against 
Acanthamoeba spp. A different in vitro assay performed to determine the 
toxicological profile for each of compounds against a human epithelial cell line. 
The human epithelial cell line was maintained and prepared as outline in chapter 
2, section 2.16 – 2.18.  
4.2.4  Composition of the contact lens base 
The solution comprised of NaCl 10 mM, KCl  1.87 mM, EDTA 0.068 mM, pluronic 
F127 0.30 mM, NaH2PO4.H2O 0.15 mM and Na2HPO4.7H2O 0.84 mM per 800 
mL of distilled water, the pH was adjusted to 7.2 with 1 M sodium hydroxide 
(NaOH) and the final volume of solution base made up to 1000 mL. 
4.2.5  Time kill assays for amidoamine compounds 
The time kill experiments where conducted for the novel and existing amidoamine 
compounds against trophozoites of Acanthamoeba spp. The reduction in viable 
trophozoites were plotted as change in log viability for each time point compared 
to zero-time viability, as described in chapter 2, section 2.13.  
4.2.6  Drug synergy assays  
4.2.6.1  Testing individual drug against trophozoites  
In order to determine the IC₅₀ for a single drug against trophozoites of 
Acanthamoeba castellanii (ATCC 50370), the experiments were accomplished in 




concentration of drugs A or B (the MTIC for drugs A or B is 50% inhibition of 
trophozoites compared with the controls) were prepared and placed in 45 mL of 
¼ strength Ringer’s solution. Subsequently, 3 different ratios were mixed as 
follows: 7.5 mL of drug A or B with 2.5 mL of ¼ strength Ringer’s solution (75:25), 
5 mL of drug A or B with 5 mL of ¼ strength Ringer’s solution (50:50) and 2.5 mL 
of drug A or B with 7.5 mL of ¼ strength Ringer’s solution (25:75). Drugs A and 
B were tested on their own by preparing the required concentrations of both drugs 
in 10 mL of ¼ strength Ringer’s solution and also a positive control was run in a 
¼ strength Ringer’s solution. Then, 100 L of 5 x 106 cells/mL of trophozoites 
were added to each tube and the tubes were placed at room temperature for 24 
hours. After that, the tubes were plated out using a time kill assay as described 
in chapter 2, section 2.14.  
4.2.6.2  Synergy testing for combinations of two drugs against 
trophozoites  
These experiments were designed to assess the antimicrobial activity of the 
drugs in combination against trophozoites of A. castellanii (ATCC 50370) as an 
alternative to single drug testing. The experiments were performed in triplicate in 
50 mL polypropylene centrifuge tubes by adding the desired concentration of drug 
A or B (the MTIC for drug A or B is 50% inhibition of trophozoites compared with 
the controls) to a 45 mL of ¼ strength Ringer’s solution. The tubes were labelled 
as drug A and drug B, with tubes 1 and 5 containing drug A and B respectively. 
The other 3 tubes contained combinations of drugs A and B in different ratios: 7.5 
mL of drug A mixed with 2.5 mL of drug B (75:25), 5 mL of drug A mixed with 5 
mL of drug B (50:50) and 2.5 mL of drug A mixed with 7.5 mL of drug B (25:75). 
Tube 6 serves as a positive control and contained a ¼ strength Ringer’s solution. 
100 L of 5 x 106 cells/mL of trophozoites were added to each tube and the tubes 
were placed at room temperature for 24 hours. Then the tubes were plated out 





4.2.6.3  Data analysis for single drug and the combinations of 
two drugs  
Initially, the concentrations of the drugs were selected from MTIC study of 
trophozoites of A. castellanii (ATCC 50370). The log kill caused by drug A or B 
alone against trophozoites from the time kill experiments was expressed as a 
percentage in Microsoft Excel against the drug concentrations. If no kill was 
observed, that indicated a 0% log kill of trophozoites, 1-log kill equalled 25%, 2-
log kill was expressed as 50%, 3-log kill was 80% and 4-log kill was 99%. The 
IC₅₀ for drug A or B in their own was determined by plotting a semi-log against 
the log kill of trophozoites. Subsequently, the IC₅₀ for the combined drugs was 
determined by drawing a log kill curve with a semi log of drug A alone and drug 
A combined with drug B. Then, the IC₅₀ for drug A was combined with drug B and 
compared to the IC₅₀ for drug A alone. The same process was repeated for drug 
B.  
The fractional inhibitory concentration (ΣFIC) was calculated according to the 
formula below:  










The interaction between the assessed drugs was determined from the ΣFIC 
value:  
                               IC₅₀ Drug A (in presence of B)  
    FIC (Drug A) =  
                              IC₅₀ Drug A (alone) 
                               IC₅₀ Drug B (in presence of A)  
    FIC (Drug B) =  




If the ΣFIC ≤ 0.5 indicates synergistic effect; If the ΣFIC >0.5 but ≥4 indicates 
additive effect;  and if the ΣFIC >4  indicates antagonistic effect (Odds, 2003).  
 
4.3  Results  
This section is presenting the antimicrobial testing data for different group of 
drugs against both trophozoites/cysts and the toxicity for human epithelial cell 
line, the time kill for novel and existing amidoamine compounds and the findings 
for single drug and in combination against trophozoites of Acanthamoeba 
castellanii (ATCC 50370). 
4.3.1  Novel and existing of amidoamines  
The C14 myristamidopropyl dimethylamine (MAPD) showed huge activity against 
cysts ranged from 7.8 – 15.6 µg/mL and against trophozoites between 1 – 3.9 
µg/mL. The toxicity test for human cell line comparable to that obtained against 
cysts at MCT 7.8 µg/mL. The next novel compound evaluated was a C14-1 
myristoleyl-amidopropyl-dimethylamine (MOPD), which showed a minor 
antimicrobial activity against cysts between 125 – 250 µg/mL and against 
trophozoites ranged from 31.3 – 125 µg/mL for both species, also this compound 
was not toxic human epithelial cell line at MCT 15.6 µg/mL. Another compound 
was tested a C16 palmitamidopropyl dimethlamine (PAPD) and was found to be 
active against the trophozoites between 3.9 – 15.6 µg/mL and against cysts 
ranged from 15.6 – 31.3 µg/mL for either species. Toxicity to human epithelial cell 
line was same as MCC values. The C16-1 palmitoleyl-amidopropyl-
dimethylamine (POPD) was found less active against cysts and had activity 
between 31.3 – 62.5 µg/mL and was found to be more active against trophozoites 




Table 4-3: Efficacy of amidoamine novel and exciting compounds against trophozoites and cysts for A. polyphaga  &  A. 
castellanii  and for their toxicity against a human epithelial cell line (Hep2) 
  In vitro drug sensitivities (µg/mL)  
  A. castellanii (ATCC 50370) 
A. polyphaga (ATCC 
30461) 
Hep2 cells 





MTIC* MTAC** MCC*** MTIC* MTAC** MCC*** MIC+ MCT++ 
Myristamidopropyl 
Dimethylamine  
MAPD C14 1 3.9 7.8 1.95 3.9 15.6 3.9 7.8 
Palmitamidopropyl 
Dimethylamine 
PAPD C16 7.8 15.6 15.6 3.9 7.8 31.3 15.6 31.3 
Myristoleyl-amidopropyl 
dimethylamine 
MOPD C14:1 62.5 125 250 31.3 62.5 125 7.8 15.6 
Palmitoleyl-amidopropyl 
dimethylamine 
POPD C16:1 15.6 31.3 62.5 3.9 7.8 31.3 15.6 31.3 
 
MTIC* Minimum trophozoite inhibitory concentration, MTAC** Minimum trophozoite amoebicidal concentration, MCC*** 
Minimum cysticidal concentration,  MIC+ Minimum inhibitory concentration, MCT++ Minimum Cytotoxic Concentration. It is clear 
from the results presented in Table 4-3 that the MAPD of amidoamine compounds demonstrated higher antimicrobial activity 




4.3.2 Compounds that showed favourable antimicrobial activity 
against cysts and trophozoites of Acanthamoeba spp.  
A series of different class of drugs have been shown encouraging activity against 
both trophozoite and cyst. Posaconazole was active against cysts within the 
concentration range 7.8 – 15.6 µg/mL and more activity was observed against 
trophozoites at concentrations of between 1 and 7.8 µg/mL. However, it was toxic 
for the human epithelial cell line at MCT 3.9 µg/mL. Voriconazole was inactive 
against cysts of both species of Acanthamoeba at an MCC of 500 µg/mL, 
amoebicidal activity occurred at a concentration of 31.3 µg/mL and inhibitory 
activity at concentrations between 7.8 and 3.9 µg/mL. When it was tested against 
the human epithelial cell line, it showed level of toxicity at MCT 7.8 µg/mL. 
Amphotericin-B showed no activity against cysts at MCC ˃500 µg/mL and also 
showed no amoebicidal activity for either species of Acanthamoeba at MTAC 500 
µg/mL. However, it was tolerated by the human epithelial cell line within the range 
62.5 – 125 µg/mL. Natamycin is a macrolide and showed no activity against cysts 
at MCC ˃500 µg/ml but was active against trophozoites within the range 1.95 – 
3.9 µg/mL for the two species of Acanthamoeba. It was toxic for the human 
epithelial cell line between 3.9 and 7.8 µg/mL (Table 4.4).  
Miltefosine is antineoplastic, it was very active against trophozoites within the 
concentration range 0.5 –1.95 µg/mL and it was also active against cysts in the 
MCC range of 31.3 – 62.5 µg/mL. This compound was slightly toxic for the human 
epithelial cell line at MCT 15.6 µg/mL. The antiprotozoal compound tested was 
fexinidazole micronized. It was found to be inactive against cysts at an MCC of 
500 µg/mL but showed moderate activity against trophozoites with a MTAC range 
of 15.6 – 62.5 µg/mL. Fexinidazole was toxic to the human cell line at MCT 250 
µg/mL. The antiparasitic drug benznidazole was found to have no cysticidal 
activity at MCC 500 µg/mL, however this compound was found to have 
acceptable amoebicidal activity within the range 31.3 – 62.5 µg/mL. It showed no 







For quaternary ammonium drugs, didecyldimethylammonium chloride showed 
incredible activity against cysts at MCC ranging from 3.9 – 7.8 µg/mL. It was very 
active against trophozoites and it showed inhibitory activity at a concentration of 
0.48 µg/mL. This compound demonstrated amoebicidal activity at concentrations 
between 0.97 and 1.95 µg/mL. Hexadecyltrimethylammonium bromide was  
active against cysts at MCC 7.8 – 15.6 µg/mL and showed great activity against 
trophozoites between 1.95 and 7.8 µg/mL. Polyquaternium-1 showed massive 
inhibitory activity against  trophozoites at concentrations between 1.95 and 3.9 
µg/mL. Amoebicidal activity occurred within the range 3.9 – 7.8 µg/mL. This 
compound was active against Acanthamoeba cysts for both species at MCC 
ranging from 15.6 – 31.3 µg/mL. Toxicity for the human epithelial cell line 
occurred at the same concentration as cysticidal activity for A. polyphaga at MCT  
15.6 µg/mL (Table 4.4). Benzethonium chloride was active against trophozoites 
at concentrations between  3.9 and 15.6 µg/mL and exhibited moderate  activity 
against cysts between  13.3 – 62.5 µg/ml. It was toxic for the human cell line at 
MCT 7.8 µg/mL. Unlike the other quaternary ammonium drugs which were tested, 
hexadecylpyridinium chloride produced only limited activity against trophozoites 
within the range 62.5 – 250 µg/mL and it was inactive against Acanthamoeba 
cysts for either species at MCC 500 µg/ml. The MCT for this compound was found 








Table 4-4:  Efficacy of different agents that showed great antimicrobial activity against trophozoites and cysts of Acanthamoeba 
spp. and the toxicity against human epithelial cell line. 
 In vitro drug sensitivities (µg/mL)  
 A. castellanii (ATCC 50370) A. polyphaga (ATCC 30461) Hep2 cells 
Drug MTIC* MTAC** MCC*** MTIC* MTAC** MCC*** MIC+ MCT++ 
Natamycin 1.95 3.9 ˃500 1.95 3.9 ˃500 3.9 7.8 
Voriconazole 7.8 31.3 500 3.9 31.3 500 3.9 7.8 
Posaconazole 1 3.9 7.8 1 7.8 15.6 1.95 3.9 
Amphotericin- B 250 500 ˃500 500 500 ˃500 62.5 125 
Fexinidazole micronized 15.6 62.5 500 7.8 15.6 500 125 250 
Benznidazole 7.8 31.3 500 7.8 62.5 500 15.6 31.3 
Miltefosine 1 1.95 62.5 0.5 1 31.3 7.8 15.6 
Benzethonium Chloride 3.9 7.8 31.3 7.8 15.6 62.5 15.6 7.8 
Hexadecylpyridinium Chloride 62.3 125 500 125 250 500 125 62.3 
Didecyldimethylammonium chloride 0.48 0.97 3.9 0.48 1.95 7.8 31.3 15.6 
Hexadecyltrimethylammonium bromide 1.95 3.9 7.8 3.9 7.8 15.6 62.5 31.3 
Polyquaternium-1 3.9 7.8 31.3 1.95 3.9 15.6 31.3 15.6 
 MTIC* Minimum trophozoite inhibitory concentration, MTAC** Minimum trophozoite amoebicidal concentration, MCC*** 
Minimum cysticidal concentration,  MIC+ Minimum inhibitory concentration, MCT++ Minimum Cytotoxic Concentration. The most 
active compounds against trophozoites and cysts from the data that presented in this table are miltefosine, posaconazole and 




4.3.3 The activity of aspirin compounds against cysts and 
trophozoites of Acanthamoeba spp.  
Aspirin analogue compounds showed minor antimicrobial activity against cysts 
for both species of Acanthamoeba and the MCC values ranged between 250 – 
500 µg/mL. As well as these compounds were not toxic against human epithelial 
cell line and more tolerated between 62.5 – 500 µg/mL. When these compounds 
assessed for their antimicrobial activity against trophozoites, it was the 
amoebicidal activity between 15.6 – 125 µg/mL as range and the trophozoites 
inhibitory was ranged from 7.8 – 62.5 µg/mL for either species of Acanthamoeba. 
Among all the aspirin analogue compounds tested against cysts of 
Acanthamoeba in this study there were only two compounds, namely bis-
carboxyphenyl fumarate and isopropyl m-bromobenzoyl salicylate, active against 
cysts between 15.6 – 62.5 µg/mL and the amoebicidal activity was at range of 




Table 4-5: Efficacy of aspirin analogues drugs against trophozoites and cysts of Acanthamoeba spp., and the toxicity against 
human epithelial cell line. 
 In vitro drug sensitivities (ug/mL) 
 A. castellanii (ATCC 50370) A. polyphaga (ATCC 30461) Hep2 cells 
Chemical name MTIC* MTAC** MCC*** MTIC* MTAC** MCC*** MIC+ MCT++ 
acetylsalicylic acid (aspirin) 15.6 62.5 500 7.8 15.6 500 125 250 
Bis-carboxyphenylsuccinate 15.6 31.3 250 7.8 31.3 250 62.5 125 
p-aminobenzoic acid  31.3 125 500 7.8 15.6 500 62.5 125 
Bis-carboxyphenyl fumarate 3.9 7.8 15.6 7.8 15.6 31.3 62.3 125 
m‑bromobenzoyl salicylic acid 31.3 125 500 7.8 31.3 250 125 250 
Methyl benzoyl salicylate 31.3 62.5 500 7.8 31.3 500 125 250 
Isopropyl m‑bromobenzoyl salicylate 7.8 15.6 31.3 7.8 31.3 62.5 250 500 
3‑acetoxybenzoic acid 62.5 125 500 15.6 62.5 500 125 250 
4‑acetoxybenzoic acid 31.3 125 500 15.6 62.5 500 125 250 
2‑acetylthiobenzoic acid 31.3 62.5 500 15.6 62.5 250 250 500 
3‑acetylthiobenzoic acid 62.5 125 500 31.3 62.5 500 62.5 125 
4‑acetylthiobenzoic acid 31.3 62.5 500 31.3 62.5 500 125 250 
MTIC* Minimum trophozoite inhibitory concentration, MTAC** Minimum trophozoite amoebicidal concentration, MCC*** 
Minimum cysticidal concentration,  MIC+ Minimum inhibitory concentration, MCT++ Minimum Cytotoxic Concentration. There 
are only two compounds included bis-carboxyphenyl fumarate and isopropyl m‑bromobenzoyl salicylate that showed good 
activity against both trophozoites and cysts of Acanthamoeba. Also, the same tested compounds demonstrated no toxicity 




4.3.4  Time kill studies for amidoamines 
More investigations for the novel compounds (including myristoleyl-amidopropyl 
dimethylamine MOPD and palmitoleyl-amidopropyl dimethylamine POPD) and 
existing amidoamines (involving  myristamidopropyl dimethylamine MAPD and 
palmitamidopropyl dimethylamine PAPD) were made to establish the 
antimicrobial activity of these compounds over the time. When they were 
formulated into a contact lens base solution at a concentration of 0.0005 % (w/v) 
and tested against trophozoites of Acanthamoeba, they were found to be more 
active as shown in Figures 4.1 and 4.2.  
 
Figure 4-1: Efficacy of novel amidoamines including myristoleyl-amidopropyl 
dimethylamine (MOPD), palmitoleyl-amidopropyl dimethylamine (POPD), 
compared to the current compounds of amidoamines; myristamidopropyl 
dimethylamine (MAPD) and palmitamidopropyl dimethylamine (PAPD) at 
concentration (0.0005% w/v) formulated in contact lens base solution and tested 
against trophozoites of Acanthamoeba castellanii (ATCC 50370). One-Way 
Analysis of Variance (ANOVA) was performed. Asterisks represent values 
statistically significant (***P<0.001) between the tested compounds of 































Interestingly, MOPD and POPD showed higher antimicrobial activity against 
trophozoites, as they gave complete kill at a 4.5 log reduction after 24 hours. 
However, the activity against trophozoites was lower at 3-log reduction for MAPD 
and PAPD with the same time exposure. One-Way ANOVA analysis confirmed 
that MOPD and POPD were significant (P < 0.001) in their antimicrobial activity 
after 24 hours compared to a ¼ strength Ringer’s control and there was also a 
significant difference (P < 0.001) for MOPD and POPD after 24 hours in terms of 
their activity against trophozoites compared with MAPD and PAPD (Figure 4.1). 
Furthermore, two sample t-test for the means showed that a significance 
correlation between the tested compounds after 24 hours-time point and a ¼ 
strength Ringer’s control, as the p value was observed at p=0.018   
 
Figure 4-2: Efficacy of novel amidoamines including myristoleyl-amidopropyl 
dimethylamine (MOPD), palmitoleyl-amidopropyl dimethylamine (POPD), compared to 
the current compounds of amidoamines; myristamidopropyl dimethylamine (MAPD) and 
palmitamidopropyl dimethylamine (PAPD) at concentration (0.0005% w/v) formulated in 
contact lens base solution and tested against trophozoites of Acanthamoeba 
polyphaga(ATCC 30461). One-Way Analysis of Variance (ANOVA) was performed. 
Asterisks represent values statistically significant (***P<0.001) between the tested 
































MOPD achieved complete kill against trophozoites of A. polyphaga (ATCC 
30461) and provided a 4.5 log reduction at 24 hours. The rate of kill slightly 
declined to a 4-log reduction for POPD at the same time point. Moreover, the 
level of the kill was only a 3-log reduction for both MAPD and PAPD against 
trophozoites of the same tested strain after 24 hours of exposure. There was a 
significant difference (P < 0.001) after 24 hours with regards of the activity against 
trophozoites between MOPD, POPD compared with a ¼ strength Ringer’s control 
and also in comparison with MAPD and PAPD over 24 hours of time point (Figure 
4.2). In addition, two sample t-test for the means demonstrated that a significance 
differences between the assessed compounds over 24 hours and the ¼ strength 
Ringer’s control as the p value was recorded at p=0.009.  
4.3.5  Single and combination of two drugs findings  
Table 4.6 below presents the IC50 findings for a number of drugs as individual 
and in combination against trophozoite of Acanthamoeba castellanii (ATCC 
50370). The results in (Table 4.7) are comparing the activity of two drugs against 
trophozoites of A. castellanii (ATCC 50370). Amphotericin-B and chlorhexidine 
(CHLX) as individual drugs were tested at a range of concentrations from 31.3  to 
250 µg/mL for amphotericin-B and from 3.9 to 15.6 µg/mL for CHLX. These 
concentrations were plotted as logs in Microsoft Excel. The same concentrations 
were used in combination assays. The IC50 for amphotericin-B was recorded at 
higher value of 73.6 µg/mL, whereas the IC50 for CHLX was observed at 5.64 
µg/mL. When the CHLX was combined with amphotericin-B, the IC50 was 
dropped to 3.23 µg/mL and this finding suggested that the CHLX has a positive 
effect when it combined with amphotericin-B. The fractional inhibitory 
concentration (ΣFIC) for both drugs was found to be 1.14 which indicates there 
was an additive effect from the combination of these drugs.  
Voriconazole and CHLX were tested at concentrations of 3.9 – 31.3 µg/mL and 
3.9 –15.6 µg/mL respectively. As single drug of voriconazole gave an IC50 of 
16.53 µg/mL in comparison with the IC50 which obtained from CHLX alone at 5.64 
µg/mL. However, much lower value of IC50 was found at 6.87 µg/mL for the 
combination of these drugs. Furthermore, the outcome of the combination study 
showed that the ΣFIC value for the two drugs was 2.4 and that resulted in the 




pentamidine (aromatic diamidine) was investigated. The selected concentrations 
were between 7.8 and 62.3 µg/mL for pentamidine and between 3.9 and 15.6 
µg/mL for CHLX. The IC50 for pentamidine was detected at 59.9 µg/mL compared 
with only 5.64 µg/mL for CHLX as individual drug. The combination of CHLX with 
pentamidine was led to the IC50 of 11.98 µg/mL and this result proposed that the 
CHLX had a positive impact when it mixed with pentamidine and tested against 
trophozoites. This study found that there is an additive effect from the 
combination of these drugs as the ΣFIC value was 1.98. The effects on A. 
castellanii trophozoites of CHLX and natamycin, both individually and in 
combination, were examined. The selected concentrations of natamycin and 
CHLX were 1.95 –15.6 µg/mL and 3.9 –15.6 µg/mL respectively. The IC50 results 
achieved from this study for natamycin at 7.82 µg/mL and a lower IC50 value of 
CHLX of 5.64 µg/mL was recorded.  
These findings indicated that the antimicrobial activity of natamycin was 
enhanced in the presence of CHLX. It was established that the ΣFIC for the 
combination of these drugs was 1.8 and this value suggested there was an 
additive effect. One Way ANOVA statistical analysis showed a significant 
correlation (P ˂ 0.001) for CHLX concentrations compared to all drugs that tested 
in this study. Also, using two sample t-test for comparing the means showed that 
a significance differences between the IC50 for the examined compounds as 
individual or in combination as the p value was found to be at p=0.04431.  
Table 4-6: Efficacy of single drugs against trophozoites of A. castellanii (ATCC 
50370). 
Single drug IC50 Combinations IC50 
Chlorhexidine  5.64 ± 0.02 Chlorhexidine + Amphotericin-B 3.23 ± 0.99 
Amphotericin-B 73.6 ± 1.18 Chlorhexidine + Natamycin 3.94 ± 0.98 
Natamycin 7.72 ± 1.02 Chlorhexidine + Pentamidine 11.98 ± 1.05 
Pentamidine 59.9 ± 1.11 Chlorhexidine + Voriconazole 6.87 ± 1.01 
Voriconazole 16.53 ± 1.05   
The results expressed as the mean of three independent experiments ± standard 
deviation (SD) after 24 hours exposure time. One-Way Analysis of Variance 




Table 4-7: Efficacy of drug combinations against trophozoites of A. castellanii 
(ATCC 50370). 
Combinations  ΣFIC Relationship 
Chlorhexidine + Amphotericin-B 1.14 Additive 
Chlorhexidine + Natamycin 1.8 Additive 
Chlorhexidine + Pentamidine 1.98 Additive 






4.4  Discussion  
This section provides a comprehensive discussion about the mechanism of 
action for a number of drugs including antifungal, macrolide, antineoplastic, 
antiprotozoal, quaternary ammonium, aspirin drugs and amidoamines. The time 
kill for novel and existing compounds of amidoamines and also the combination 
of two drugs against trophozoites.   
4.4.1  Antifungal/macrolide/antineoplastic drugs 
In this study, several of triazole antifungal agents including voriconazole, 
posaconazole, amphotericin-B and natamycin have been tested against 
trophozoites and cysts. The chemical structures for these compounds are 
different as can be seen in Figure 4.3. The mechanism of action for the 
antifungals is block the synthesis of ergosterol in Acanthamoeba and lead to 
increased permeability and cell ion leakage. Miltefosine (antineoplastic) drug has 
also been tested and the chemical structure for this drug consists of hexadecyl 




















Figure 4-3: Chemical structure of (A) Posaconazole (B) Voriconazole, (C) 




The first compound tested was voriconazole, which showed no activity against 
cysts at a concentration of MCC 500 µg/mL, but it was highly active against 
trophozoites. It inhibited trophozoite growth at concentrations of between 3.9 –
7.8 µg/mL and showed amoebicidal activity at 31.3 µg/mL. The results obtained 
in this study reflect a previous study (Schuster et al., 2006) in which activity 
against trophozoites at 40 µM and this concentration is similar to 16 µg/mL was 
observed but with no cysticidal  activity. However, the authors utilized a different 
methodology to that study, as they tested a clinical strain with a final 
concentration of 1x106 cells/mL and the time for exposure was 10 days, whereas 
in the current study the final concentration of cell density for cysts or trophozoites 
was 1 x 104 cells/mL and the exposure time for trophozoites and cysts was 1 and 
2 days respectively. The findings of the present study contradict the outcomes of 
past study by Iovieno et al. (2014b) who found that, for voriconazole, the MCC at 
which observed activity occurred against the ATCC strain and clinical isolates 
was 33.13 and 46.25 µg/mL respectively. Voriconazole had previously been 
shown to have higher activity against Acanthamoeba cysts with IC50 of 4.59 
µg/mL (IC50 means 50% inhibition of trophozoites) and IC90 at concentration of 
15.43 µg/mL (IC90 indicates 90% inhibition has occurred for trophozoites) (Martin-
Navarro et al., 2013). The observed increased in the activity of voriconazole 
against cyst of Acanthamoeba could be related to the drug version used by the 
authors, they tested eye drops (VFEND®) of voriconazole which are preserved 
with sulfobutyl ether β-cyclodextrin sodium as this salt may behind the activity 
and also the incubation period for around 1 week. In contrast, the current study 
tested the voriconazole as a pure drug with less exposure time of 3 days.  
Furthermore, another possible explanation for the significant differences between 
these previous studies and the present study is that the studies by (Martín-
Navarro et al., 2013, Iovieno et al., 2014b) used IC50, IC90, MMC₅₀ and MMC₉₀ to 
evaluate cysticidal activity whereas in the current study, only the activity for total 
kill for a given concentration is reported. Posaconazole was found to be active 
against Acanthamoeba cysts at MCC concentrations ranging from 7.8 – 15.6 
µg/mL. This compound showed great activity against trophozoites, with inhibition 
of 1 µg/mL for both species of Acanthamoeba and amoebicidal concentrations 




observed between 7.8 – 15.6 µg/mL and these values are lower than that seen 
in the study by (Iovieno et al., 2014b) which reported 43.75 µg/mL for clinical 
isolates and was higher up to 52.5 µg/mL for  ATCC isolates. The posaconazole 
had greater clinical efficacy than voriconazole against fungal keratitis (Torres et 
al., 2005). A recent in vitro research reported high effective concentration (EC50) 
activity of posaconazole and voriconazole at 0.045 µM which equal to (0.031 
µg/mL) and 0.6 µM which equivalent to (0.2 µg/mL) respectively against 
trophozoites of Acanthamoeba castellanii clinical strains (Shing et al., 2020) and 
these findings are consistent with those obtained for both drugs against 
trophozoites in the current study  
The antineoplastic agent miltefosine had previously been shown to have great 
activity against Leishmania donovani (Achterberg, 1987), and also against 
Trypanosoma cruzi, which causes Chagas disease (Saraiva et al., 2002). The 
mechanism by which miltefosine acts is to interfere with carrier proteins systems, 
leading to a reduction in essential nutrients, and eventually to cell death (Croft et 
al., 2003). In the present study, miltefosine showed excellent activity against 
trophozoites of both species in the range 0.5 – 1.95 µg/mL. However, it was less 
active against cysts with an MCC of 31.3 – 62.5 µg/mL. It is interesting to note 
that the miltefosine showed slight toxicity against the human cell line at MCT 31.3 
µg/mL. The findings from the present study largely support those of (Walochnik 
et al., 2002), who tested miltefosine along with alkiphosphocholines against three 
different strains of Acanthamoeba, including A. castellanii (strain 1BU),  A. 
polyphaga (strain 5SU) and A. lenticulata (strain 72/2). In Walochnik et al. (2002) 
study, time kill was performed in order to evaluate antimicrobial activity of 
miltefosine over time. Great activity was found against trophozoites of all three 
strains of Acanthamoeba at <30 min at a concentration of 80 µM which is 
equivalent to the 32 µg/mL. When the same testing was repeated with cysts from 







A more recent in vitro investigation conducted by Chao et al. (2020) which tested 
the miltefosine at the concentration of 2.42, 4.84, 9.68, 19.36, 38.72 and 77.44 
mM for different times: 1, 3, 5, 7 days at 37 °C against cysts of Acanthamoeba 
species associated to the genotypes T3, T4 and T5. All concentrations assessed 
of miltefosine showed that a 100% elimination of cyst, but the level of activity was 
different against several genotypes, the miltefosine at a concentration of 38.72 
mM killed both T4 and T5 after 1 day of incubation, whereas the killing of T3 
required a higher concentration at 77.44 mM with similar incubation time (Chao 
et al., 2020). In a newer case study, miltefosine was used as an effective oral 
treatment for patients who had a microbial diagnosis of Acanthamoeba, and the 
findings of this research showed that two patients improved after only 1 week of 
miltefosine treatment (Naranjo et al., 2020). The antifungal macrolide natamycin 
showed reasonable activity against trophozoites of both species but was not 
active against cysts at an MCC ˃ 500 µg/mL. This result is in line with in vitro study 
performed by Nakaminami et al. (2017) which found a higher activity for 
natamycin against trophozoites after 7-day with IC90 of 4.1 µg/mL and after 12 
hours the IC90 found at 11.6 µg/mL. Amphotericin- B showed no activity against 
cysts of both species of Acanthamoeba at MCC ˃500 µg/mL and it was also 
inactive against trophozoites. The results obtained from this study support early 
medical treatments by Wright et al. (1985), who confirmed that amoebicidal 
activity for amphotericin-B was >125 µg/mL.   
4.4.2  Antiparasitic/ antiprotozoal drugs 
Benznidazole, an antiparasitic made of carboxy group of (2-nitroimidazol-1-
yl)acetic acid and aromatic amino group of benzylamine (Figure 4.4.A). This drug 
exhibited elevated activity against trophozoites, but when the experiment was 
repeated against cysts, it showed no activity for either species of Acanthamoeba 
with MCC ˃500 µg/mL. Benznidazole had previously been shown to have higher 
activity against the protozoan parasitic Trypanosoma cruzi in mouse models 
(Garcia et al., 2005). Fexinidazole micronized ((1H-imidazole, 1-methyl-2-((4-
(methylthio)phenoxy) methyl)-5-nitroimidazole) (Figure 4.4.B) is an antiprotozoal 
and exhibited activity against trophozoite between 7.8 up to 62.5 µg/mL and the 




Previously, the fexinidazole had an MIC of 5 µg/mL against Trypanosoma cruzi 







4.4.3  Quaternary ammonium compounds 
Among the quaternary ammonium compounds tested in this study, 
didecyldimethylammonium chloride which has 2 long alkyl groups (Figure 4.5.A) 
demonstrated excellent antimicrobial activity against trophozoites and cysts of 
both species of Acanthamoeba at lowest concentrations and as far as we know, 
this compound has not been tested against Acanthamoeba before. The chemical 
structures for quaternary ammonium compounds consist of no less than one 
hydrophobic hydrocarbon chain that is attached to a positively charged nitrogen 
atom and other alkyl groups (Figure 4.5). It is believed that the antimicrobial 
activity of these compounds is related to the alkyl chain length (McBain et al., 
2004). The results obtained of this study reflect the findings of a previous study 
by Beier et al. (2015), which found that the didecyldimethylammonium chloride 
very active against the gram-negative bacteria Pseudomonas aeruginosa at 
MIC₅₀ of 16 µg/mL and MIC₉₀ of 32 µg/mL. Didecyldimethylammonium chloride 
has been used across a broad spectrum against different types of bacteria, 
including Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa 
(Walsh et al., 2003). Additionally, the mechanisms by which these compounds 
act are related to denaturation of the key cell proteins and disruption  of the cell 
membrane (Gerba, 2015). The present findings for benzethonium chloride also 
support (Yip et al., 2006) study which found antimicrobial activity for this 
compound against cancer cell lines at 3.8 µmol/L. However, it contradicts the 
findings of Lukáč et al. (2013) which reported that the minimal trophocidal 








µg/mL against Acanthamoeba lugdunensis, and a double MTC value of 500 µM 













In this study, hexadecyltrimethylammonium bromide produced elevated activity 
against trophozoites and Acanthamoeba cysts at lowest concentrations and the 
results are in line with the past study by Lukac et al. (2013), which found this 
compound is active against Candida albicans and Acanthamoeba lugdunensis at 
15.6 µM which is equal to 5.6 µg/mL. An in vitro study by Zanetti et al. (1995) 
reported that polyquaternium-1 had no activity when incorporated into a contact 
lens solution and tested over time against Acanthamoeba trophozoites and cysts. 
This finding was at variance with the results of the current study. The only 
quaternary ammonium drug tested which showed antimicrobial activity at highest 
concentrations was hexadecylpyridinium chloride. This provides support for a 
pervious study by Beier et al. (2015) which tested this compound against 
Pseudomonas aeruginosa and MIC₅₀ and MIC₉₀ obtained were 128 and up to 






Figure 4-5: The chemical structures of (A) Didecyldimethylammonium chloride 
(B) Hexadecyltrimethylammonium bromide, (C) Hexadecylpyridinium Chloride, 




4.4.4  Aspirin analogues 
In the current study, several aspirin analogues are tested for the first time against 
cysts and trophozoites of Acanthamoeba, and the results have shown that the 
minimum cysticidal concentration values range from 15 µg/mL to 500 µg/mL. The 
minimum trophozoite inhibitory concentration ranged from 3.9 µg/mL to 62.5 
µg/mL and the minimum trophozoite amoebicidal were observed at between 15.6 
–125 µg/mL. Aspirin, also commonly known as acetylsalicylic acid, is classified 
as a member of nonsteroidal anti-inflammatory drugs (NSAIDs) (Tosco and 
Lazzarato, 2009). The aspirin-related compounds tested in the present study, 
previously have been shown a huge activity against cell proliferation and caused 
apoptosis of colorectal cancer cells (Deb et al., 2011, Claudius et al., 2014). The 
mechanism of action for aspirin analogues is inhibit the activity of the 
cyclooxygenase (COX) enzyme in cancer cell line (Zha et al., 2004). The function 
for COX in human is synthesising of prostaglandins as a response to pain signals 
which produce inflammation in the body (Vane and Botting, 2003).  
As revealed in subheading 3.1.1 of this chapter, the COX enzyme exists in 
Acanthamoeba and so aspirin analogues should inhibiting the activity of this 
enzyme (Lanocha-Arendarczyk et al., 2018). In an  in vivo study, it was reported 
that Acanthamoeba produced a strong expression of cyclooxygenase-1 and 
cyclooxygenase-2 proteins in the lungs of immune-competent mice (Łanocha-
Arendarczyk et al., 2018). The current study found that two compounds of aspirin 
analogues included bis‑carboxyphenyl fumarate and isopropyl 
m‑bromobenzoylsalicylate were active against both cysts and trophozoites of 
Acanthamoeba spp. at lowest concentrations compared with other aspirin 
compounds tested in this study. The observed increase in antimicrobial activity 
for these compounds is associated with the structure activity relationship (the 
relation between the chemical structure of a molecule and its biological activity). 
The chemical structure for bis‑carboxyphenyl fumarate consists of  2-formyloxy 
benzoic acid groups at each end connected to an ethylene group at the centre 
and changing ethylene group with ethyl group or simple 8 carbon chain, the 
compound loses its activity. Isopropyl m‑bromobenzoylsalicylate compound is 
produce from propan-2-yl benzoate which linked to 3-bromobenzoic acid. This 




eliminating the propyl group makes the compound inactive and the other aspirin 
based analogues studied in this analysis have different chemical structures (see 

































Figure 4-6: The chemical structures of (A) Bis-carboxyphenyl fumarate, (B) 
Isopropyl m‑bromobenzoylsalicylate, (C) Bis-carboxyphenylsuccinate, (D) 
acetylsalicylic acid (aspirin), (E) Methyl benzoyl salicylate, (F) m-bromobenzoyl 
salicylic acid, (G) 3-acetoxybenzoi acid, (H) 4-acetoxybenzoic acid, (I) 2-




The findings of this study are in accord with those obtained in a previous study 
by Claudius et al. (2014), which was found that the aspirin analogues inhibited 
the colorectal cancer cell line at a millimolar concentrations. The other aspirin 
analogues tested in this study found to be active against trophozoites, but a little 
or inactive against cysts of either species of Acanthamoeba at a highest 
concentrations from 250 µg/mL up to 500 µg/mL. The present outcomes also 
support Malvezi et al. (2014) study which concluded that aspirin analogues were 
inhibited the entry of Trypanosoma cruzi in mouse peritoneal macrophages at 
concentrations of 0.625 mM, 1.25 mM, and 2.5 mM and these concentrations are 
equivalent to 112.5 µg/mL, 225 µg/mL and 450 µg/mL respectively. 
4.4.5  Efficacy of novel and existing of amidoamines on cysts 
and trophozoites viability  
The compounds of amidoamine tested in this study, including myristamidopropyl 
dimethylamine (MAPD) and palmitamidopropyl dimethylamine (PAPD) were 
found to be active against trophozoites at between 1 and 15.6 µg/mL and against 
cysts at concentrations of 7.8 – 31.3 µg/mL as range for both species of 
Acanthamoeba. Among the new compounds of amidoamines, palmitoleyl-
amidopropyl dimethylamine (POPD) showed greater activity against 
trophozoites, ranging from 3.9 to 31.3 µg/mL and against cysts at between 31.3 
and 62.5 µg/mL. However, the antimicrobial activity of myristoleyl-amidopropyl 
dimethylamine (MOPD) against trophozoites was lower, ranging from 31.3 to 125 
µg/mL and the MCC was found at the highest concentrations of 125 to 250 µg/mL. 
It seems possible that these results are due to the pH 6.5 of the Ac#6 medium 
used in the trophozoite assay, as the antimicrobial activity of MOPD was affected 
by the pH compared with the activity of this compound in the time kill experiment. 
The present compound of amidoamine, myristamidopropyl dimethylamine 
(MAPD) has been previously tested against cysts of Acanthamoeba and the MCC 
values were found to be between 6.25 and 25 µg/mL (Kilvington et al., 2002), and 





4.4.6 Comparing the activity of saturated and unsaturated fatty 
acid derived amidopropyl amines in relation to time kill 
Myristamidopropyl dimethylamine (MAPD) at a concentration of 0.0005% (w/v) 
formulated into a contact lens solution showed a 3-log reduction against 
trophozoites of A. polyphaga (ATCC 30461) over 24 hours. The activity increased 
against A. castellanii (ATCC 50370) and slightly more than a 3-log reduction was 
exhibited at the same time point. Palmitamidopropyl dimethylamine (PAPD) at 
the same concentration of MAPD exerted a 3-log reduction against trophozoites 
of both species of Acanthamoeba. Notably, MOPD at a concentration of 0.0005% 
(w/v) demonstrated complete kill against trophozoites of both species of 
Acanthamoeba at 4.5-log after 24 hours of exposure. The activity for POPD was 
found to be a 4.5-log reduction against trophozoites of A. castellanii and the 
activity was slightly reduced against trophozoites of A. polyphaga and gave 4-log 
reduction. There is a clear difference between the chemical structure of 
amidoamines and that related to the carbon chain whose length differs depending 
on two factors, the fatty acid source, and the functional group which gives the 
chemical characteristics of the compound. The novel compounds, MOPD is 
derived from ω-5 monounsaturated fatty acid whereas POPD is derived from ω-
7 monounsaturated fatty acid. The difference between C14, C16 and C14-1, C16-
1 is the branches in the carbon chain which corresponds to number (1) and this 
means unsaturated bonds as illustrated in Figure 3.5 below. Also, the physical 
properties are different, the C14 & C16 the fatty acid is solid whereas the fatty 
acid for C14-1 & C16-1 is liquid in room temperature, these variations are the 
potential reason for getting different activity against trophozoites. 
Furthermore, the amidoamines possess two major functional sites for reactions 
which are the tertiary amine group and the amide hydrogen (Muzyczko et al., 
1968). A possible explanation for the increased antimicrobial activity for the new 
compounds myristoleyl-amidopropyl-dimethylamine (MOPD) and palmitoleyl-
amidopropyl-dimethylamine (POPD) may be related to the unsaturated bonds in 
their structures (Figure 4.7.C&D), which demonstrated superior activity against 
trophozoites when those compounds formulated into contact lenses solution 















It was found that the plasma membrane of Acanthamoeba mostly comprises of 
C18 and C20 lipids (Jones et al., 1993). As revealed in the introduction section 
(4.1.1). following the binding of the polar head group, the carbon chain of the 
surfactant is integrated into the lipid bilayer of Acanthamoeba and producing 
lateral expansion of the membrane (Denyer and Stewart, 1998). MAPD as a pure 
drug has been previously tested at a higher concentration of 50 mg/L against 
cysts of Acanthamoeba polyphaga and found to be active within 2 hours and 
showed a 4.18 log reduction (Hughes et al., 2003a). The MOPD time kill findings 
in this study raise the possibility of using MOPD instead of MAPD as a new 
amidoamine compound for contact lens solutions at a concentration of 0.0005% 
(w/v).  
4.4.7  Effect of several drugs in combination on the trophozoites 
viability 
A single drug has not been effective against Acanthamoeba spp. and the 
treatment in vivo remains a major challenge. This study investigated the 
combined effect of 4 different drugs with chlorhexidine digluconate (CHLX) to 
check for the possibility of synergistic or additive effects against trophozoites of 
Acanthamoeba castellanii (ATCC 50370). The examined concentrations of the 





Figure 4-7: Chemical structures of (A) Myristamidopropyl dimethylamine (MAPD), 
(B) Palmitamidopropyl dimethylamine (PAPD), (C) Myristoleyl-amidopropyl 




the present study, there no synergistic effects for the combination of two drugs 
were found; all four drug combinations investigated showed an additive effect 
against trophozoites. The CHLX had a positive impact on the pentamidine, 
voriconazole, natamycin and amphotericin-B. The ΣFIC for the combination of 
CHLX and amphotericin-B against trophozoites of  A. castellanii (ATCC 50370) 
was found to be 1.14 and this value is referred to an additive effect. On the other 
hand, in vitro study by (Taravaud et al., 2017) on combination of CHLX with 
voriconazole against trophozoites of Acanthamoeba has reported that the ΣFIC 
value of 1.23 which differs to the result of ΣFIC= 2.4 obtained of the present study. 
In recent an in vitro study conducted by Talbott et al. (2019) which observed that 
antagonistic impact from the combination of voriconazole with CHLX against 
cysts of Acanthamoeba clinical isolates. The findings of the combination of CHLX 
with voriconazole contradict with the combination study conducted by Kratzer et 
al. (2006) for CHLX plus voriconazole, the authors have showed that the FIC₅₀ = 
0.28 and FIC₉₀ = 0.54 against Trichoderma. The FIC values reported by the 
authors have indicated a synergistic effect for the combination of voriconazole 
with CHLX against this fungi. In the present study, the combination of CHLX with 
the diamidine (pentamidine) against trophozoites was found to be an additive as 
the ΣFIC found to be 1.98 and this finding is consistent with those of (Hay et al., 
1994a) who reported that the combination of pentamidine with CHLX against 
trophozoites of Acanthamoeba resulted in the additive effect. In vitro, it has been 
shown that a combination of natamycin and CHLX had a much stronger potency 
than monotherapy and this could be a promising treatment for Acanthamoeba 
keratitis (Kitagawa, 2003). Additionally, a combination of CHLX with carbosilane 
dendrimers that contains the ammonium or guanidine moieties in vitro had 
synergistic impact against trophozoites of Acanthamoeba polyphaga after 24 
hours of incubation (Heredero-Bermejo et al., 2016). The current study is clearly 
demonstrated that the existing of CHLX enhanced the antimicrobial activity in 
vitro as the reduction against trophozoites was found to be 4-log kill compared 





4.5  Conclusion  
Overall, this study tested 28 compounds against Acanthamoeba castellanii 
(ATCC 50370) and Acanthamoeba polyphaga (ATCC 30461) and also examined 
their toxicity against the human epithelial cell line. Several compounds included 
posaconazole, miltefosine and didecyldimethylammonium chloride were showed 
excellent antimicrobial activity against both cysts and trophozoites of 
Acanthamoeba spp. These compounds, therefore, need further investigation for 
their potential use as treatments against Acanthamoeba keratitis. The current 
study found that the novel compounds of amidoamine included myristoleyl-
amidopropyl-dimethylamine (MOPD) and palmitoleyl-amidopropyl-
dimethylamine (POPD) when formulated into contact lens base solution at 
concentration of 0.0005% (w/v) and tested against trophozoites, these 
compounds exhibited complete kill at 4.5 log reduction after 24 hours compared 
with the MAPD and PAPD as an existing compounds. This finding raises the 
possibility of incorporating MOPD and POPD into the contact lens solution at a 
concentration of 0.0005% rather than MAPD as an existing disinfectant. Among 
the 4 drug combinations assessed against trophozoites in this study, no 
synergistic effect was observed, and the findings of the current study indicated 
that an additive effect. The antimicrobial activity was enhanced when the CHLX 
combined with amphotericin–B, voriconazole, pentamidine and natamycin 
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5. Chapter 5: Developing novel treatments against Acanthamoeba 
spp. and analysing the corneal penetration of chlorhexidine 
 
5.1  Introduction 
5.1.1 Identifying new treatments against Acanthamoeba Keratitis 
Many therapeutic agents have been tested against Acanthamoeba spp., and a 
number of these drugs have shown greater in vitro activity. However, the 
treatments in vivo against AK is still a big challenge and this is due to the fact that 
the findings from in vitro sensitivities do not always correlate with clinical outcome 
(Alexander et al., 2015). In recent years, there has been an increasing interest in 
used a wide range of nanoparticles-based technologies such as gold and silver 
as delivery vehicles to enhance the antimicrobial activity for a variety of 
therapeutic agents. The main reason for using the Lipodisq® carrier is because 
of it able to cross the lipid membrane and increase the antimicrobial activity for a 
different class of the drugs. Lipodisq® nanoparticles are high-density lipoproteins 
and range in size between 10 and 40 nm. They are considered to be a 
biodegradable delivery system and currently Lipodisq®  nanoparticles are used as 
a carrier to deliver lipophilic drugs, such as fat-soluble vitamins and botanical 
extracts, into the outer layer of the skin (Malvern, 2015, Tonge, 2014).  
The chemical structure for Lipodisq® nanoparticles are made of poly(styrene-co-
maleic acid) (PSMA) and dipalmitoylphosphatidylcholine (DPPC) at a ratio of 1 of 
PSMA to 2 of DPPC (Tonge, 2014) as can be seen in Figure 5.1. There is a 
similarity between Lipodisq® nanoparticles and nanodiscs which are lipid protein 
nanoparticles and exist in high-density lipoproteins (Jonas, 1986), however, the 
membrane scaffold protein in nanodiscs used for the peripheral of the lipid disk, 
whereas a styrene/maleic acid copolymer is used as an edge for Lipodisq® 
nanoparticles (Zhang et al., 2017). The first serious discussions and analyses of 
nanoparticles emerged during the (1986) against different diseases, and the 
nanoparticles are promising drug delivery and that due to a number of factors 
including; their small size, cell penetration, enhancing the antimicrobial activity 
for drug and finally decreasing drug resistance via targeting any cellular function 






















The nanoparticle carriers were classified depended on two aspects firstly, how 
the carries are carrying the substances and secondly related to the characteristics 
of the matrix (Zazo et al., 2016). The nanoparticles were broadly divided into two 
main groups: organic nanoparticles (which include liposomes, polymeric 
nanoparticles, polymeric micelles, and solid lipid nanoparticles) and inorganic 
nanoparticles (which include silicon dioxide, magnetic oxide, gold and silver 
nanoparticles) (Zazo et al., 2016, Xu et al., 2006). All these carriers have played 
an important role for effectiveness of different kinds of drugs against many 














poly(styrene-co-maleic acid) (PSMA) 
Cross-sectional of Lipodisq® 








Figure 5-1: Diagram showing the synthesis of Lipodisq® nanoparticles. (A) 
Chemical structure of dipalmitoylphosphatidylcholine (DPPC) which represents a 
phospholipid and  lecithin comprising of two palmitic acids linked with a 
phosphatidylcholine head-group. (B) Chemical structure of poly(styrene-co-maleic 
acid) (PSMA) which is made of styrene and maleic acid monomers. (C) Lipodisq®  





nanoparticles with fluconazole had a major effect on the viability of Candida 
albicans and gave a MIC of 2.17 µg/mL compared with fluconazole alone which 
exhibited a MIC of >128 µg/mL after 24 hours of exposure (Longhi et al., 2015). 
 For bacterial infection, the combination of penicillin and methicillin-resistant with 
surface-functionalized silica nanoparticles enhanced the antimicrobial activity 
against Escherichia coli and Staphylococcus aureus (Wang et al., 2014) Whilst 
for parasitic infection, the used of silver nanoparticles at a concentration of 100 
µg/mL achieved 83% inhibition against Plasmodium falciparum (Panneerselvam 
et al., 2011). Upon incorporation of silver nanoparticles into contact lenses, 
superior antimicrobial activity is achieved leading to prevention of bacterial and 
AK infections (Willcox et al., 2010). Furthermore, pentamidine isethionate was 
incorporated into liposomes and the outcomes for this study were confirmed that 
a significant difference between the antimicrobial activity which was increased 
more than12 times than pentamidine isethionate as monotherapy for prevented 
Acanthamoeba binding to human cells (Siddiqui et al., 2009), also this 
combination was considerably more effective in inhibiting Acanthamoeba  
mediated human cell cytopathogenicity. In this chapter, a combinations of 
biguanide compounds with Lipodisq® carriers have been made for the first time 
to establish their antimicrobial activity against trophozoites and cysts of 
Acanthamoeba and to compare the activity with the use of biguanides alone. As 
reviewed  in chapter 1 of this thesis subheading (1.14) that the mechanism of 
action for biguanides producing damage in the membranes of Acanthamoeba. 
PHMB and chlorhexidine are positively charged and interfering with 
mucopolysaccharide plug of the ostiole and causing penetration of the 
Acanthamoeba (Khunkitti et al., 1997). Subsequent, these drugs bind to the 
phospholipid bilayer of the cell membrane, which is negatively charged, causing 
structural and permeability changes, ion leakage, cytoplasmic cell damage and 







5.1.2  Penetration of chlorhexidine into the corneal tissue  
Corneal drug penetration evaluation is important for the development of effective 
ophthalmic medications. Several methods utilised to enhance the ocular 
bioavailability (including pre-corneal drug retention, the use penetration 
enhancers, liposomes, micro-and nanospheres) have been previously 
investigated (Agarwal and Rupenthal, 2016, Krishnaswami et al., 2018). It has 
been revealed in the literature that, three distinct concentrations of CHLX at 
0.02% (v/v). 0.1% (v/v) and 0.2% (v/v) were used to study the penetration profile 
of corneal and anterior chamber of rabbit, and the findings of this investigation 
revealed that the mean corneal of CHLX concentration was 0.28 µg/mg, 0.105 
µg/mg and 0.575 µg/mg respectively, so the CHLX can penetrate across the 
intact cornea (Banich et al., 2003). The penetration of CHLX combined with 
Lipodisq® nanoparticles was investigated as it is used for different applications 
such as skin penetration, it was reported that the Lipodisq® carrier improved the 
pentation of the skin compared with CHLX alone (Karpanen et al., 2008). To date, 
a recent publication has assessed the penetration into corneal tissue of 
chlorhexidine (CHLX) in eye drops at a concentration of 0.2% (v/v) and 2% (v/v) 
of CHLX combined with β-cyclodextrin as a carrier. The findings showed that the 
β-cyclodextrin had a major impact on improving the penetration of CHLX: the 
volume of CHLX plus β-cyclodextrin increased 5-fold compared with CHLX alone 











5.1.3  Aims and objectives of this chapter  
AK is a concerning disease which still fails to respond to many antimicrobial 
agents. The description of the development of a new formulation of biguanides 
incorporated with Lipodisq® nanoparticle carriers is one of the aims of this 
chapter. These compounds were tested against cysts and trophozoites of 
Acanthamoeba spp. The antimicrobial kinetics for the novel combinations are 
then evaluated and the toxicity of the novel compounds against human epithelial 
cell line are determined. Finally, the penetration profile into cornea tissue of 
Lipodisq® carries combined with chlorhexidine is examined. The objectives of this 
chapter are as follows:  
I. The testing of biguanide compounds combined with Lipodisq® carries 
against trophozoites and cysts of Acanthamoeba spp.  
II. Performing a time kill study for the combination of biguanides with 
Lipodisq® and the existing biguanides against cysts of Acanthamoeba spp. 
and comparing the activity of the novel combination with existing 
compounds of biguanide.  
III. Assessing the toxicity of the biguanide compounds plus Lipodisq®  and the 
current compounds against the human epithelial cell line. 
IV. Investigating the capacity of the Lipodisq® nanoparticle carriers in enabling 
trans-corneal penetration of the hydrophilic drug chlorhexidine into the 










5.2  Materials and Methods  
5.2.1  Preparation of organisms  
The Acanthamoeba castellanii (ATCC 50370) and Acanthamoeba polyphaga 
(ATCC 30461) test organisms were grown and prepared according to the 
methods detailed in chapter 2, sections 2.4–2.8.       
5.2.2  Novel and existing drugs sensitivity testing assays 
The current biguanide drugs used to treat AK were tested in their own in this study 
and then incorporated with Lipodisq® nanoparticle carries as novel combinations 
and assessed their activity against trophozoites and cysts of Acanthamoeba spp.   
Table 5-1: List of  novel formulation of Lipodisq®  with biguanides and the existing 
of biguanides, class/use and solubility which they were tested for their 
antimicrobial activity and toxicity. 
Drug Class/Use Solubility 









Chlorhexidine digluconate (CHLX) (existing 
drug)   
Biguanide 
H2O 
CHLX + Lipodisq®  (novel formulation) Biguanide 
H2O 









PHMB + Lipodisq® non-particle (LQNP) 
(novel formulation): The LQNP means the 
solution formulation contains a polystyrene-





PHMB + Surfactant (novel formulation): The 
surfactant means the solution formulation 
comprises of polysorbate 20 (Tween 20) instead 
of PSMA and performs a similar role to the 




CHLX + Surfactant (novel formulation) Biguanide H2O 








The novel biguanides as stock solutions, included PHMB incorporated with 
Lipodisq® at a concentration of 0.6% or CHLX and octenidine combined with 
Lipodisq® at a concentration of 0.1% were obtained from our collaborators in 
Malvern, Worcestershire, U.K. The other formulations involved Lipodisq® non-
particle and surfactant were prepared in our laboratory by combining the existing 
compound solutions of PHMB or CHLX with Lipodisq® nanoparticle carrier 
solution or surfactant solution at ratios of 1 : 199 to give a final concentrations of 
1 mg/mL. All formulations were mixed by vortexing and were subsequently 
assayed to determine their antimicrobial activity against trophozoites and cysts 
of both species of Acanthamoeba as outlined in chapter 2, sections 2.11–2.13, in 
order to determine the Minimum Trophozoite Inhibitory Concentration (MTIC), the 
Minimum Trophozoite Amoebicidal Concentration (MTAC) and the Minimum 
Cysticidal Concentration (MCC) for each of the compounds. Formulations were 
considered as a suitable candidates if they had the same or greater antimicrobial 
activity as the compounds that are now used in the treatment of AK. 
5.2.3  In vitro toxicological testing against human epithelial cell 
line 
After determining the antimicrobial activity for all compounds against 
Acanthamoeba spp. a different in vitro assay was performed to determine the 
toxicological profile for each of the formulations against a human epithelial cell 
line. The human epithelial cell line was maintained and prepared as outline in 
chapter 2, section 2.16–2.18.   
5.2.4  Time kill assays for novel and existing biguanides 
The time kill experiments where performed for novel and existing biguanide 
compounds which they showed excellent antimicrobial activity against Neff’s 
cysts and trophozoites of Acanthamoeba spp. The reduction in viable cysts or 
trophozoites were plotted as change in log viability for each time point compared 





5.2.5  Ex vivo corneal penetration  
For these experiments whole eyes were removed from pigs shortly after slaughter 
and transported to the laboratory for testing. The eyes were obtained from Gill’s 
slaughterhouse in Wolverhampton and were taken from animals that were being 
processed for the food industry making use of material that would otherwise be 
discarded. The entire eyes were incubated anterior side down in the test solution 
into the wells of a 6-well plate, the well containing 5 mL of phosphate buffer saline 
(PBS) as control or chlorhexidine (CHLX) and chlorhexidine combined with 
Lipodisq® carrier at a concentration of 0.02% (v/v) with care taken to make sure 
the level of solution did not exceed the limbus which is the interface between the 
cornea and the sclera (the white part of the eye). Subsequently, the eyes were 
processed in duplicate and incubated for 10 min and 1 hour in either CHLX or 
CHLX combined with Lipodisq® nanoparticle carrier. After incubation the corneas 
were removed from the rest of the eye using a surgical blade and curved scissors 
(SLS, Nottingham, U.K.) and then stored at -80°C until HPLC testing was 
performed. 
5.2.6 High Performance Liquid Chromatography (HPLC) analysis 
The penetration into the corneal tissue of CHLX and CHLX incorporated with 
Lipodisq®  carriers was determined by HPLC analysis. When the incubation time 
was complete for CHLX and CHLX plus Lipodisq®, the corneal tissue was 
prepared for HPLC analysis by incubating the tissue samples in HPLC mobile 
phase solution and then heated to 60°C for 1 hour as previously described by 
(Karpanen et al., 2008). The separation method was performed by using C18 
column in the mobile phase comprised  methanol : water (HPLC grade) 75:25 
(v/v) with 0.005 M of sodium heptane sulfonate and 0.1% (v/v) of diethylamine. 
The pH was adjusted to 4 by using glacial acetic acid. The detection wavelength 
was set at 254 nm, the injection volume at 10 μL and the flow rate at 1.5 mL/min. 
Under these conditions, CHLX and CHLX plus Lipodisq® were found to have a 





5.2.7  Ethics statement 
The corneal tissue from pig eyes was approved by the Life Sciences Ethics 
Committee, Faculty of Science and Engineering, University of Wolverhampton 
and the approval number is: LSEC/201920/WH/111. 
5.3  Results 
The results in this chapter are presenting the novel biguanides formulations 
testing along with the current treatments and also the HPLC findings for the 
penetration of chlorhexidine as a monotherapy and in combination with Lipodisq®  
carrier into the corneal tissue as an ex vivo models.  
5.3.1  Biguanides combined with Lipodisq® nanoparticle carriers 
PHMB alone was demonstrated a lower antimicrobial activity ranged 7.8 – 15.6 
µg/mL against cysts and between 0.48 – 3.9 µg/mL against trophozoites for both 
species. Interestingly, when the PHMB incorporated with Lipodisq® it shows 
higher activity ranged from 0.24 – 0.48 µg/mL against cysts for either species, 
the amoebicidal activity was 0.97 µg/mL for both species. PHMB combined with 
Lipodisq® was more tolerated to the human epithelial cell line at MCT 125 µg/mL 
than PHMB as its own which was demonstrated MCT 31.3 µg/mL. The other two 
combinations were showed a higher activity against trophozoites ranged 0.48 – 
0.97 µg/mL for both species and between 1.95 – 3.9 µg/mL against cysts for 
either species, also these two compounds were toxic to the human epithelial cell 
line at MCT 1.95 µg/mL (Table 5.2). CHLX as monotherapy showed minor 
cysticidal activity with MCC 31.3 µg/mL and the amoebicidal activity ranged from 
7.8 – 15.6 µg/mL, also CHLX on its own was slightly toxic to human cell line at 
MCC 3.9 µg/mL. When the CHLX was combined with Lipodisq® carrier the 
antimicrobial has enhanced against cysts of both species of Acanthamoeba with 
MCC ranged from 1.95 – 3.9 µg/mL as well as the antimicrobial activity has 
increased against trophozoites between 0.48 – 0.97 µg/mL for both species. This 
compound was not toxic to human epithelial cell line with MCT 31.3 µg/mL. 
The other two combinations of CHLX were showed a significant activity against 
trophozoites for both species ranged from 0.97 – 3.9 µg/mL, but the activity lower 
down when they were tested against cysts for either species ranged from 15.6 –




MCT between 1 – 1.95 µg/mL. In this study the Lipodisq® in its own was tested 
against both species of Acanthamoeba and no activity was observed. Also, when 
the Lipodisq® was assessed on the human epithelial cell line it gave MIC 62.5 
µg/mL and MCT 125 µg/mL, so it was not toxic to the human epithelial cell line. 
The octenidine hydrochloride (OCT) was tested alone and it exhibited activity 
against cysts between 3.9 – 7.8 µg/mL as a range against either species. A great 
activity was observed against trophozoites for OCT ranged from 0.5 – 1.95 µg/mL 
for both species. When the OCT combined with Lipodisq®  carriers, the 
antimicrobial activity against cysts was increased as the activity observed 
between 1.95 µg/mL and elevated to 3.9 µg/mL. The activity for OCT against 
trophozoites was ranging from 0.48 – 1.95 µg/mL against each of the tested 
species. The toxicity test showed that the OCT alone was toxic to the human 
epithelial cell line at MCT of 1.95 µg/mL. However, the combination of OCT with 
the Lipodisq® carriers demonstrated a little toxicity on the human cell line as the 




Table 5-2: Efficacy of antimicrobials in the presence of lipodisq nanoparticles against trophozoites and cysts for A. polyphaga  &  
A. castellanii  and for their toxicity against a human epithelial cell line (Hep2). 
 In vitro drug sensitivities (µg/mL)  
 A. castellanii (ATCC 50370) A. polyphaga (ATCC 30461) Hep2 
Drug MTIC* MTAC** MCC*** MTIC* MTAC** MCC*** MIC+ MCT++ 
Octenidine hydrochloride alone 1 1.95 7.8 0.5 1 3.9 3.9 1.95 
Octenidine combined with Lipodisq®   0.97 1.95 3.9 0.48 0.97 1.95 7.8 15.6 
Polyhexamethylene biguanide (PHMB) 
alone 
1 3.9 15.6 1 7.8 7.8 62.3 31.3 
PHMB combined with Lipodisq®   non-
particle 
0.48 0.97 3.9 0.48 0.97 1.95 3.9 7.8 
PHMB combined with surfactant 0.48 0.97 1.95 0.48 0.97 1.95 3.9 15.6 
PHMB combined with Lipodisq®   0.48 0.97 0.48 0.48 0.97 0.24 62.3 125 
Chlorhexidine digluconate (CHLX) 1.95 7.8 31.3 3.9 15.6 31.3 7.8 15.6 
CHLX combined with Lipodisq®   0.48 0.97 3.9 0.48 0.97 1.95 7.8 31.3 
CHLX combined Lipodisq®  non-particle 0.97 3.9 7.8 0.97 3.9 15.6 3.9 7.8 
CHLX combined with Surfactant 0.97 1.95 15.6 0.48 3.9 7.8 7.8 15.6 
Lipodisq alone as a control  ˃500 ˃500 ˃500 ˃500 ˃500 ˃500 62.5 125 
 MTIC* Minimum trophozoite inhibitory concentration, MTAC** Minimum trophozoite amoebicidal concentration, MCC*** 
Minimum cysticidal concentration, MIC+ Minimum inhibitory concentration, MCT++ Minimum Cytotoxic Concentration. The 
testing was carried out with the other forms of the Lipodisq® included non-particle and surfactant in order to verify the activity of 




5.3.2  Time kill studies for biguanides  
After determining the MCC for the new biguanide  formulations using a microtitre 
plate, the next step was to examine the kinetics of those compounds against 
Neff’s cysts of Acanthamoeba utilizing time-kill experiments, as shown in Figures 
5.2, 5.3 & 5.4 below.  
 
Figure 5-2: Effect of PHMB, PHMB plus Lipodisq® (PHMB+LQ), PHMB Lipodisq® 
non-particle (PHMB+LQ NP) and PHMB plus surfactant (PHMB+ST) at 
concentration of 31.3 µg/mL against Neff’s cyst of Acanthamoeba castellanii 
(ATCC 50370). One-way analysis of variance (ANOVA) was performed. Asterisks 
represent values statistically significant (***P<0.001) between the tested 
combinations of PHMB and the ¼ strength Ringer’s control. 
PHMB combined with Lipodisq®, PHMB Lipodisq® non-particle and PHMB 
combined with surfactant were showed a comparable log reduction at ≈4-log kill 
against cysts of A. castellanii (ATCC 50370) after the 24 hours of the experiment. 
PHMB as monotherapy exhibited moderate activity against cysts of the same 
strain, giving only 2-log kill over 24 hours. One Way ANOVA analysis showed 
that PHMB plus Lipodisq®, PHMB Lipodisq® non-particle and PHMB plus 
surfactant were statistically significant (P < 0.001) over 24 hours compared to the 
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hours for all evaluated compounds in relation to the ¼ strength Ringer’s control 
were subjected to two sample t-test analysis and the p-value was observed at 
p=0.0105 and this value is less than 0.05.  
 
Figure 5-3: Effect of CHLX, CHLX combined with Lipodisq® (CHLX+LQ), CHLX 
plus Lipodisq® non-particle (CHLX+LQ NP) and CHLX plus surfactant 
(CHLX+ST) at a concentration of 15.6 µg/mL against Neff’s cyst of 
Acanthamoeba castellanii (ATCC 50370). One-way analysis of variance 
(ANOVA) was conducted. Asterisks represent values statistically significant 
(***P<0.001) between the tested combinations of CHLX and the ¼ strength 
Ringer’s control. 
Interestingly, over the 24 hours of the experiment, CHLX combined with Lipodisq® 
was found to be highly active against Neff’s cysts of A. castellanii providing a 4.5-
log reduction. During 24 hours of exposure, CHLX encapsulated with Lipodisq® 
was statistically significant (P < 0.001) in terms of the antimicrobial activity in 
comparison with ¼ strength Ringer’s control and other combinations of CHLX 
(Figure 5.3). Further statistical analysis, two sample t-test showed that the p-



































Figure 5-4: Effect of octenidine hydrochloride at a concentration of 7.8 µg/mL and 
octenidine hydrochloride combined with Lipodisq® carrier at a concentration of 
3.9 µg/mL against Neff’s cysts of Acanthamoeba castellanii (ATCC 50370). One-
way analysis of variance (ANOVA) was performed. Asterisks represent values 
statistically significant (***P<0.001) between the tested concentrations of 
octenidine or octenidine plus Lipodisq® and the ¼ strength Ringer’s control. 
After the 24 hours of the time kill experiment, octenidine incorporated with 
Lipodisq® carriers at a concentration of 3.9 µg/mL achieved  a 3-log kill against 
Neff’s cysts of A. castellanii, whereas octenidine in its own and at a concentration 
of 7.8 µg/mL, gave ≈3 log reduction at the same time point. There was no 
significant difference between octenidine combined with Lipodisq® and octenidine 
hydrochloride used as a monotherapy at the 24-hour time point as the two sample 
t-test showed that the p-value (p=0.0717) and this is more than 0.05, but a 
significant was observed for octenidine alone and octenidine plus Lipodisq® 





























5.3.3  Corneal penetration investigations 
The Lipodisq® nanoparticle carrier is currently used to improve the delivery of 
hydrophilic drugs into the skin as it has the ability to traverse the lipid membranes 
of intact cells. Our anticipation was that this carrier would be able to deliver the 
hydrophilic compound CHLX into the corneal tissue that would be highly 
important for its use in the treatment of AK. Our in vitro findings of drugs screening 
showed that the antimicrobial activity for CHLX was enhanced in the presence of 
Lipodisq® nanoparticle carrier against trophozoites and cysts of Acanthamoeba 
spp. The results from the drug testing of this study indicated that the antimicrobial 
activity for biguanides has increased in the presence of the Lipodisq® carrier 
against cysts and trophozoites and these results are likely to be related to the 
ability of Lipodisq® nanoparticle carrier to cross the lipid membrane of 
Acanthamoeba. 
Initially, a standard curve of CHLX as monotherapy was created to enable the 
quantification of the CHLX extracted from the corneal tissue using a range of 
concentrations from 200 µg/mL to 2 µg/mL. After that a calibration curve was 
generated by plotting the peak area of CHLX analysis against CHLX 
concentration for each of the standards from Table 5.3.  
Table 5-3: The corresponding peak area obtained for each of the CHLX standards 
Standard Concentration (µg/mL) Peak Area 
1 200 7454578 
2 100 3780456 
3 50 1829043 
4 10 386586 
5 5 159336 








Figure 5-5: Calibration curve showing the peak area against CHLX 
concentrations 
It is clear from the HPLC analysis that the CHLX alone showed a major peak at 
retention time of 2.513 min as shown in Figure 5.6. The CHLX incorporated with 
Lipodisq® nanoparticle peak was observed in comparable retention time with 
CHLX in its own at 2.502 min, see Figure 5.7. The other detected peaks in the 
chromatogram may related to noise and they are compounds that could be 
impurities or from the corneal tissue itself. 
 
Figure 5-6: Chromatogram shows the analysis of the CHLX alone concentration 
corneal tissue which had been incubated for 1 hour in 200 µg/mL of CHLX. 
 
























Figure 5-7: Chromatogram shows the analysis of the CHLX concentration corneal 
tissue which had been incubated for 1 hour in 200 µg/mL of CHLX combined with 
Lipodisq® nanoparticle carrier. 
The CHLX in the presence of the Lipodisq® nanoparticle (the initial of exposure 
concentration to the cornea is 0.02% (v/v) demonstrated a lower concentration at 
10.8 µg/mL, whereas the concentration was increased up to 16.3 µg/mL in the 
absence of the carrier at the same exposure concentration that used for CHLX + 
carrier as shown in Table 5.4 below. So, the results of this study suggested that 
the Lipodisq® nanoparticle carrier was not penetrated deeply inside the corneal 
tissue compared with CHLX alone and the possible reason for that is the limitation 
of the detected method.  
Table 5-4: The quantification of the CHLX concentration from the corneal tissue 
exposed to CHLX in the presence and absence of the Lipodisq® nanoparticle 
carrier. The standard curve from Figure 5.5 was used to determine the 
concentration of CHLX. 
Sample Time Peak Area 
Concentration 
(µg/mL) 
CHLX as monotherapy  10 min 308966 8.5 
CHLX combined with Lipodisq® 10 min 262195 7.3 
CHLX as monotherapy  1 hour 643164 16.3 




5.4  Discussion  
5.4.1  Increases in the activity of biguanides in the presence of 
Lipodisq® nanoparticles 
Most of the studies in the scientific literature have reported that the first therapy 
line used for the treatment of AK is biguanides, either PHMB or CHLX as 
monotherapies at concentration of 0.02 % (v/v) or in combination with  diamidine 
compounds, such as propamidine isethionate and hexamidine at a concentration 
of  0.1% (v/v) (Elder et al., 1995, Bouheraoua et al., 2014, Papa et al., 2020). 
Chlorhexidine is bisbiguanides which has previously been tested and it showed 
strong activity against a number of bacterial species, the minimal bactericidal 
concentration (MIC) for Streptococcus mutans found to be 1.60 mM and a much 
lower concentration of MIC was observed at 0.40 mM for other strains included 
S. sanguis, Actinomyces viscosus and A. naeslundii (Tanzer et al., 1977). PHMB 
is a biguanide polymer and is comprised of repeating simple biguanide units 
linked with hexamethylene hydrocarbon chains (Chindera et al., 2016). 
PHMB is a broad-spectrum biocide that is used to eradicate a number of 
microorganisms, such as parasites, bacteria, fungi and some viruses (Müller and 
Kramer, 2008). The chemical structure of biguanide compounds comprises two 
or more biguanide groups and a lipophilic 6-carbon chain (Figure 5.8). One of the 
most interesting observations is that PHMB, CHLX and octenidine, when 
incorporated with Lipodisq® nanoparticle carriers, demonstrated excellent 
antimicrobial activity against cysts and trophozoites of both species of 
Acanthamoeba. The antimicrobial activity was enhanced in the presence of 
Lipodisq® carriers. This may be due to several reasons including the following: 
the carrier is able to target the cell function and reduce drug resistance; it is easier 
to penetrate inside the cell and its small size enables the carrier to cross the lipid 
membranes of intact cells.  
To our knowledge, no study has tested a combination of PHMB, CHLX and 
octenidine with Lipodisq® nanoparticle carriers against trophozoites and cysts of 
Acanthamoeba, so this is first study to show the antimicrobial activity of these 
combinations against trophozoites and cysts. Previously, PHMB and CHLX have 
been tested in vitro against cyst of Acanthamoeba castellanii and both drugs 




al., 1996). Conversely, the results from the combination of PHMB and CHLX with 
Lipodisq® carrier in the current study suggested that the activity of PHMB is 
enhanced in the presence of this carrier up to around 7-fold and also 4-fold 

















The Lipodisq® nanoparticle solutions were formulated by our collaborators in 
Malvern, Worcestershire, U.K. Essentially, the formulation was made through the 
synthesis of lipodisq nanoparticles from poly(styrene-co-maleic acid) and 
dipalmitoylphosphatidylcholine (DPPC) at ratio of 1:2 (Tonge, 2014). The lipodisq 
particles size was monitored by using dynamic light scattering and then the 
Lipodisq® solution was combined with CHLX and octenidine hydrochloride at a 
concentration of 0.1% (v/v) and with PHMB at a concentration of 0.6% (v/v). The 
other new formulations of surfactant and Lipodisq® non-particle were combined 







Figure 5-8: Chemical structures of biguanide compounds: (A) Octenidine 
















A different carrier of gold nanoparticles was incorporated with chlorhexidine and 
tested against trophozoites of Acanthamoeba and the findings showed that at  a 
lower concentration of 5 µM caused 60% of inhibition compared with 
chlorhexidine alone which exhibited only 40% of inhibition against trophozoites 
(Bouheraoua et al., 2014). The antimicrobial activity observed in the existence of 
Lipodisq® nanoparticles against trophozoites and cysts in this study is very 
interesting. The way forward may be to apply a combination of biguanide 
compounds with Lipodisq® carriers in a clinical trial setting. However, it must be 
remembered that there is no association between in vitro drug sensitivities and 
the in vivo response of most of the drugs used for the treatment of AK (Pérez-
Santonja et al., 2003).  
5.4.2  Evaluating the activity of new formulation and existing of 
biguanides in relation to time kill 
Polyhexamethylene biguanide (PHMB), chlorhexidine digluconate (CHLX) and 
octenidine hydrochloride (OCT) were evaluated on their own and then 
encapsulated with nanoparticles Lipodisq® carriers to establish their antimicrobial 
activity over time against cysts of Acanthamoeba. It is clear from the time kill 
results for biguanides that a large improvement was observed in antimicrobial 
PHMB 





carrier solution  
PHMB was encapsulated 
with Lipodisq® nanoparticle 
and surfactant solutions at 
ratio of 1:199 to give the final 
concentration of 1mg/mL 
Figure 5-9: Formulation of a Lipodisq® nanoparticle solution with biguanides, 




activity against Neff’s cyst of Acanthamoeba castellanii (ATCC 50370). There 
was a large increase in the activity of biguanides against both trophozoites and 
cysts of A. castellanii in the presence of Lipodisq® nanoparticle carriers in 
comparison with the absence of such carriers. As presented earlier in the result 
section 5.3.4 of this chapter, PHMB and CHLX plus Lipodisq® at a concentration 
of 31.3 and 15.6 respectively showed a 4, 4.5 and 3-log kill respectively against 
Neff’s cysts within 24 hours which is double the rate seen in the absence of the 
Lipodisq® carriers at 2-log kill for PHMB and CHLX. The OCT combined with 
Lipodisq® at a concentration of 3.9 µg/mL gave 3-log reduction compared with a  
≈3-log of OCT in its own at higher concentration of 7.8 µg/mL over 24 hours.  
This is first time to show that the activity of Lipodisq® carriers combined with 
biguanide compounds over time kill against cysts of Acanthamoeba. PHMB 
incorporated with nanoliposomes has been shown to have higher antibacterial 
activity at 10 mm of zone inhibition against Staphylococcus aureus and 
Escherichia coli compared with the zone inhibition obtained from PHMB alone at 
25 and 21 mm respectively against S. aureus and E. coli (Ahani et al., 2017). 
Octenidine was tested against Staphylococcus epidermidis and showed more 
efficient activity at MIC 0.0125% compared with chlorhexidine which showed MIC 
at a concentration of 0.05% (Chum et al., 2018). Recently, the combination of 
octenidine with lavender essential oil has been investigated against methicillin-
resistant Staphylococcus aureus ATCC 43300 and the MIC was found to be at a 
lower concentration of 0.12–0.86 µg/mL (Kwiatkowski et al., 2020). 
5.4.3  Corneal penetration observations  
The corneal penetration findings of this study have shown that the penetration of 
CHLX in the absence of Lipodisq® nanoparticle carriers (the initial of exposure 
concentration to the cornea is 0.02% (v/v) showed 16.3 µg/mL after 1 hour of 
incubation, while the penetration of CHLX in the presence of the carriers at the 
same exposure concentration that utilized for CHLX plus carrier decreased to 
10.8 µg/mL after the same period of incubation. These results could be explained 
by the fact that when the combination of CHLX and Lipodisq® solution was heated 
to 60 C before the solution was placed in the HPLC mobile phase, the carrier 
might have been dislocated from the CHLX solution resulting in inadequate 




with the different structures (the size, polarity of the carrier). Another possible 
elucidation for this is that extraction method for CHLX plus Lipodisq® carrier was 
not sufficient and also there was a limitation of the HPLC detected method, as we 
believe that the nanoparticles Lipodisq® carriers have been used in many studies 
for a range of applications. Lipodisq® carrier has been measured throughout the 
skin by using near-infrared chemical imaging (NIRCI) and it has been found that 
this carrier penetrated into deeper layers of skin over 30 min (Malvern, 2015). A 
different carrier of eucalyptus oil has been used to deliver hydrophilic drugs into 
the skin, due to its small size and its ability to speed up the penetration process. 
It has been shown that when this carrier is combined with 2% (w/v) of CHLX at a 
concentration of 10% (v/v) in 70% isopropyl alcohol (v/v), the CHLX achieved 
penetrated of the skin within only 2 min (Karpanen et al., 2008).  
 
5.5  Future research work  
The hypothesis for penetration study was that the Lipodisq® carrier would be able 
to increase the delivery of CHLX into the cornea. However, the findings obtained 
in this study showed that the concentration of CHLX encapsulated with Lipodisq® 
carrier that entered the cornea was only 10.8 µg/mL from the former exposure 
concentration of 0.02% (v/v) after 1 hour and the possible explanation is the 
limitation of the detected method. In future investigations, it might be possible to 
use a different extraction approach, such as a fluorescent dye, to monitor the 
penetration of CHLX combined with a Lipodisq® carrier into intact porcine eyes 
and compare the results with CHLX as a monotherapy. It would be interesting to 
see the amount of CHLX plus the carrier that penetrates into the cornea, as this 
combination is potentially promising as a new treatment for AK in vivo.  
On the other hand, the biguanide compounds, in particular PHMB and 
chlorhexidine are currently used in the treatment of patients suspected of having 
Acanthamoeba in their eyes. For further studies, it would be important to use a 
pig or sheep eyes as an ex vivo models to analyse and observe the depth of 
penetration of these compounds within corneal tissue. This essay helps to identify 
which compound can be more penetrated within a short time inside the cornea 
and will use these observations as a recommendation for in vivo treatment. The 




assay which does not require ethical approval and special laboratories to carry 
out the experiments. Also, I would much prefer to use an ex vivo model as it not 
expensive, accessible, easy to handle and manage. Conversely, there are 
several disadvantages of using mice, hamster, rabbit as in vivo models, including 
the following: requiring animal ethics approval for in vivo research, difficult to 
handle and needing animal laboratories, and often expensive to order. 
 
5.6  Conclusion  
Taken together, the findings of the drug testing in the current study showed that 
the combination of biguanides with Lipodisq® carriers enhanced the antimicrobial 
activity ≈ 1 up to 7-fold against cysts and trophozoites of Acanthamoeba spp. 
compared with the use of biguanides in their own. Also, complete kill was 
observed at a 4 and 4.5-log reductions when the PHMB and CHLX were 
incorporated with Lipodisq® carriers compared with PHMB and CHLX alone, 
which gave only 2-log reduction. Octenidine alone found to be more active than 
PHMB and CHLX in their own and these results may support using octenidine as 
an effective treatment for AK. Furthermore, no toxicity was observed from the 
combination of biguanide compounds with Lipodisq® carriers when they were 
tested on human epithelial cell lines and this is a significant indication of the 
potential use of these formulations for the future treatment of AK. The HPLC 
analysis of corneal penetration indicated that the Lipodisq® carrier  incorporated 
with CHLX  did not enhance the penetration of CHLX into the corneal tissue, as 
the initial exposure concentration was  0.02% (v/v) and the concentration that 
penetrated inside the cornea being 10.8 µg/mL after 1 hour of exposure 
compared with 16.3 µg/mL for CHLX alone, which penetrated more deeply and 
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6. Chapter 6: Examining the effect of adrenoceptors and cellulose 
synthesis inhibitors on the conversion of Acanthamoeba 
trophozoites into the cyst and protocyst form 
 
6.1  Introduction  
6.1.1  The encystment of Acanthamoeba 
As stated in chapter 1 section 1.1, Acanthamoeba has two distinct stages to its 
life cycle: the vegetative stage known as the trophozoite, in which it grows, feeds 
and multiplies and the dormant stage, known as a cyst, that forms when the 
organism encounters hard environmental conditions such as heat and hyper 
osmolarity (Byers et al., 1991). A number of signals have been found to induce 
the encystment in Acanthamoeba including starvation, elevated pH, osmolarity 
and the presence of certain drugs (Neff et al., 1964). A physical barrier can be 
produced from the cysts of Acanthamoeba, which makes this organism resistant 
to most of the antimicrobial agents and biocides that used for contact lens 
disinfection (Turner et al., 2000a). When the trophozoites of Acanthamoeba 
exposed to a disinfection containing propylene glycol, it switched to another form 
termed immature (protocyst) and the process took around 2 hours to complete, 
unlike cysts which takes around 24 hours to form and so this could be a potential 
new stage of Acanthamoeba (Kilvington et al., 2008).  
The catecholamines including dopamine, norepinephrine, and epinephrine in 
mammalian systems are often hormones or neurotransmitters. Epinephrine is a 
hormone released from the adrenal medulla and is involved in the coordination 
of physiologic functions including blood pressure, heart rate and levels of 
circulating glucose (Malven, 1993). There are five different enzymes involved in 
the synthesis pathway of catecholamines (Figure 6.1). The synthesis begins from 
the amino acid phenylalanine, which involves the conversion of tyrosine to 
levodopa (L-DOPA) by the enzyme tyrosine hydroxylase and then 
decarboxylation of DOPA to dopamine by decarboxylase enzyme. Subsequent 
step is convert dopamine to norepinephrine by dopamine-β- hydroxylase enzyme 
and finally the phenylethanolamine-N-methyltransferase enzyme methylated the 




Figure 6.1 below, the chemical structure for epinephrine consists of catechol ring 
and an amine group consisting of a benzene ring with two hydroxyl groups.  
 
Figure 6-1: Synthesis pathway of epinephrine 
 
6.1.2  G protein coupled receptors and Acanthamoeba 
G-protein coupled receptors (GPCRs) are seven transmembrane proteins and 
form the largest, diverse group of mammals (Schöneberg et al., 1999). These 
proteins are encoded by the genomes and can regulate the signalling system. G-
proteins can be divided into two major classes, the monomeric, small GTPases 
and the heterotrimeric G-protein complexes (Oldham and Hamm, 2008, LeVine, 
1999). The G- proteins that are associated with GPCRs are heterotrimeric, 
meaning they have three different subunits, Gα, Gβ, and Gγ, two of which,  Gβ 
and Gγ,  are attached to the plasma membrane by lipid anchors as illustrated in 
Figure 5.2 (Morris and Malbon, 1999). G-proteins in normal state, the Gα subunit 
is bound to the GDP and this complex is bound with high affinity to the 
heterodimer segment Gβγ (Morris and Malbon, 1999). Once the receptor (GPCR) 
is activated, GDP is released from Gα allowing binding GTP as an alternative 
(Oldham and Hamm, 2008). GPCRs play a crucial role in mammalian cells by 
regulating a number of cellular functions, such as cell cycle, proliferation and 










































Also, in human GPCRs regulate numerous physiological activities included 
metabolism, secretion, growth, inflammatory, and immune responses 
(Chattopadhyay, 2014). In a study conducted by Clarke et al. (2013) found that 
Acanthamoeba genome encodes 35 G protein couple receptors, which act as 
sensors for extracellular inducements and consequently represent prospective 




Figure 6-2: A diagram showing the seven transmembrane proteins of G-protein 
coupled receptors (GPCRs) and these proteins convert extracellular signals to 
inside the cells. There are a variety of ligands that can stimulated the GPCRs 
included biogenic amines, amino acids, ions, lipids, peptides, and several 
exogenous ligands for instance pheromones. As can be seen in this diagram the 
ligand (in black colour) binds at the transmembrane region of the GPCRs. 
Activation of heterotrimeric G proteins α, β, and γ subunits is related to the binding 
of particular ligands to the GPCRs. The other subunits of G proteins involving 𝛼s, 
𝛼i, 𝛼q, and α₁₂  play an important role in regulating the signaling cascades. The 





The first messenger system contains extracellular factors, often hormones or 
neurotransmitters, such as epinephrine, growth hormones. These first 
messengers may not physically cross the phospholipid bilayer to initiate changes 
within the cell in the mammalian system and because of this functional limitation 
(Lodish et al., 2000), the transduction mechanisms transduce from the first 
messenger system to the second messengers (Lodish et al., 2000).  The second 
messengers are small molecules such as cyclic AMP (cAMP), which are initiate 
intracellular signalling pathways (Lodish et al., 2000), and these molecules 
alternate signals that received by the receptors on the surface of the cell and the 
activation of single G-protein leads to the production of thousands of second 
messenger molecules. Furthermore, G-protein and its downstream signalling 
molecules such as Rab GTPases, Rho and Ras, are involved in the pathogenesis 
of Entamoeba histolytica and they have been highlighted as possible targets for 
pharmacological manipulation (Bosch and Siderovski, 2013). 
Epinephrine plays a critical role in targeting the encystment of Acanthamoeba 
and the process is probably mediated by a receptor that stimulates cyclic AMP 
(cAMP) synthesis (Srivastava and Shukla, 1983, Krishna, 1975). In a number of 
eukaryotic cells in mammalian systems cyclic cAMP dependant signalling 
pathways play an important role in regulating three important mechanisms 
involved in cell growth, metabolism and differentiation (Abel et al., 2001). 
Acanthamoeba shares a similarity with the mammalian in response to the action 
of the endogenous epinephrine, it was observed that in mammalian system the 
activity for glycogen phosphorylase is increased and resulted in breakdown of the 
livers glycogen stores (Riley and Haynes, 1963). Likewise, the breaking down of 
glycogen into glucose monomers by glycogen phosphorylase enzyme is one of 
the most important activities that is detected during the encystment of 
Acanthamoeba (Weisman et al., 1970). 
6.1.3  Production of cellulose in Acanthamoeba  
Acanthamoeba cyst walls are mostly made up of cellulose polymer. A recent 
study by Garajová et al. (2019) used a variety of techniques, included light, 
confocal laser scanning and transmission electron microscopy, to investigate the 
elements of cysts. They found that cellulose fibrils exist in the endocyst and 




a previous study by Chavez‑Munguia et al. (2005) which reported that cellulose 
polymers are found in both layers of the Acanthamoeba cyst wall. The synthesis 
of cellulose polymers during the encystment of Acanthamoeba is initiated by the 
breakdown of glycogen in the trophozoites into glucose-1-phosphate caused by 
glycogen phosphorylase (Greenberg et al., 2006). There are four enzymatic steps 
involved in the synthesis of cellulose polymers from glucose in Acanthamoeba: 
the first step is the phosphorylation of glucose into glucose-6-phosphate by 
hexokinase and then the isomerisation of glucose-6-phosphate to glucose-1-
phosphate by phosphoglucomutase. The next step is the synthesis of UDP-
glucose by UDP-glucose pyrophosphorylase and the final step is the formatting 















































Figure 6-3: Diagram showing the cellulose biosynthesis pathway in 
Acanthamoeba. The process begins with the breakdown of the glycogen in the 
trophozoites when Acanthamoeba triggers to encyst into glucose. The 
biosynthesis of cellulose in the cyst wall of Acanthamoeba occurs through several 





6.1.4  Aims and objectives of this chapter  
The first aim of this chapter is to investigate the transformation of Acanthamoeba 
trophozoites into cysts and protocysts in the presence and absence of a variety 
of adrenoreceptors, including agonists and antagonists. The second aim is to 
examine the effect of cellulose synthesis inhibitors (CSI) including isoxaben and 
2,6-dichlorobenzilnitrate (DCB) on their own and in combination on the formation 
of Acanthamoeba cysts and protocysts. This chapter provides a more detailed 
investigation regarding the effects of CSI on the transformation of trophozoites 
into cysts and protocysts in Acanthamoeba. It is known that the cyst walls of 
Acanthamoeba are partially made of cellulose, so this study investigated the 
ability of these cellulose synthesis inhibiting herbicides to block the encystment 
process and also inhibit the protocyst formation of Acanthamoeba. The 
mechanism of action for DCB and Isoxaben is interfering and blocking the 
cellulose synthase enzyme during cellulose biosynthesis in Acanthamoeba. The 
present work is an extension of the work reported earlier by (Heaselgrave and 
Kilvington, 2016) and this study is different from the aforementioned study, as the 
current research attempted to examine the effect of the β ultra-long agonist 
indacaterol in order to target the receptor in the trophozoites membrane of 
Acanthamoeba. The agonist indacaterol can bind to the receptor and will not 
diffuse compared with β₂ agonist salbutamol which can bind to the receptor for a 
short period. Also, to examine different antagonists included levobunolol and 
betaxolol against the conversion of trophozoites into cysts and protocysts 
alongside the other antagonists which tested previously against cyst formation of 
Acanthamoeba. The objectives of this chapter are stated below:  
I. Test adrenoceptor agonists and antagonists against the transformation of 
trophozoites into cysts and protocysts in the presence and absence of 
epinephrine. 
II. Test adrenoceptor antagonists against the conversion of trophozoites into 
protocysts in the presence of epinephrine. 
III. Evaluate the effect of isoxaben and DCB on the transformation of 
trophozoites into cysts and protocysts, as these compounds inhibit the 
cellulose synthase enzyme in Acanthamoeba. 
IV. Investigate the effect of DCB and isoxaben in their own and in combination 




6.2  Methods  
6.2.1  Preparation of organisms   
Acanthamoeba castallanii (ATCC 30868) was cultured and maintained as 
detailed in chapter 2, section 2.3. Acanthamoeba castallanii (ATCC 30868) was 
selected for the encystment investigations among Acanthamoeba castallanii 
(ATCC 50370) and Acanthamoeba polyphaga (ATCC 30461) as it has more 
favourable encystment profile in Neff’s medium and provided natural encystment 
levels. In contrast, the other strains, Acanthamoeba castallanii (ATCC 50370) 
and Acanthamoeba polyphaga (ATCC 30461), encysted rapidly and it was 
difficult to distinguish between the normal encystment process and encystment 
in the presence of the agonists or antagonists. Acanthamoeba castallanii (ATCC 
50370) was used for the production of protocysts as this strain provided natural 
protocyst formation.  
6.2.2  Preparation of adrenoreceptor agonists and antagonists  
The agonists and antagonists were prepared and dissolved in appropriate solvent 
at different concentrations in order to be tested against the transformation of 
trophozoites of A. castallanii (ATCC 30868) into cyst or protocyst forms (Tables 
6.1 & 6.2).  
Table 6-1: The agonists used in this study for the encystment assay 
Name  Specificity Supplier Chemical Name 













































Table 6-2: The antagonists used in this study for the encystment assay 














































6.2.3  Acanthamoeba encystment assay  
The encystment experiments were performed in polypropylene (50 mL) tubes. 
Initially, 5 mL of AC#6 growth medium was added to each tube and trophozoites 
at a density of 2.5 x 105 cells/mL were added at time 0 to each tube. Then, 
different concentrations of agonists and antagonists and the required 
concentration of MgCl₂ were applied. Subsequently, the tubes were incubated in 
an orbital shaking incubator at 30 °C and 120 rpm for 7 days. The number of cysts 
were determined using a Modified Fuchs Rosenthal haemocytometer count. To 
count the number of cysts, an aliquot of the test solution in triplicate was used, to 
which was added 20 µL of 0.1% (v/v) N-lauryl sarcosinate Sarkoysl in order to aid 
the counting of the cells under an inverted microscopy. 
  6.2.4  Acanthamoeba protocyst assay  
The protocyst experiments were carried out also in polypropylene (50 mL) tubes. 
5 mL of Neff’s medium plus 0.5% (v/v) of propylene glycol was added to each 
tube and trophozoites at a density of 2.5 x 105 cells/mL were added at time 0. 
Agonists and antagonists were added to the corresponding tubes and then the 
tubes were incubated in an orbital shaking incubator at 30 °C and 120 rpm for 24 




the test solution and the counting was performed using a haemocytometer under 
an inverted microscopy.  
6.2.5 Effect of DCB and isoxaben on the conversion of 
trophozoites into cysts assay  
In order to determine the effect of cellulose synthesis inhibitors 2,6-
dichlorobenzonitrile (DCB) and isoxaben on the Acanthamoeba encystment 
process, a method adapted from Moon et al. (2015) was used in this study. DCB 
and isoxaben were dissolved in methanol at a concentration of 1 mM and then 
serially diluted to give a range of 500-50 µM. The assay was performed in 12-well 
plates containing 3 mL of Neff’s encystment medium per well (as presented in 
Figure 6.4). The wells were seeded with 2.5 x 105 cells/mL of Acanthamoeba 
castellanii (ATCC 50370) trophozoites. Several concentrations of DCB and 
isoxaben, ranging from 50 µM to 500 µM, were added to the wells and the plates 
were incubated at 30°C for 72 hours. After incubation, the cells were enumerated 
to determine the number of cysts. This was achieved by removing an aliquot of 
the test solution in triplicate to which was added 20 uL of 0.1% (v/v) N-lauryl 
sarcosinate (Sarkoysl) as used for encystment study which detailed in section 
6.2.3.  
6.2.6  Effect of DCB and isoxaben on the transformation of 
trophozoites into protocysts assay  
This assay was performed to examine the effect of DCB and isoxaben on the 
formation of protocysts of Acanthamoeba castellanii (ATCC 50370). The method 
detailed in section 5.2.5, modified from Moon et al. (2015), was used. Again, to 
each well, 30 µL of 2.5 x 105 cells/mL trophozoites of A. castellanii (ATCC 50370) 
were seeded in 12-well plates containing 3 mL of Neff’s + 0.5% (v/v) propylene 
glycol and incubated for 24 hours. Similarly, various concentrations of DCB and 
isoxaben were tested and the protocyst count was performed in triplicate using a 






Figure 6-4: The 12-well plate used for cellulose synthesis inhibitor assays 
 
6.3  Results 
The results in this chapter are focused on the effect of different adrenoreceptors 
agonists and antagonists and cellulose synthesis inhibitors including 2,6-
dichlorobenzonitrile (DCB) and isoxaben on the encystment process of 
Acanthamoeba and protocysts formation.  
6.3.1 The effect of agonists on the cysts formation of 
Acanthamoeba 
Different agonists were tested in this study to see if they were able to prevent or 
block the encystment of Acanthamoeba castellanii (ATCC 30868) in AC#6 growth 
medium supplemented with 50 mM MgCl₂. A higher level of encystment was 
observed with 0.5 mM of epinephrine at 90.3%. A lower concentration of 
indacaterol at 100 µM also demonstrated high encystment level of 85.7% and the 
percentage of encystment decreased slightly with 100 µM of dobutamine at 
83.5%. Using One Way ANOVA analysis indicated that the concentrations of 0.5 
mM of epinephrine and 100 µM of indacaterol and dobutamine were statistically 
significant (P ˂ 0.001) compared to 50 mM of MgCl₂ or AC#6 medium as a 
controls. Only a concentration of 10 µM of salbutamol was tested in this study, 
due to when the concentration was increased the salbutamol caused huge lysis 
of the Acanthamoeba trophozoites, and the concentration of 10 µM resulted in a 




that salbutamol at a concentration of 10 µM was significant (P ≤ 0.001) compared 
to the AC#6 medium as a control but no significant was observed from the tested 
the same concentration of salbutamol in relation to the MgCl₂ as a control. 
Isoprenaline and clenbuterol at a concentration of 1 mM showed encystment at 
75.4% and 60% respectively (Figure 6.5). Additional statistical analysis of two 
sample t-test for the means of all the agonists examined relative to the controls 
demonstrated p-value at p=0.0003. 
 
Figure 6-5: The effect of different agonists on the encystment of Acanthamoeba 
castellanii (ATCC 30868) in AC#6 growth medium. The standard error of the 
mean (SEM) represented the error bars (n=3). One-way analysis of variance 
(ANOVA) was performed. Asterisks represent values statistically significant  
(***P<0.001) between the tested agonists and the AC#6 medium or 50 mM of 
MgCl2 as controls. 
 
6.3.2  The effect of antagonists on the cysts formation of A. 
castellanii  
The results obtained from the antagonists are presented in Figure 6.6. 
Levobunolol at a concentration of 500 µM induced the encystment at 53.7% and 
at the same concentration, a small decrease in the level of the encystment was 
observed with both butaxamine and propranolol, at 46.2% and 43.9% 


























was significant (P ˂ 0.001) compared to that of the MgCl₂ or AC#6 medium as a 
controls. Also, two sample t-test for the mean of all the antagonists evaluated 
compared to the controls given p-value at p=0.002 and this is statistically 
significant. Clear inhibition of the encystment process was found with metoprolol 
and betaxolol at concentrations of 500 µM exhibiting only 14.6% and 22.3 % of 
encystment respectively.  
 
Figure 6-6: The effect of antagonists on the encystment of Acanthamoeba 
castellanii (ATCC 30868) in AC#6 growth medium. The antagonists tested to 
block endogenous of catecholamines in Acanthamoeba. The standard error of 
the mean (SEM) represented the error bars (n=3). One-way analysis of variance 
(ANOVA) was performed. Asterisks represent values statistically significant  
(***P<0.001) between the tested antagonists and the AC#6 medium and 50 mM 
of MgCl2 as controls. 
The experiment was repeated with the same antagonists but in the presence of 
500 µM of epinephrine to check the effect of these antagonists on the encystment 
of Acanthamoeba. Epinephrine was tested alone, and it led to a higher level of 
encystment at 87.8% and combined with β₁ metoprolol at a concentration of 500 
µM showed the lowest level of the encystment at 33.3%. Also, a higher rate of 
encystment was observed with indacaterol in its own at a concentration of 100 
µM gave 85.7% encystment and when this agonist mixed with 100 µM of β₁ 





































concentration of 500 µM combined with epinephrine was exhibited 64.8% of 
encystment. The next antagonist that was combined with epinephrine at a 
concentration of 500 µM was β₂ levobunolol and the percentage of encystment 
decreased to 62.5 %. Of the antagonists that were tested in the current study, β₁ 
betaxolol and β₂ butaxamine, at the same concentration of 500 µM combined with 
epinephrine, giving 48.7% and 52.3% encystment respectively. Furthermore, all 
the antagonists that were mixed with epinephrine at a concentration of 500 µM 
promoted the encystment process (P ˂ 0.001) compared with MgCl₂ or AC#6 
medium as a controls, excepted the metoprolol which had biggest reduction on 
the encystment compared to the MgCl₂ as a control (Figure 6.7). Moreover, two 
sample t-test for all antagonists combined with epinephrine in comparison to the 
controls displayed p-value at p=0.0001. 
 
Figure 6-7: The effect of antagonists in the presence of epinephrine on the 
encystment of Acanthamoeba castellanii (ATCC 30868) in AC#6 growth medium. 
The epinephrine combined with the antagonists to block endogenous & 
exogenous of catecholamines in Acanthamoeba. The standard error of the mean 
(SEM) represented the error bars (n=3). One way analysis showed of variance 
(ANOVA) was performed. Asterisks represent values statistically significant  
(***P<0.001) between the tested antagonists plus epinephrine and the AC#6 




























6.3.3  The effect of antagonists on the protocysts formation of 
Acanthamoeba  
Further investigations were performed with the antagonists to assess their effect 
on the transformation of trophozoites into the protocyst form of Acanthamoeba 
castellanii (ATCC 50370). In this study, levobunolol at a concentration of 500 µM 
gave the highest percentage of protocyst production at 62.6%. Betaxolol at the 
same concentration gave 52.7%. However, the other three antagonists that were 
tested in the current study, metoprolol, butaxamine and propranolol, at a 
concentration of 500 µM prevented the development of trophozoites into 
protocysts at 22.9%, 26.6% and 27.3% respectively. These findings showed that 
different antagonists at a concentration of 500 µM were significant (P ˂ 0.001) 
compared with MgCl₂ or AC#6 medium as a controls (Figure 6.8). In addition, for 
all assessed antagonists, two sample t-test of the mean proved p-value at 
p=0.004.
 
Figure 6-8: The effect of different antagonists on the conversion of trophozoites 
into protocysts of A. castellanii (ATCC 50370) in Neff’s medium plus 0.5% (v/v) 
propylene glycol (PG). The antagonists tested to block endogenous of 
catecholamines in Acanthamoeba. The standard error of the mean (SEM) 
represented the error bars (n=3). One-way analysis of variance (ANOVA) was 
performed. Asterisks represent values statistically significant (***P<0.001) 







































As can be seen from the data in Figure 6.9, the protocysts production was 
increased in the presence of epinephrine. Higher percentages of protocysts were 
observed with levobunolol and betaxolol at a concentration of 500 µM, giving 
69.7% and 57.7%, respectively. Conversely, the other antagonists, propranolol, 
butaxamine and metoprolol, combined with epinephrine at a concentration of 500 
µM prevented protocyst formation, giving figures of 37.4%, 35.6% and 30.9% 
respectively. One Way ANOVA statistical analysis showed a significant 
correlation (P ˂ 0.001) for all antagonists that were tested in this experiment 
relative to the MgCl₂ or AC#6 medium as a control. Also, two sample t-test 
analysis of the examined antagonists revealed p-value at p=0.003. 
 
Figure 6-9: The effect of several antagonists in the presence of epinephrine on 
the conversion of trophozoites into protocysts of A. castellanii (ATCC 50370) in 
Neff’s medium plus 0.5% (v/v) propylene glycol (PG). The epinephrine combined 
with the antagonists to block endogenous & exogenous of catecholamines in 
Acanthamoeba. The standard error of the mean (SEM) represented the error bars 
(n=3). One-way analysis of variance (ANOVA) was performed. Asterisks 
represent values statistically significant (***P<0.001) between the tested 




































6.3.4  The effect of 2,6-dichlorobenzonitrile (DCB) and isoxaben 
on the encystment of Acanthamoeba  
Four different concentrations of 2,6-dichlorobenzonitrile (DCB) and isoxaben 
(Isox) were evaluated to observe the inhibitory effect of these cellulose synthesis 
inhibitors on the transformation of trophozoites into the cyst stage.  
 
Figure 6-10: The effect of (2,6-dichlorobenzonitrile) DCB on the encystment of A. 
castellanii (ATCC 30868) in Neff’s medium. The haemocytometer counts for cysts 
were performed after 3 days of incubation. The standard error of the mean (SEM) 
represented the bars (n=3). One-way analysis of variance (ANOVA) was 
performed. Asterisks represent values statistically significant (***P<0.001) 
between the tested concentrations of DCB and the Neff’s medium or 500 uM 
MeOH as controls. 
When tested against trophozoites, DCB at concentrations of 50 µM, 100 µM and 
200 µM prevented the encystment at 38.4%, 31.8% and 24.4% respectively. The 
encystment level that observed at these concentrations, compared to that of the 
Neff’s or 500 µM of methanol as controls, was statistically significant according 
to the One-Way ANOVA analysis. A higher concentration of DCB at 500 µM was 
blocked the encystment of Acanthamoeba at 17.7% and the One-Way ANOVA 
analysis of the concentration of 500 µM of DCB showed significance (P < 0.001) 
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(Figure 6.10). Two sample t-test analysis was undertaken for the different tested 
contractions of DCB in relation to the controls showed p-value at p=0.004.  
 
Figure 6-11: The effect of isoxaben on the encystment of A castellanii (ATCC 
30868) in Neff’s medium. The haemocytometer counts for cysts were performed 
after 3 days of incubation. The standard error of the mean (SEM) represented the 
error bars (n=3). One-way analysis of variance (ANOVA) was performed. 
Asterisks represent values statistically significant (***P<0.001) between the 
tested concentrations of isoxaben and the Neff’s medium or 500 uM MeOH as 
controls. 
The higher concentration of isoxaben of 500 µM showed a 45% encystment of 
Acanthamoeba, which is significant (P < 0.001) compared with the Neff’s or 
methanol at concentration of 500 µM as controls. The results revealed that 
isoxaben concentrations of 50 µM, 100 µM and 200 µM showed relatively similar 
levels of encystment at 70.4%, 68.8% and 62.2% respectively. Furthermore, 
when isoxaben was correlated with the methanol control, the effect was not 
significant as the p-value of t-test showed p=0.07, but at these concentrations of 
isoxaben, the effects were statistically significant compared with the Neff’s as 































Figure 6-12: The effect of DCB & isoxaben alone and in combination on the 
encystment of A castellanii (ATCC 30868) in Neff’s medium. The 
haemocytometer counts for cysts were performed after 3 days of incubation. The 
standard error of the mean (SEM) represented the error bars (n=3). One-way 
analysis of variance (ANOVA) was performed. Asterisks represent values 
statistically significant (***P<0.001) between the tested concentrations of DCB 
and the Neff’s medium or 500 uM MeOH as controls. 
More testing was carried out to examine the effect of DCB and isoxaben 
individually and in combination at a concentration of 100 µM on the conversion of 
trophozoites into cysts. Based on the findings that obtained from this experiment, 
the DCB alone at a concentration of 100 uM gave encystment level at 31.8% and 
much higher rate of encystment was occurred at 68.8% for isoxaben at a 
concentration of 100 uM. However, when 100 uM of isoxaben was added to the 
same concentration of DCB and tested, an antagonistic impact was observed as 
the transformation of trophozoites into cysts was found to be at rate of 49.1% as 
presented in Figure 6.12. Two sample t-test analysis for the of DCB in its own 
and in combination with isoxaben was found to be significant compared to the 
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6.3.5  The effect of DCB and isoxaben on the transformation of 
trophozoites into protocysts 
The effect of the same compounds, DCB and isoxaben on the conversion of 
trophozoites into protocysts was also examined. 
 
Figure 6-13: The effect of DCB on the transformation of trophozoites of A. 
castellanii (ATCC 50370) into protocysts in Neff’s medium plus 0.5% (v/v) 
propylene glycol. The haemocytometer count for protocysts was performed after 
24 hours of incubation. The standard error of the mean (SEM) represented the 
error bars (n=3). One-way analysis of variance (ANOVA) was performed. 
Asterisks represent values statistically significant (***P<0.001) between the 
tested concentrations of DCB and the Neff’s-PG or 500 uM MeOH as controls. 
It can be seen from the results in Figure 6.13 that there is a clear increase in the 
inhibition of protocysts. The higher concentration of DCB at 500 µM exhibited a 
24.6% of protocysts and this value was significant (P < 0.001) compared with the 
controls. At other concentrations of DCB of 50 µM, 100 µM and 200 µM, the 
protocysts production was found to be 57.6%, 36.9% and 33.4% respectively, 
and these effects are considered significant in comparison with Neff’s or methanol 



























all tested concentrations of DCB in relation to the Neff’s-PG medium or 500 uM 
MeOH as controls. 
 
Figure 6-13: The effect of Isoxaben on the transformation of trophozoites into 
protocysts of A. castellanii (ATCC 50370) in Neff’s medium plus 0.5% (v/v) 
propylene glycol. The haemocytometer count was performed after 24 hours of 
incubation. The standard error of the mean (SEM) represented the error bars 
(n=3). One-way analysis of variance (ANOVA) was performed. Asterisks 
represent values statistically significant (***P<0.001) between the tested 
concentrations of isoxaben and the Neff’s-PG or 500 uM MeOH as controls. 
 
The results in Figure 6.14 indicate that the effect of isoxaben on protocyst 
development at the higher concentration of 500 µM achieved a protocyst 
production level of only 37.2% and this rate was significant (P < 0.001) compared 
with the controls. Two sample t-test showed that the p-value for all tested 
concentrations of isoxaben compared to the controls was at p=0.0015. The 
production of protocysts was increased at concentrations of 50 µM, 100 µM and 






























Figure 6-14: The effect of Isoxaben and DCB individual and in combination on 
the transformation of trophozoites into protocysts of A. castellanii (ATCC 50370) 
in Neff’s medium plus 0.5% (v/v) propylene glycol. The haemocytometer count 
was performed after 24 hours of incubation. The standard error of the mean 
(SEM) represented the error bars (n=3). One-way analysis of variance (ANOVA) 
was performed. Asterisks represent values statistically significant (***P<0.001) 
between the tested concentrations of DCB and the Neff’s-PG and 500 uM MeOH 
as controls. 
The data in Figure 6.15 present the testing results for DCB and isoxaben in their 
own and in combination at a concentration of 100 µM on the transformation of 
trophozoites into protocysts. The DCB alone at 100 uM inhibited the protocysts 
at 36.9%. However, a significantly higher rate of protocysts production was 
observed at 63% for isoxaben at concentration of 100 uM. When the experiment 
was conducted for the combination of DCB and isoxaben at the same 
concentration for tested those compounds individually, a 45.7% of protocysts 
formation was occurred. This result could be related to an antagonistic effect in 
comparison to the use of DCB alone (Figure 6.15). Two sample t-test showed 
that the p-value=0.0025 for the tested compounds individually and in combination 



























6.4  Discussion  
This section outlines an extensive discussion about the effect of various agonists/ 
antagonists and cellulose synthesis inhibitors on the transformation of trophozoite 
into cyst and protocyst forms.  
6.4.1 The encystment of Acanthamoeba in the presence of 
different agonists and antagonists   
The research to date has tended to focus on the transformation of trophozoites 
into cysts of Acanthamoeba in vitro and has attempted to understand the 
mechanism behind the encystment process. This discussion begins with the 
nonspecific adrenoceptor agonists epinephrine exhibited grater encystment at 2-
fold lower concentration than isoprenaline. The level of encystment that observed 
with selective β₁ dobutamine was close to epinephrine encystment at a 5 times 
lower concentration. Heaselgrave and Kilvington (2016) demonstrated that the 
selective β₁ dobutamine at 5-fold lower concentration to epinephrine gave 92.4%, 
also dobutamine gave comparable encystment to isoprenaline at 10-fold lower 
concentration 100µM. The potential thought for getting different results with the 
same concentrations of the agonists is could be related to the strain tested in the 
present study been affected by continuous culture or laboratory conditions. On 
the other hand, the specific agonist β₂ salbutamol exhibited limited agonist activity 
and led to encystment at a level of 36.8% and this result reflects the finding of a 
prior study by Heaselgrave and Kilvington (2016), who reported that this agonist 
has induced the encystment at a level of 50% of that observed with dobutamine, 
but at a 10-fold lower concentration. The effect of β₂ agonist salbutamol was 
probably through it utilising some activity at a β₁ receptor.  
The current study demonstrated that the ultra-long agonist β indacaterol ( which 
means this agonist has a duration of action of 24 hours) promoted the encystment 
in Acanthamoeba to level of encystment was near of that triggered by 
epinephrine, but the concentration was at 5-fold lower. The percentage of 
encystment decreased when the experiments were performed with antagonists 
and the largest reduction in encystment levels were found with the 
adrenoreceptor β₁ antagonists, metoprolol and betaxolol, giving around 30% of 
encystment levels. However, when the β₁ antagonists, metoprolol and betaxolol, 




around 60% .These results suggest that epinephrine stimulates encystment in 
Acanthamoeba. The level of encystment was observed with a non-selective β₂ 
antagonist levobunolol was approximately 50% and the rate of encystment was 
increased slightly when this antagonist combined with epinephrine and gave 
around 60%. According to the results of this study, it can be concluded that the 
β₁ subtype is the receptor implicated in encystment of Acanthamoeba and these 
observations fit with the findings that the β₁ receptor is positively linked to the 
cAMP, whereas β₂ receptor is negatively linked to the cAMP.  
Taken together, the results are consistent with findings of past studies by 
Heaselgrave and Kilvington (2016) the encystment in Acanthamoeba castallanii 
and Coppi et al. (2002) the encystment in Entamoeba invadens, which they 
reported that adrenoreceptor β₁ agonists and antagonists are capable of 
promoting or preventing the encystment process. Furthermore, in Coppi et al. 
(2002) study the authors were used a radio-labelled nonselective β 
adrenoreceptor agonist (³H)-CGP-12177 and their findings indicated that 
nonlabelled adrenoreceptor antagonists, including metoprolol, might block the 
binding of (³H)-CGP-12177 and inhibit encystment in Entamoeba invadens. 
There is no study has examined the effect of ultra-long agonist β indacaterol and 
antagonists included β₁ betaxolol and β₂ levobunolol on the encystment of 
Acanthamoeba. The reason for testing betaxolol and levobunolol on the cysts 
formation, due these drugs used to treat glaucoma and so they are safe in vivo 
in terms of toxicity. The glaucoma’s are a group of optic neuropathies defined by 
progressive degeneration of retinal ganglion cells which lead to visual loss 
(Kountouras et al., 2004). The contribution of the present study is obvious as the 
indacaterol at a 5 times lower concentration gave comparable encystment level 
to epinephrine. Betaxolol caused a reduction in the level of encystment of around 
30% and the β₂ levobunolol had slight reduction of around 10% on the 
encystment rate. On the other hand, the antagonist promethazine (antihistamine) 
has been tested against trophozoites and cysts of Acanthamoeba. It was found 
to be amoebicidal, but its cysticidal activity occurred at higher concentrations 
(Baig et al., 2019). It has been demonstrated that bioinformatic computational 
and 3D modelling techniques are useful tools to determine homology for the 




promethazine in Acanthamoeba (Baig and Ahmad, 2017). Promethazine binds to 
the histamine H1 and dopamine D2 receptors in humans and the function of this 
antagonist is to block the dopamine and histamine receptors in the 
chemoreceptor trigger areas (Welliver, 2014).  
6.4.2  The effect of magnesium chloride on the encystment of 
Acanthamoeba 
The magnesium chloride (MgCl₂) played an essential role in mediated the 
encystment process of Acanthamoeba, as the encystment was increased a round 
3-fold in comparison with the AC#6 growth medium as positive control. One of 
the important observation that encystment induced in the presence of Mg²⁺ ion, 
due this ion is capable of increase the fluidity of the lipid bilayer as a result of 
interacting this ion with negatively charged phospholipids leading to the alteration 
in the activity of membrane bound enzymes (Fuyu et al., 1983). Prior research 
has shown that the chloride ion able to be replaced for a sulphate ion without any 
decrease in encystment of Acanthamoeba (Srivastava and Shukla, 1983). It has 
been suggested that the divalent metal ions involving Mg²⁺ ion enhance the 
affinity of phosphorylase kinase enzyme (Xu et al., 1996),  which is responsible 
for transforming from the inactive b form to the active a form during the 
encystment of Acanthamoeba (Heilmeyer Jr, 1991). The evidence from these 
findings suggested that the existence of MgCl₂ stimulates the encystment in 
Acanthamoeba. This process is achieved by the released of glucose from the 
glycogen store and producing further sugar as free for cell wall synthesis.  
6.4.3 The effect of antagonists on the transformation of 
Acanthamoeba trophozoites into protocysts   
The findings of the present study contribute to our knowledge by addressing the 
effect of different antagonists in the presence and absence of epinephrine on the 
conversion of trophozoites into protocysts in Acanthamoeba. The present 
investigations showed that adrenoreceptor β₁ antagonist metoprolol and β₂ 
antagonists including propranolol and butaxamine had a major effect on protocyst 
formation. Furthermore, β₁ antagonists betaxolol and β₂ levobunolol at 500 µM 
concentration were exhibited higher percentages of protocyst production. In 
addition, when these antagonists were mixed with the same concentration of 




protocysts in the presence of epinephrine. These results indicated that 
epinephrine had no effect when it combined with these antagonists and these 
outcomes are differ to what have seen with the cyst observations. No attempt 
was made to establish the potential effects of adrenoreceptor β₁ betaxolol and β₂ 
levobunolol. This is the first study that has demonstrate the effect of antagonists 
betaxolol and levobunolol on the formation of protocyst of Acanthamoeba and the 
present work is motivated by the need to block the protocyst formation of 
Acanthamoeba.  
This result may be explained by the fact that the binding affinity of β₂ levobunolol 
for the receptor in Acanthamoeba is different, as this antagonist has previously 
shown higher affinity binging to the heart of endogenous guinea pig at 42 ± 15 
nM (Sharif and Xu, 2004). In vitro, protocyst stage can rapidly form in the 
presence of propylene glycol 0.5% (v/v) and this product is a major constituent of 
contact lenses which impose the most risk for Acanthamoeba keratitis. The 
outcomes of the present study suggested that adrenoreceptor antagonists 
included betaxolol and levobunolol can prompt protocyst production, whereas the 
other antagonists included butaxamine, propranolol and metoprolol were blocked 
the protocyst formation. It seems that the receptor ligands in the protocyst form 
behave for β₂ levobunolol in the same way as observed in the encystment of 
Acanthamoeba. The current findings also support a study by Heaselgrave and 
Kilvington (2016), which concluded that the β₁ antagonist metoprolol and β₂ 
antagonists propranolol were massively inhibited encystment of Acanthamoeba.  
6.4.4 The encystment of Acanthamoeba in the presence of 
cellulose synthesis inhibitors  
In Figure 5.10, the DCB at a concentration of 500 µM blocked the encystment of 
Acanthamoeba at 17.7% compared with methanol (MeOH) at concentration of 
500 µM and Neff’s as a positive control which they showed encystment rate at 
59.6%  and 76.1% respectively. The encystment level was increased at lower 
concentrations of DCB at 50 µM, 100 µM and 200 µM, which gave 38.4%, 31.8% 
and 24.4% respectively. The results from this study showed that, at lower 
concentrations of 50 µM, 100 µM and 200 µM, isoxaben exhibited slight effect on 





Isoxaben at a concentration of 500 µM was reduced the encystment rate to 45%. 
Interestingly, this study demonstrated that the combination of DCB with isoxaben 
at a concentration of 100 µM demonstrated encystment level at 49.1% in 
comparison to the controls and those drugs in their own at the same tested 
concentration. The findings from the present study at a concentration of 500 µM 
from DCB in agreement with the previous research by Dudley et al. (2007), which 
reported that a top concentration of DCB at 400 µM and 480 µM produced around 
19% and 15% respectively of Acanthamoeba encystment. When the authors 
tested a lower concentration of DCB at 240 µM and 320 µM, the rate of 
encystment found to be around 42% and 35% respectively, whereas in this study 
at concentration of 50 µM, 100 µM and 200 µM of DCB were proved 38.4%, 
31.8% and 24.4% encystment respectively.  
There are several possible explanation for getting different results: the method 
utilized by Dudley et al. (2007) contrasts to our study, those authors used a PYG 
medium (0.75% proteose peptone and yeast extract, glucose 1.5%, followed by 
the addition of 8% of glucose) to induce encystment, with 48 hours of incubation. 
Surprisingly in Dudley et al. (2007) research, 8% of glucose was added to PYG 
medium to promote the encystment, this observation contradicted to the findings 
from Byers et al. (1980), which reported that the encystment level of 
Acanthamoeba increased 70% up to 80% in the absence of glucose in growth 
media. Neff’s medium was used in the present study and the incubation time was 
72 hours. The strain tested in (Dudley et al., 2007) research was Acanthamoeba 
castellanii (ATCC 50492), while the present study tested a different strain, 
Acanthamoeba castellanii (ATCC 30868).  
A study by Moon et al. (2015) found that, at a concentration of 400 µM, DCB 
demonstrated around 22% of encystment and lower concentrations of 50 µM, 100 
µM and 200 µM showed around 42.9%, 44% and 39.4% of the encystment 
respectively. DCB has also been found to be effective in plant studies, in the past 
Anderson et al. (2002) tested DCB on two species of plants, Lilium auratum and 
Petunia hybrida, and found that a low concentration of DCB at 10 μmol/L caused 
90% disruption of pollen tubes after only 8 hours of exposure. As can be seen in 
Figure 5.11, isoxaben showed minor effect on the encystment of Acanthamoeba 




respectively, but the encystment of Acanthamoeba was decreased to 45% at a 
concentration of 500 µM. The findings from the present investigation agrees 
relatively well with that from Moon et al. (2015), who concluded that 
concentrations of 1 µM and 5 µM of isoxaben showed encystment level at around 
70% and 66% respectively. When those authors increased the concentrations of 
isoxaben to 10 µM, 50 µM and 100 µM, the percentages of encystment were 
found to be around 56.6%, 61% and 64% respectively. A possible reason for the 
slight difference in the results between the two studies is that Moon et al. (2015) 
tested a different strain of  Acanthamoeba castellanii (ATCC 30011) and a 
different incubation temperature of 25 °C, whereas the present study tested 
Acanthamoeba castellanii (ATCC 30868) and used an  incubation temperature of 
30 °C. 
 In comparison with Dudley et al. (2007) and  Moon et al. (2015) studies, the 
current study is demonstrated for the first time that the combination of DCB and 
isoxaben at a concentration of 100 µM exhibited encystment at 49.1% and 45.7% 
for protocysts formation (as shown in figures 6.12 & 6.15). This observation could 
be explained by the fact that an antagonistic effect was caused when the 
isoxaben mixed at a concentration of 100 uM with DCB and tested on the 
conversion of trophozoites into cysts and protocysts. This means the ability of 
DCB was decreased in the combination with isoxaben compared to the DCB 
effect alone on the encystment rate and protocysts formation. it seems possible 
that this result is due to DCB blocking the cellulose synthase enzyme and 
preventing the cyst and protocyst formation. Isoxaben and DCB both target 
cellulose synthase enzyme which is involved in the cellulose biosynthesis during 
the encystment and protocysts production in Acanthamoeba. Based on the 
findings obtained from this study that the DCB particularly the 500 uM 
concentration was inhibited the transformation of trophozoites into cysts at 17.7% 
compared with the same tested concentration 500 uM of isoxaben which showed 
only 45% encystment. There are three different explanations for the poor activity 
of isoxaben on Acanthamoeba included: firstly, it could be due to the isoxaben 
not being transported to the active site of the cellulose synthase enzyme for 
Acanthamoeba. Second, the isoxaben may not be taken up by Acanthamoeba. 
Third, the isoxaben might not be inhibiting the active sites of cellulose synthase 




In the plants, Isoxaben targets certain CesA proteins and leads to a reduction in 
this protein in the cellular membrane (Heim et al., 1991, Peng et al., 2002). The 
effect of isoxaben in plants is most likely that it binds to the amino acid included 
glycine and threonine which aid the process of cellulose synthesis (Desprez et 
al., 2002, Scheible et al., 2001). On the other hand, the effect of DCB appears to 
be to disrupt the cellulose synthase complex subunits (CSCs) in the plasma 
membrane and is also involved in blocking the CSCs in the process of cellulose 
synthesis (Doblin et al., 2002, Mutwil et al., 2008). The mechanism of action of 
DCB in plants is that it causes alterations in cytoskeleton organisation in 
Arabidopsis thaliana (Peng et al., 2001). Possibly the mechanism for DCB in 
Acanthamoeba is similar to that working in plants by distribution of the 
cytoskeleton of Acanthamoeba or the inhibition of glucose polymerization, 
preventing the formation of cellulose in the cyst wall during the encystment 
process. The main elements of the cytoskeleton of Acanthamoeba are the fibres 
and networks of actin that are organized in cytoplasmic locomotion (González-
Robles et al., 2008). Furthermore, It has been reported by Dudley et al. (2009) 
that the encystment of Acanthamoeba could be blocked by using particular 
inhibitors, such as cytochalasin D and Y27632 and the findings from their 
investigations indicated that cytoskeleton re-arrangements play a crucial role in 
the encystment process.  
6.4.5 The effect of cellulose synthesis inhibitors on the 
transformation of trophozoites into protocysts  
Isoxaben and DCB were tested in this study to assess their effect on the protocyst 
formation. The results in Figure 6.13 suggest that the correlation between higher 
and lower concentrations of DCB is interesting as the production of protocysts 
was further reduced at a concentration 500 µM which produced 24.6%. The effect 
of DCB on the protocysts formation was slightly decreased at concentrations of 
50, 100, 200 µM, giving 57.6%, 36.9% and 33.4% protocysts production 
respectively.  
The present study has demonstrated for the first time that the effects of DCB on 
protocysts formation in Acanthamoeba and the results are in line with prior study 
conducted by (Moon et al., 2015), who found that a concentration of DCB at 50 




respectively of Acanthamoeba encystment. The novel observation of the current 
study is that the combination of isoxaben with DCB at a concentration of 100 µM 
gave protocysts formation at 45.7% compared with isoxaben and DCB as 
individual which produced protocysts level at 63% and 36.9%. The combination  
results refer to antagonistic effect related to the activity of DCB alone. Fugelstad 
et al. (2009) found that, at a concentration of 200 µM, DCB inhibited the growth 
of Saprolegnia monoica mycelium. After 4 days, DCB inhibited around 40 and 60 
% of growth compared with the positive controls of methanol and water, 
respectively. It seems possible that these results are due to the blocking effect of 
DCB on cellulose synthases complex in moulds which has an impact on 
Saprolegnia monoica growth. 
It can be seen from the data in Figure 6.14 that isoxaben at concentrations of 50 
µM, 100 µM and 200 µM inhibited the development of protocysts by 67.3%, 63% 
and 57% respectively. These results are in the line of Moon et al. (2015) research 
that found at concentrations of 10, 50 and 100 µM of isoxaben exhibited 
encystment rate at around 56.6%, 61% and 64% respectively. Furthermore, the 
protocyst formation decreased at the higher concentration of 500 µM of isoxaben, 
giving a level of protocyst of 37.2%. The results from this study indicate that DCB 
inhibited the conversion of Acanthamoeba trophozoites into protocysts, on the 
basis of this data, it is possible to hypothesise that the mechanism of action for 
DCB in Acanthamoeba protocyst is similar to that operating in cysts by inhibiting 
the cellulose synthase enzyme. The most surprising findings of this study relate 
to the isoxaben results, as this herbicide showed only slight inhibition of 
Acanthamoeba encystment even at a higher concentration of 500 µM compared 
with DCB. When isoxaben was combined with DCB at a concentration of 100 µM, 
the formation of protocysts was found to be 45.7% compared with the use of DCB 
which at the similar tested concentration it gave 36.9%. This suggested a 
potential antagonism impact on the use of two compounds compared with tested 
of DCB alone. The resistance of Acanthamoeba to isoxaben during the 
transformation of trophozoites into protocysts might be related to the same 






6.5  Future research work    
Future studies should be carried out to isolate and sequence the receptor which 
the β ultra- long agonist, β₁ adrenoreceptor agonists and antagonists interact with 
and investigate how this receptor is involved in the encystment process of 
Acanthamoeba. Further experimental investigation is needed to assess the 
effects of irreversible antagonists such as pindobind on the transformation of 
trophozoites into cysts, as this antagonist can irreversibly bind to the receptor for 
a long period and it will not be able to respond to endogenous catecholamine of 
Acanthamoeba. Conversely, when the antagonist combined with epinephrine it 
competed for the receptor and had an antagonistic effect and the reason for that 
is due epinephrine is in a dynamic equilibrium and it associated and disassociated 
from the receptor in Acanthamoeba. The findings from this investigation 
established that a micromolar concentration of the adrenoreceptor β ultra-long 
agonist indacaterol promoted the encystment process in Acanthamoeba. 
Considerably more work will need to be done to isolate the receptor from the 
trophozoite membrane lysate by using indacaterol as a ligand for the receptor 
along with a bead-based column approach. It would be interesting to perform N-
terminal sequencing of the receptor/protein structure using the SDS page and 
further analysis could also be undertaken to characterise the receptor/protein 
using LC/MS protein analysis. The outcomes of the recently sequenced 
Acanthamoeba genome confirmed that no sequence shares homology with well-
known mammalian adrenergic receptor systems and a research conducted by 
Clarke et al. (2013) reported that the Acanthamoeba genome encoded 35 G-
protein-coupled receptors are involved in cell signalling.  
6.6  Conclusion     
The results of the present study demonstrate that the agonists and antagonists 
promoted and blocked both the encystment process and the transformation of 
trophozoites into protocysts. This is the first study to investigate the effect of a 
number of adrenoceptor agonists and antagonists on the conversion of 
trophozoites into protocysts and this research has gone some way towards 
enhancing our understanding of how these agonists and antagonists work in 
Acanthamoeba. Overall, the results of the current study indicate that the β₁ and 




encystment in Acanthamoeba, whereas β₁ and β₂ antagonists, including 
metoprolol, propranolol and betaxolol, inhibit the encystment process. The 
findings from the protocyst investigations reveal that the β₁ and β₂ antagonists, 
including metoprolol, propranolol, and also butaxamine, prevent the formation of 
Acanthamoeba protocysts, while the β₁ levobunolol and betaxolol stimulate 
protocysts production. Targeting cellulose biosynthesis in Acanthamoeba is very 
important, due to the failure of the current drug regimen to kill the cysts of 
Acanthamoeba and recurrent the infection. The findings from this study showed 
that DCB blocked both the encystment and protocysts production. The 
mechanism of action for DCB in Acanthamoeba is blocking the cellulose synthase 
enzyme which is involving in catalysing cellulose biosynthesis pathway. This 
study offers the potential of using DCB as an effective treatment against both 
cysts and protocysts production of Acanthamoeba in vitro. However, DCB and 
isoxaben compounds are soluble in methanol and may be not safe to use for the 
treatment of AK in vivo. A minor inhibition was observed from isoxaben on the 
encystment and protocysts formation, but the combination of isoxaben and DCB 
at a concentration of 100 µM reduced the encystment and protocysts formation. 
However, the combination results could be referred to antagonistic effect 
compared with the use of DCB alone on the conversion of trophozoites into cysts 
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7. Chapter 7: Examining the carbohydrates composition of cyst 
and protocyst walls of Acanthamoeba  
 
7.1  Introduction  
As detailed previously in chapter 1, section 1.3.2, under unfavourable conditions 
such as lack of food, hyperosmolarity, the trophozoites of Acanthamoeba switch 
to another form which is the cyst with a thick wall and makes the organism highly 
resistant to the disinfection and able to survive in adverse environmental 
conditions for many years.  
7.1.1 Composition of the walls of Acanthamoeba cysts and 
protocysts 
At 35%, carbohydrates form the highest percentage of the cyst wall structure of 
Acanthamoeba, proteins form 33%, lipids 4-6%, 8% ashes (dust) and 20% is 
composed of undetermined materials (Neff and Neff, 1969). Data from past 
studies suggested that the exocyst of Acanthamoeba mainly comprises 
hydroxyproline-rich, acid-resistant proteins but cellulose and lipids were also 
detected in this layer (Barrett and Alexander, 1977, Bowers and Korn, 1969). 
Cellulose is mainly found in Acanthamoeba endocysts and earlier literature 
demonstrated that cellulose represents around 10% of the total dry weight of the 
cyst wall (Tomlinson and Jones, 1962). However, a more recent study (Garajová 
et al., 2019) has reported that the cellulose fibrils exist in both layers the endocyst 
and ectocyst of the Acanthamoeba cyst wall.  
The sugar composition of Acanthamoeba cyst walls has been investigated using 
fluorescein labeled lectins and it has been found that glucose, mannose, 
galactosamine and glucosamine residues are present (Elloway et al., 2004, 
Magistrado-Coxen et al., 2019). In another study utilising gas chromatography, 
coupled with a mass spectrometry (GC-MS) instrument, Dudley et al. (2009) 
showed it was possible to analyse the sugar moieties and glycosidic linkages in 
the cyst walls and trophozoites of Acanthamoeba castellanii (ATCC 50492) which 
belongs to the T4 genotype and the carbohydrates were found to form 0.7% of 
the components of cyst walls. The significant difference between the amounts of 




most likely caused by the loss of intracellular contents such as glycogen (Dudley 
et al., 2009). The chemical analysis of glycosidic linkages for cyst and trophozoite 
is important in terms of pharmaceutical therapeutics approach to design a new 
agents for AK infection.  
GC-MS analysis of the glycosidic linkages of A. castellanii (ATCC 50492) cyst 
walls showed that there are 1,4-linked glucosylpyranose representing (22%) 
which is an obvious sign of cellulose, and the percentage increased to (28.6%) 
for 1,3-linked galactopyranose (galactose linkage polymer). Other linkages were 
identified, including 3,4-linked galactopyranose (13.6%) (galactose linkage 
polymer), 4,6-linked mannopyranose (7.8%) (mannose linkage polymer), 3,6-
linked galactopyranose (7.2%) (galactose linkage polymer), 5-linked 
xylofuranose (7%) (xylose linkage polymer), 3,4-linked glucopyranose (6%) 
glucose linkage polymer), 2,4-linked gluco or galactopyranose (4.4%) 
(glucose/galactose linkage polymer) and terminal mannopyranose (3.2%) 
(Dudley et al., 2009). 
Under the laboratory conditions the trophozoite of Acanthamoeba is transformed 
into protocyst form by incubating the trophozoite in Neff’s medium plus 0.5% (v/v) 
propylene glycol in an orbital shaking incubator at 32°C and 120 rpm for 2 hours. 
The propylene glycol (PG) contributes in the transformation of Acanthamoeba 
trophozoite into a protocyst form. When the PG is added to the Neff’s medium it 
has a significant role in the transformation process; it may interfere with the plasm 
membrane of Acanthamoeba and resulted in protocyst stage of this organism. 
There has been no detailed investigation of the structure of protocyst walls. 
However, a study conducted by Kliescikova et al. (2011) used various lectins to 
detect the presence of specific sugars within cyst and protocyst walls of 
Acanthamoeba. The authors showed that the protocyst cell wall reacted only with 
Concanavalin A lectin, which suggests that only α-glucose and mannose are 
present, whereas the exocyst layer of the cyst walls was reacted with all lectins 
which suggested that the ectocyst layer of cyst walls mainly consists of protein. 
The protocyst is unlike the mature cyst, it’s cell wall appears under transmission 




7.1.2 The presence and structure of cellulose and chitin 
polymers 
Cellulose is the most plentiful natural polymer on earth, a particular product of 
solar energy because of its source in the photosynthetic process (Klemm et al., 
2005). Cellulose is the most important component of plant biomasses. It is also 
generated in significant amounts by green algae, such as Micrasterias, a Gram-
negative soil bacterium Acetobacter xylinum, slime mold Dictyostelium, sea 
animals such as Halocynthia  and protists, such as the cyst walls of 
Acanthamoeba (Schwarz, 2001, Lynd et al., 2002, Bishop et al., 2002). Around 
30 distinct cellulose molecules join together and produce major units referred to 
as ‘primary fibrils’. These fibrils assemble into larger units known as ‘microfibrils’ 
and hydrogen bonds hold together the chains of cellulose microfibrils (Brown Jr 
and Saxena, 2000, Lynd et al., 2002). 
The chemical hydrolysis of cellulose polymer into glucose monomers is cheaper 
than the digestion by enzymes and requires acids, such as hydrochloric acid 
(HCl) and sulfuric acid (H2SO4). It has been reported that H2SO4, at a 
concentrations of 1.0 M & 2.5 M,  gives 12% & 24% yield respectively of glucose 
after treatment for 2 hours at 100 °C. Hydrolysis with HCl under the same 
conditions as those used for H2SO4, gives lower percentage yields of glucose, at 
10 and 19% respectively (Hutomo et al., 2015). A possible explanation for this 
difference H2SO4 is a stronger than HCl. The chemical structure of the cellulose 
polymer is made up of D-glucose monomers, which are compressed through β-
1,4 glycosidic bonds (Figure 7.1). β D-glucose is an essential subunit of the 






Figure 7-1: The chemical structure of cellulose polymer, which is made up of 




The rationale for providing a review for chitin is because we hypothesised that 
the Acanthamoeba protocyst consists of N-acetylglucosamine. Chitin is a 
polymer comprising N-acetylglucosamine linked by covalent β-1,4 glycosidic 
bonds and is present in the cell walls of plants and fungi, in the exoskeletons of 
insects such as Arthropoda such as mosquitos, in the cyst walls of some 
protozoa, such as the species Giardia intestinalis and Entamoeba histolytica and 
on the cell surface of Trichomonas vaginalis, Phytomonas nordicus and 
Blastocystis hominis (Martínez et al., 2001). Earlier studies have found a high 
amount of chitin, at around 25%, in the cyst wall of Entamoeba invadens and also 
the chitin synthase enzyme is expressed in this organism during the encystment 
process (Arroyo-Begovich et al., 1980, Arroyo-Begovich and Cárabez-Trejo, 
1982). The chemical structure of the chitin polymer consists of repeating units of 
N-acetyl-glucosamine linked by covalent β-1,4 glycosidic bonds and it has free 














7.1.3  Aim and objectives of this chapter 
The aim of this chapter is to investigate and confirm the potential existence of a 
3rd life cycle stage of Acanthamoeba, by differentiating the sugar composition of 
protocyst wall in Acanthamoeba castellanii (ATCC 50370) and the cyst wall using 
LC/MS analysis. To achieve this aim, the following objectives were set: 
V. Prepare solutions of standard sugars for LC/MS analysis for comparison 
purposes. 
VI. Undertake acid hydrolysis and LC/MS analysis for cellulose/chitin as 
standards to compare with cyst and protocyst samples.   
VII. Perform enzymatic treatments for cysts and protocysts to digest the 
intercellular components.  
VIII. Conduct acid hydrolysis and LC/MS analysis for cyst and protocyst walls 

















7.2  Materials and Methods 
7.2.1  Analysis of sugar standards by LC/MS  
These experiments were performed on standard sugars to ensure that the 
instrument worked and to validate the method used to separate the sugars. All 
the standard sugars were obtained from VWR (Lutterworth, Ltd, U.K.) and the 
purity for all sugars is ≈98%. The samples were prepared and analysed by 
adapting the procedure used by Bawazeer et al. (2017). The mobile phase was 
prepared by weighing out 10 mg of the standard sugars and the powder was 
dissolved in 10 mL of acetonitrile (ACN) (LC-MS grade) and water (50:50) 
(Sigma, Dorset, U.K.). The samples were placed in LC/MS glass vials and 
transferred to the LC-MS instrument (Agilent 6200 Series TOF/6500 Series Q-
TOF system) and the analysis was carried out by Surila Darbar, a technician in 
the Chemistry and Analytical Service of the Department of Biology, Chemistry 
and Forensic Science at the University of Wolverhampton. The separation was 
achieved on a ZIC®-HILIC column (150 x 4.6 mm, 3.5 µm particle size, supplied 
by Sigma, Dorset, U.K.), the injection volume was 0.5 µL and the flow rate was 
0.1 mL/min.  
7.2.2  Hydrolysis of cellulose and chitin  
To prove that the hydrolysis procedure worked, the cellulose and chitin polymers 
were obtained from (Sigma, Dorset, U.K.) and hydrolysed using a method 
modified from that proposed by Morales-delaRosa et al. (2014). Initially, 250 mg 
of cellulose or chitin were added to a sealed tube containing 20 mL of distilled 
water and the analyte was vortexed. The mixture was transferred to a tight steel 
container reactor and heated to 140 °C in an oven incubator for 1 hour. 
Subsequently, 5 mL of distilled water containing 0.2 M and 1.1 M concentrations 
of H2SO4 were added in drops to the chitin and cellulose respectively to give the 
final concentration of 1.1 M for cellulose and 0.2 M for chitin, and then the reaction 
time of the samples was recorded from this point for 2 hours. After 2 hours, the 
mixture of the samples was immediately cooled with ice -20°C in order to stop 
the reaction and the samples were centrifuged at 3000 × g for 10 min. The 
hydrolysed samples were filtered using a vacuum filter (0.2 µm) to remove the 






Figure 7-3: Hydrolysis of cellulose polymer in H2SO4 and distilled water at a 
concentration of 1.1 M into glucose monomers. 
 
Figure 7-4: Hydrolysis of chitin polymer in H2SO4 and distilled water at a 
concentration of 0.2 M into monomers of D-glucosamine. 
7.2.3  LC-MS analysis of the hydrolysed samples of cellulose and 
chitin 
The mobile phase was prepared by diluting the hydrolysed cellulose and chitin 
samples in acetonitrile and water (50:50) to a concentration of 1 mg/mL. As 
detailed in section 7.2.1 above, the separation was accomplished on a ZIC®-
HILIC column (150 x 4.6 mm, 3.5 µm particle size, Sigma, Dorset, U.K.). The 
injection volume was 0.5 µL and the flow rate was 0.1 mL/min. 
 
7.2.4  Enzyme treatments of the cysts and protocysts 
Cysts and protocysts were prepared as detailed in chapter 2, sections 2.8 – 2.9. 
The experiments followed the method previously described by Gerwig et al. 
(2002) and Jarroll et al. (1989) in relation to Giardia with modifications. Around 1 
x 107 cells/mL of cysts or protocysts of Acanthamoeba castellanii (ATCC 50370) 




min. The pellets were suspended in 10% sodium dodecyl sulphate (SDS) (to 
solubilize the intracellular components) and heated up in a 100 °C water bath for 
5 min and then washed in distilled water until there were no visible indications of 
detergent remaining. This step was repeated once, and the supernatant was 
discarded. The resulting cyst or protocyst pellets were resuspended in 
amyloglucosidase buffer (20 mM acetate buffer, pH 4.5), and transferred to a 
centrifuge tube. Subsequently, 80 units of amyloglucosidase (13.3 mg) were 
added to the centrifuge tube on a rotary shaker in a 55 °C warm incubator and 
the samples were stirred for 60 min (to break down the linkages between 
saccharides). This step was repeated once, and the supernatant was discarded. 
The cyst or protocyst pellets that resulted from the amyloglucosidase treatment 
were washed in papain buffer (100 mM phosphate buffered saline (PBS), pH 7.2, 
with 5 mM cysteine and 5 mM ethylenediaminetetraacetic acid (EDTA) and then 
the pellets were resuspended in 3 mL of papain buffer and again placed in a  
centrifuge tube. The samples were stirred with 50 units of papain (157 µg) for 2 
hours at 60 °C (to digest the intracellular elements). This step was repeated again 
for one time, and the supernatant was discarded. 
The next step was to collect the cyst or protocyst pellets by centrifuging at 21,000 
× g for 30 min and the samples were then washed with 10% SDS and distilled 
water. After the papain treatments, the samples were subjected to DNase and 
RNase treatments by resuspending the pellets in 3 mL of XNase buffer (0.1 M 
PBS, pH 7.2, with 5 mM MgCl2) in a centrifuge tube. The samples were incubated 
with 500 kunitz units of DNase (1.25 mg) and 80 kunitz units of RNase (1.6 mg) 
(to degrade the DNA and RNA) and stirred for 2 hours at 37 °C. These treatments 
were repeated once, and the pellets were washed with amyloglucosidase buffer. 
The next step was the centrifugation of the pellets at 21,000 × g for 30 min at 10 
°C (in order to separate the cell walls from the other components). After the 
DNase/RNase treatments, the pellets subjected to further amyloglucosidase 
treatments as described above. The pellets were washed with proteinase K buffer 
(50 mM Tris, pH 8.0, 0.2% Triton X-100, 1 mM CaCl2). The resulting pellets were 
suspended in fresh proteinase K buffer, 50 units of proteinase K (1.6 mg) (to 
degrade the protein) were added and the samples were stirred for 2 hours at 60 
°C. This step was repeated, and the supernatant was discarded. Then the pellets 




dithiothreitol for 5 min at 100 °C (to remove the intercellular components). After 
the enzymatic treatments, the resulting pellets were washed five times in distilled 
water to eradicate the detergent and dithiothreitol. The final step of the procedure 
was lyophilizing the resulting pellets in a freeze dryer (to remove the distilled 
water) for 48 hours and then the dry powder was subjected to the process of 
hydrolysis.  
7.2.5  Hydrolysis and LC-MS analysis of the cyst and protocyst 
walls 
As detailed in sections 7.2.2 and 7.2.3 describing the hydrolysis and LC-MS 
analysis of cellulose/chitin, the same method of hydrolysis and LC-MS conditions 
were employed for the cysts and protocysts with some modifications. First, 20 mg 
of enzyme treated lyophilised cyst or protocyst were added to tubes then sealed 
containing 3 mL of distilled water and the analyte was vortexed. The suspension 
was heated to 140 °C in an oven for 1 hour and then 2 mL, containing 0.2 M and 
1.1 M concentrations of aqueous H2SO4, were added in drops to the protocysts 
and cysts respectively to give the final concentration of 1.1 M for cyst and 0.2 M 
for protocyst and the samples were heated to 140 °C for 2 hours. After 2 hours of 
hydrolysis, the reaction was stopped, and the samples were cooled in ice -20°C. 
When it was observed by a visual that the hydrolysed solution of cyst and 
protocyst samples was completely soluble, the solution was centrifuged at 3000 
× g for 10 min and then filtered using a syringe filter (0.2 µm). The mobile phase 
was made up by diluting the hydrolysed solution of cysts and protocysts with 
acetonitrile and water (50:50, LC/MS grade) to a concentration of 1 mg/mL and 
the separation was performed under the same conditions as described in sections 
7.2.1 and 7.2.3 above. 
7.3  Results  
This section presents the results from the inverted light microscopy images 
showing the morphology changes of cysts and protocysts after enzyme 
treatments, LC-MS data for sugar standards analysis, hydrolysed cellulose/chitin 





7.3.1  Observations from inverted light microscopy 
Significant changes occurred in the morphology of NNA cysts and protocysts of 
Acanthamoeba castellanii (ATCC 50370) after enzymes treatment, as shown in 
Figure 7.5. Healthy cysts with a clear double cell walls can be observed in Figure 
7.5.A. Figure 7.5.B. shows the cysts after being treated with different enzymes 
and the intercellular constituents were removed. Healthy protocysts with single 
layers can be seen in Figure 7.5.C. However, when the protocysts were exposed 
to the enzyme treatments, all the intercellular elements were eradicated and only 




















Figure 7-5: Inverted light microscopy images of Acanthamoeba castellanii (ATCC 
50370). (A) Healthy NNA cysts as control with double cell walls the endocyst (red 
arrow) and ectocyst (yellow arrow) (B) Treated NNA cysts with several enzymes 
(C) Untreated protocysts as control with single cell wall (red arrow); (D) Enzymes 




7.3.2  LC-MS analysis of standard sugars 
Preliminary experiments were performed to confirm that the column adequately 
separated the sugar components. For these experiments, a ZIC®-HILIC HPLC 
column was utilised, and this column contains a zwitterionic stationary phase 
covalently attached to porous silica. The reason for used this particular column, 
due it has hydrophilic zwitterion makes the column suitable for hydrophilic 
compounds (carbohydrates) and enhances the peak resolution of the analyte. 
The standard sugars are isomers, which they have an identical molecular formula 
(the same number of atoms of each component), but the structure is different. 
The blank can be observed in Figure 7.6.B. As illustrated in Figures 7.6.C & D, 
the molecular ion peak for glucose as a standard was found to be 203.056 m/z 
and it was detected within a retention time of 3.675 min. The other two sugars, 
mannose and galactose, showed comparable molecular ion peaks of 203.054 
m/z and 203.057 m/z, with retention times of 3.658 min and 3.682 min 













































Figure 7-6: Separation of standard sugars: (A) Retention time for blank sample, (B) 
Extracted ion chromatogram peak for blank sample, (C) Retention time for glucose, 
(D) Separated ion chromatogram peak for glucose, (E) Retention time for mannose, 
(F) Extracted ion chromatogram peak for mannose, (G) Retention time for galactose, 





The same molecular ion peaks were obtained from LC/MS analysis for ribose and 
xylose, at 173.042 m/z, with different retention times of 3.666 min for xylose 
(Figure 7.7.B) and 3.658 min for ribose (Figure 7.7.D). myo-Inositol was run as a 
control and, with a retention time of 3.831 min, it gave a molecular ion peak at 
203.059 m/z. N-acetyl-D-glucosamine was detected to have a molecular ion peak 
of 244.086 m/z and a retention time of 3.460 min (Figure 7.7.G & H).  A number 
of peaks have been observed in the MS spectra, and those peaks are known to 
be background instrumental noise; each individual sugar can only give one 























































Figure 7-7:Separation of standard sugars: (A) Retention time for ribose, (B) 
Extracted ion chromatogram peak for ribose, (C) Retention time for xylose, (D) 
Obtained ion chromatogram peak for xylose, (E) Retention time for myo-inositol, (F) 
Extracted ion chromatogram peak for myo-inositol, (G) Retention time for N acetyl-




7.3.3  LC/MS analysis of cyst and protocyst walls 
The retention time for the glucose which was extracted from the hydrolysed cyst 
wall in 1.1 M of aqueous H2SO4  was 3.402 min and the molecular ion peak was 
found to be 203.020 m/z as shown in Figure 7.6. A & B. This is consistent with 
the expected result, glucose from the cellulose of the cyst cell wall of 
Acanthamoeba. Interestingly, in liquid chromatography (LC) analysis of the 
hydrolysed protocyst wall sample (prepared in 0.2 M of aqueous H2SO4) peaks 
related to two different components were observed. The first component was 
detected with a retention time of 3.712 min and the mass spectrometry (MS) ion 
peak for this fragment was observed at 203.023 m/z (Figure 7.6. C & D) which is 
consistent with the ion peak of the glucose used as a standard in terms of 
molecular ion, but the retention time is slightly different as the standard of glucose 
was detected within a retention time of 3.675 min. The second component from 
the hydrolysed protocyst wall in in 0.2 M of aqueous H2SO4 was identified from 
LC with different retention time of 4.139 min, and molecular ion of 236.937 m/z 
(Figure 7.6.E & F). Based upon the mass data, the structure for this fragment ion 
may be in line with a methylated analogue of N-acetylglucosamine; more analysis 
is required in the future to unequivocally characterize this component. The 
presence of these two different components clearly indicates a difference 

















































Figure 7-8: Separation of sugars: (A) Retention time for glucose formed from the cyst 
wall of A. castallanii, (B) Ion chromatogram peak for glucose extracted from the cyst 
wall of A. castallanii by hydrolysing in 1.1 M of aqueous H2SO4, (C) Retention time 
for glucose, (D) Ion chromatogram peak for glucose a which was obtained from the 
protocyst wall of A. castellanii by hydrolysing in 0.2 M of aqueous H2SO4. (E) 
Retention time for a methylated analogue of N-acetylglucosamine, (F) Ion 
chromatogram peak for possibly a methylated analogue of N-acetylglucosamine 
which was extracted from the protocyst wall of A. castellanii by hydrolysing in 0.2 M 




7.4  Discussion  
This section provides an explanation for standard sugars, cellulose/chitin data 
that obtained from the LC/MS analysis and the comparison of findings related to 
cysts and protocysts from the LC/MS analysis and makes comparisons with 
previous studies for different microorganisms. 
7.4.1  LC/MS analysis of sugars as standards 
Liquid chromatography coupled with mass spectrometry (LC/MS) is a technique 
widely used to detect sugars in various applications. However, the separation of 
sugar through LC/MS is still complicated (Nagy et al., 2017). The method 
development and validation are always necessary for LC/MS and the MS 
detection limit is associated with the minimum efficiency of ionization related to 
the low acidic character of sugars (Licea-Perez et al., 2016). As the standard 
sugars are isomers, so the molecular weight for glucose, mannose and galactose 
is identical at 180.156 g/mol and for ribose and xylose it is also identical at 150.13 
g/mol. In this study the sugars were analysed using LC/MS tool and were 
detected as their sodium ion adducts (M+Na)+ ; this meant the ions detected were 
23 m/z higher than the expected molar mass of the sugars (as a Na+ weighs ~23 
atomic mass units). The key step in the hydrolysis of cellulose and chitin polymers 
is breaking the 1,4 glycosidic bonds. The current study showed that a 1.1 M 
concentration of H2SO4 at a temperature of 140 °C for 2 hours gave optimal 
hydrolysis of cellulose into glucose monomers w. A concentration of 0.2 M of 
H2SO4, in the same conditions as used for cellulose, demonstrated a higher 
hydrolysis of chitin into N-acetyl-d-glucosamine monomers. 
7.4.2  Comparing the data from the LC/MS analysis of cyst and 
protocyst walls with other microorganisms 
The LC/MS analysis conducted in this study showed a glucose peak for treated 
cysts with a molecular ion peak of 203.020 m/z at a retention time of 3.402 min. 
A different retention time of 3.712 min was observed for protocysts, with fragment 
ion of 203.023 m/z which is matched with glucose peak of cyst in terms of 
molecular ion. However, another component was detected in the hydrolysed 
protocyst wall with a distinct molecular ion of 236.9672 m/z and a different 




sodiated (which meant the addition of a proton to the molecular ion of the detected 
component peak). These findings suggest that the walls of Acanthamoeba 
protocysts and cysts are different, with the protocyst wall containing glucose and 
possibly a methylated analogue of N-acetyl-d-glucosamine.  
Previously, it has been reported that the 3-O-methyl-N-acetyl-d-glucosamine is a 
component of monosaccharides composition in Clostridium thermocellum 
bacteria, and this type of methylated sugar has a molecular ion of 235.2 m/z 
(Gerwig et al., 1989), which is comparable to that found in the current study as a 
methylated analogue of N-acetylglucosamine (i.e. m/z 236; detected as [M+H]+). 
This is the first study to demonstrate the existence of potential component of β-
methyl-N-acetyl-d-glucosamine in the wall of protocysts of Acanthamoeba 
castellanii  (ATCC 50370). In the past, GC-MS was utilised to identify the 
composition of carbohydrates in the cyst walls of Acanthamoeba castellanii 
(ATCC 50492) and the findings showed that the walls of treated cysts contain 
mainly galactose (48.1%), glucose (44.4%) and a minor percentage (3.7%) of 
mannose and xylose (Dudley et al., 2009). The results of that research are in line 
with the data obtained from the LC/MS analysis in the present study, as the 
analysis of the hydrolysed cyst walls of Acanthamoeba castellanii (ATCC 
50370)showed a glucose peak and the molecular ion was identical for both 
galactose and mannose (i.e. our data does not distinguish between these 
hexoses).  Also, in the current study, both xylose and ribose peaks with the same 
molecular ions were detected by LC/MS in the cyst walls of A. castellanii  (ATCC 
50370), whereas Dudley et al. (2009) did not detect ribose within the cyst walls. 
There are two possible reasons for this difference: the first relates to the type of 
strain, as Dudley et al. (2009) used  A. castellanii (ATCC 50492) and, in the 
current study, the strain analysed was A. castellanii (ATCC 50370). The second 
could be associated with the use of different instruments for the analysis, GC-MS 
in the earlier research and LC/MS in this study, as this could lead to cause 
limitation in the detection of the component.  
In earlier research, Kliescikova et al. (2011) carried out analyses of different 
strains by utilized fluorescein labelled lectins to determine the carbohydrate 
components of the walls of Acanthamoeba cysts and protocysts. They 




including α-glucose/galactose, mannose, α-N-acetylglucosamine, galactose/N-
acetylgalactosamine, galactosyl-β-N-acetylgalactosamine and α/β-N-
acetylgalactosamine, whereas only a few sugars, including α-glucose/α-
mannose, mannose and N-acetylglucosamine, were detected in endocysts 
(Kliescikova et al., 2011). However, the walls of protocysts reacted only with 
Concanavalin A lectin, and based on this observation, it has been suggested that 
the walls of protocysts contain only α-glucose and mannose (Kliescikova et al., 
2011).  
Conversely, in the present study, LC/MS analysis of the walls of protocysts 
obtained two different MS peaks for glucose and possibly β-methyl-N-acetyl-d-
glucosamine, and these results contradict the findings reported in (Kliescikova et 
al., 2011). According to research by Dudley et al. (2009), the treated cyst walls of 
A. castellanii  (ATCC 50492) contain cellulose, and the current study agrees with 
this observation. However, the findings from Kliescikova et al. (2011) showed that 
the cyst walls contain cellulose and N-acetylglucosamine and the protocyst wall 
consists of only cellulose. These findings are different from the results obtained 
in the present study. The possible explanation for this difference could be related 
to the strain types analysed, as Kliescikova et al. (2011) used three clinical 
isolates (V/01; B/04; N/05) which were taken from corneal scrapes of keratitis 
patients and another environmental strain (RB728/07SR), isolated from 
swimming pools, whereas in this study, Acanthamoeba castellanii  (ATCC 50370) 
was analysed. Another potential reason may be due to the different 
methodologies employed: the present study utilised LC/MS analysis of 
hydrolysed cyst and protocyst walls of A. castellanii (ATCC 50370), which is 
superior to the fluorescein labelled lectins utilised by Kliescikova et al. (2011).  
The auto-fluorescence spectroscopy was used to differentiate between 
Acanthamoeba castellanii and other pathogens, including Escherichia coli, 
Staphylococcus aureus, Pseudomonas aeruginosa, Elizabethkingia miricola, 
Achromobacter ruhlandii and Candida albicans. It has been shown that the cyst 
of A. castellanii is green under auto-fluorescence (Molyneux et al., 2015), so 
maybe Kliescikova et al. (2011) confused with auto-fluorescence and non-
specific binding to the cyst walls of Acanthamoeba. On the other hand, It was 




β(1-3)-N-acetyl-D-galactopyranosamine homopolymer (Gerwig et al., 2002). 
Prior to that study, early work was carried out by Arroyo-Begovich et al. (1980), 
in which the walls of Entamoeba invadens cysts were purified and analysed, It 
was observed that the walls are composed mostly of chitin.  
7.5  Future research work  
Further analysis would be required to establish the exact structure of the 
postulated methyl-N-acetyl-d-glucosamine in order to provide a more detailed 
evaluation of the variations between mature cysts and other stage of 
Acanthamoeba protocysts. This would involve the use of nuclear magnetic 
resonance (NMR) spectroscopy to deduce the exact structure of the sample. This 
prospect will be very challenging as NMR is much less sensitive than LC/MS and 
both sample size and purity may be mitigating factors.   
7.6  Conclusion  
Overall, the LC/MS analysis showed a clear difference in the composition of 
monosaccharides between the walls of Acanthamoeba cysts and protocysts, as 
the cyst wall contains only one glucose peak which is indicative of cellulose, 
whereas the protocyst wall has two peaks, the glucose peak indicated cellulose 
and another peak that corresponds to a different component (possibly a 
methylated sugar of N-acetylglucosamine based upon MS data) which 
contradicts a prior study by Kliescikova et al. (2011). To this end, the current study 



































8. Chapter 8: General Conclusions   
 
Acanthamoeba Keratitis (AK) is a serious, eye-threatening disease and infection 
caused by Acanthamoeba spp. it is often associated with wearing contact lenses. 
Misdiagnosis and ineffective treatment may lead to loss  of vision. There are three 
different methods used to diagnosis of AK including: microbiological culture of 
corneal scrapings, In vivo confocal microscopy and quantitative polymerase 
chain reaction (qPCR) which well known for its sensitivity. As indicated in the 
previous chapters that the present medical treatment for AK entails biguanide 
either polyhexamethylene biguanide or chlorhexidine at concentration of 0.02% 
(v/v) as single drug or in combination with diamidines. Remarkably, in the current 
study, the octenidine hydrochloride had an excellent in vitro activity against cysts 
and trophozoites of both tested species of Acanthamoeba compared with PHMB 
and chlorhexidine.  
This chapter summarises the work in this thesis aimed to optimizing the current 
treatment, developing novel compounds of amidoamines and new formulations 
of  biguanides against cysts and trophozoites of Acanthamoeba castellanii (ATCC 
50370) and Acanthamoeba polyphaga (ATCC 30461). To assess the toxicity on 
the human epithelial cell line in order to use the compounds which demonstrated 
superior in vitro activity and low toxicity for in vivo treatment. The other aims for 
my project are to test a range of agonists and antagonists on the cysts and 
protocysts formation to activate and block the receptor which involves in the 
encystment of Acanthamoeba. Also, to prevent the production of cysts and 
protocysts by utilizing cellulose synthesis inhibitors assays. Employing chemical 
analysis (LC/MS) to differentiate between the cyst and the potential new stage of 
Acanthamoeba named protocyst to confirm the presence of 3rd life cycle of 
Acanthamoeba.  
A serious of anaesthetics and antibiotics have been tested in this study to 
investigate their possible in vitro effects against trophozoites and cysts of 
Acanthamoeba spp. As the anaesthetics applied in vivo to anesthetise the patient 
eye for a corneal scrape being performed and the antibiotics used prior to 
diagnosis of AK. Anaesthetics, in particular tetracaine, have shown superior 




and these drugs may perhaps lead to the limited sensitivity of culture observed in 
corneal scrape. The presence of benzalkonium chloride (BAC) in propamidine 
(Brolene®) eye drops and levofloxacin (Oftaquix®) as preserved appeared to have 
direct impact on the in vitro activity against trophozoites and cysts of both species. 
Different class of drugs have been tested in the current study including aspirin 
analogues, quaternary ammonium, antifungal, macrolide, antineoplastic for their 
antimicrobial activity and various compounds involving posaconazole, alexidine, 
didecyldimethylammonium chloride, miltefosine showed a higher in vitro activity 
against trophozoite and cyst and low toxicity toward the human epithelial cell line. 
The formulation of Lipodisq® carrier with biguanide compounds enhanced the 
antimicrobial activity from 1-fold to approximately 7-fold against trophozoites and 
cysts of Acanthamoeba spp. 
Remarkably, the combination of chlorhexidine with Lipodisq® carrier showed a 
massive increased in the activity when it was tested over the time against Neff’s 
cysts of Acanthamoeba as it demonstrated a 4.5 log reduction after 24 hours 
compared with the use of chlorhexidine alone which resulted in only 2 log kill at 
the same time point. The findings from encystment study indicated that the 
adrenoreceptor agonists bind to the receptor and had one effect and the 
antagonists interacted with the receptor in Acanthamoeba but gave an opposite 
impact and possibly these drugs bind to the evolution basic version of the 
receptor in Acanthamoeba. Based on the results from the encystment 
investigation, the β ultra-long agonist indacaterol at a lower concentration of 100 
µM demonstrated a higher encystment level of 85.7%. This finding is very 
interesting as the indacaterol has an ability to bind to the receptor for a long 
duration and is considered to be the optimal ligand for the receptor in 
Acanthamoeba.  
A significant finding was achieved from using the herbicide 2,6-
dichlorobenzonitrile (DCB) which inhibits the biosynthesis of cellulose in 
Acanthamoeba by preventing the cellulose synthase enzyme. The higher 
concentration of 500 µM of BCB prevented the cysts formation at 17.7%. Best of 
our knowledge, no chemical investigation such as LC/MS, has been conducted 
in the past to analyse the cell wall components of the protocyst. Therefore, it is 




of Acanthamoeba, as these findings enhance our understanding of resistant 
mechanism in Acanthamoeba. We have predicted that the protocyst wall made 
of N-acetylglucosamine which is present in the cyst wall of Giardia intestinalis. In 
this study, LC/MS analysis was performed for both cyst and protocyst walls 
alongside the standard sugars to determine the type of sugar. The LC/MS 
analysis data proposed that the cyst and protocyst of Acanthamoeba are 
different, as the analysis results of cyst wall indicated the existing of cellulose 
whereas the analysis of protocyst wall showed cellulose and a methylated 
analogue of N-acetyl-d-glucosamine.  
The findings of this study have drawn a good attention for ophthalmologists to the 
use of adequate anaesthetics prior to corneal scarp and antibiotics for diagnosis 
of AK. The in vitro results of this study showed a massive inhibition of the viability 
of trophozoites and cysts by tetracaine, which means that this anaesthetic cannot 
be used in vivo. The current study has highlighted several new compounds that 
can be applied for clinical trial as an alternative in vivo treatment for AK. The 
alexidine, posaconazole, didecyldimethylammonium chloride and octenidine 
hydrochloride are currently not using in the treatment of AK, so it is possible to 
employing these drugs in vivo instead of using PHMB and chlorohexidine. The 
novel combination of biguanides in particular chlorhexidine incorporated with 
Lipodisq® carrier demonstrated excellent in vitro activity against trophozoites and 
the highly resistant cyst stage with minimum toxicity. The way forward is to use 
these combinations as an effective therapies for in vivo treatment against AK. For 
the first time this study has synthesised novel compounds of amidoamine 
involved myristoleyl-amidopropyl-dimethylamine (MOPD) and palmitoleyl-
amidopropyl-dimethylamine (POPD). When these compounds were formulated 
into contact lens base solution at concentration of 0.0005% (w/v) and tested 
against trophozoites over the time, a complete kill at 4.5 log reduction after 24 
hours was observed compared with only 3 log reduction for MAPD and PAPD as 
an existing compounds. This observation has raised the possibility to incorporate 
these compounds at a concentration of 0.0005% (w/v) into contact lens 
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